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Methylation controlled J protein (MCJ) is a negative regulator of 
mitochondrial metabolism that has a substantial impact on overall cell metabolism 
and function. MCJ is highly expressed by naïve CD8+ T cells, however its role in 
their immune effector functions was unknown. In this dissertation, it will be 
demonstrated that MCJ restricts the mitochondrial metabolism of CD8+ T cells, in 
part by reducing respiratory supercomplex formation. MCJ deficiency enhances 
the immune effector functions and memory responses of CD8+ T cells in a 
mitochondrial ATP dependent manner. As a consequence, protection to influenza 
virus infection is substantially improved. Reduced expression of MCJ therefore 
promotes viral immunity, however the loss of MCJ is not always beneficial. In 
cancer, decreased MCJ expression is correlated with ATP binding cassette (ABC) 
transporter mediated chemotherapy resistance and poor patient responses. This 
dissertation will also address the role of MCJ in chemoresistance. Increased 
mitochondrial ATP production due to MCJ deficiency is sufficient to fuel ABC 
transporter activity, thereby directly promoting chemoresistance. This can be 
reversed by restoration of MCJ function in chemoresistant cells. Overall, the 
results presented in this dissertation identify MCJ as a potential therapeutic target, 
as modulating MCJ expression can significantly affect the severity of viral 
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CHAPTER 1. Comprehensive Literature Review 
1. Introduction to metabolism 
One of the major characteristics that has been proposed to delineate life 
from nonlife is metabolism (Koshland, 2002; McKay, 2004), which is the ability to 
perform the chemical reactions necessary for the production and breakdown of 
biomolecules, the conversion of nutrients and food sources into usable energy, and 
the elimination of waste byproducts. In order for an organism to maintain 
homeostasis, regulatory mechanisms must exist to control the flow of metabolites 
through the catabolic and anabolic reactions that are performed by cells. To 
facilitate these metabolic reactions, all mammalian cells ultimately depend on the 
production of the energy carrier adenosine triphosphate (ATP), of which the 
majority is synthesized via glycolysis, the tricarboxylic acid cycle (TCA), and 
oxidative phosphorylation. 
1.1. Glycolysis 
Glycolysis occurs in the cytosol and functions to break down carbohydrates 
for the production of ATP and the reducing equivalent NADH (Berg et al., 2002; 
Voet and Voet, 2011). The most common carbohydrate utilized by cells is glucose, 
a six-carbon simple sugar that is ubiquitously used as a fuel source and molecular 
building block. Glucose enters cells through one of 14 known glucose transporters 
that are differentially expressed throughout the body (Thorens and Mueckler, 
2010). Once inside the cell, glucose is readily phosphorylated by the enzyme 
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hexokinase to glucose 6-phosphate. The negatively charged phosphate group 
prevents glucose from exiting the cell and also facilitates entry into glycolysis. 
The reactions of glycolysis are broadly characterized into two groups, the 
preparatory and the payoff phases (Figure 1-1) (Berg et al., 2002; Voet and Voet, 
2011). The preparatory phase reactions break down the carbons of glucose into two 
molecules of glyceraldehyde 3-phosphate and require the hydrolysis of two 
preformed molecules ATP. In the payoff phase, glyceraldehyde 3-phosphate is 
ultimately converted into pyruvate. In the process four ATP and two NADH 
molecules are produced, therefore the overall yield of glycolysis per molecule of 




Figure 1-1. The reactions of glycolysis 
Preparatory phase reactions, red; payoff phase reactions, blue. G6P, glucose 
6-phosphate; F6P, fructose 6-phosphate; F-1,6-BP, fructose 1,6-bisphosphate; 
DHAP, dihydroxyacetone phosphate; G3P, glyceraldehyde 3-phosphate; 1,3-BP, 
1,3-bisphosphoglycerate; 3PG, 3-phosphogycerate; 2PG, 2-phosphoglycerate; PEP, 
phosphoenolpyruvate; HK, hexokinase; PI, phosphoglucose isomerase; PFK-1, 
phosphofructose kinase 1; F-BA, fructose-bisphosphate aldolase; TPI, triose 
phosphate isomerase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 
PGK, phosphoglycerate kinase; PGM, phosphoglycerate mutase; PPH, 




















The activity of glycolysis is regulated by several mechanisms (Berg et al., 
2002; Voet and Voet, 2011). The amount of glucose entering cells, and thereby the 
overall cytosolic concentration, is controlled by the expression and activity of 
glucose transporters (GLUT) at the cell surface (Thorens and Mueckler, 2010). 
Reactions that are highly thermodynamically favorable are essentially irreversible, 
and the enzymes catalyzing them are under reversible allosteric regulation. This 
is generally due to downstream metabolic intermediates that serve as feedback 
inhibitors or activators. The rate limiting step of glycolysis is catalyzed by 
phosphofructokinase (Bosca and Corredor, 1984). Metabolic enzymes are also 
regulated by posttranslational modifications such that signals from other 
metabolic pathways or extracellular cues can alter the flux through glycolysis 
(Wiese and Hitosugi, 2018). 
Additionally, transcriptional regulation can limit or increase enzyme 
abundance in response to major changes that substantially alter metabolic needs 
(e.g., cell growth and division). In addition, GAPDH can bind the 3’ UTR of some 
RNAs, thereby regulating protein translation (White and Garcin, 2016). The time 
required for each of these regulatory mechanisms varies significantly from 
milliseconds to hours, however all play roles in controlling the flux of 
intermediates through glycolysis. 
While glycolysis is not substantially efficient in terms of net ATP 
production as the yield is only two ATP per glucose molecule entering the 
pathway, it is carbon sparing and produces intermediates that can be shuttled to 
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other metabolic pathways (Berg et al., 2002; Voet and Voet, 2011). The pentose 
phosphate pathway uses glucose 6-phosphate to generate NADPH and five 
carbon sugars needed for nucleotide synthesis. Glucose 6-phosphate is also used 
for the production of glycogen, which predominantly occurs in the liver and 
skeletal muscle. Glyceraldehyde 3-phosphate is a substrate used for triglyceride 
and lipid synthesis. The glucose dependent production of the amino acid serine 
requires 3-phosphoglycerate. In addition, pyruvate serves as a metabolic 
branchpoint as it can be transaminated to alanine for amino acid synthesis, 
carboxylated to oxaloacetate for use in the TCA cycle or gluconeogenesis, reduced 
to lactate (with the corresponding oxidation of NADH) to maintain cellular redox 
balance, or further oxidized in the mitochondria. 
1.2. Mitochondrial respiration 
In organisms that can perform aerobic respiration, the complete oxidation 
of carbon substrates and the production of ATP ultimately occurs via the reactions 
of the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) in 
the mitochondria. 
1.2.1. Tricarboxylic acid cycle 
The TCA cycle is a set of cyclic reactions that integrates intermediates from 
a number of metabolic pathways including the breakdown products of 
carbohydrates, amino acids, and fatty acids (Figure 1-2) (Berg et al., 2002; Voet and 
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Voet, 2011). The net yield of one round of the TCA cycle is one GTP (equivalent to 





Figure 1-2. The reactions of the tricarboxylic acid cycle 
CS, citrate synthase; IDH, isocitrate dehydrogenase; α-KGDH, α-ketoglutarate 
dehydrogenase; SCS, succinyl-CoA synthetase; SDH, succinate dehydrogenase; 
MDH, malate dehydrogenase.  
 
 
Carbons derived from glucose enter the TCA cycle in the form of acetyl-
CoA, which is also the final break down product of fatty acid oxidation (Berg et al., 
2002; Voet and Voet, 2011). Fatty acids are a significant source of energy and 


























the form of a carboxylic acid. Saturated fatty acids contain no double bonds 
between the carbon atoms of the chain (i.e., they are saturated with hydrogen 
atoms), while unsaturated fatty acids contain one or more double bonds in either 
a cis or trans configuration. 
The breakdown of fatty acids occurs mainly in the mitochondrial matrix via 
the process of b-oxidation. Fatty acids are also metabolized to a lesser degree in 
peroxisomes (Poirier et al., 2006). Similar to glycolysis, b-oxidation is tightly 
regulated by different mechanisms (Eaton, 2002; Schulz, 1994). The majority of 
fatty acids in the body are stored in adipocytes, which, along with the liver, control 
their availability to other cells. Skeletal muscle also serves as a depot for fatty acid 
storage (Berg et al., 2002; Voet and Voet, 2011). Allosteric regulation plays a major 
role in regulating b-oxidation, with a notable example being the potent inhibition 
of the carnitine shuttle by malonyl-CoA (Foster, 2012). Additionally, the overall 
abundance of mitochondria varies between cell types based on metabolic needs, 
which limits the overall capacity for b-oxidation (and mitochondrial respiration in 
general) (D'Erchia et al., 2015). 
Amino acids are also a significant fuel source used by mammalian cells 
(Berg et al., 2002; Voet and Voet, 2011). These biomolecules consist of a central 
carbon atom bound to an amine (-NH2), a carboxylic acid (-COOH), and a variable 
side chain (R group). The side chains found in eukaryotes differ in length, charge, 
and polarity, all of which provide different chemical properties that are exploited 
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by cells. In addition, the amine functional group is a weak base that can be 
protonated at cytosolic pH to produce a positively charged ammonium group (-
NH3+). Likewise, the carboxylic acid group can be deprotonated to become a 
negatively charged carboxylate (-COO-). Amino acids are therefore zwitterions 
that exist in a pH-dependent equilibrium between all three possible charge states 
(neutral, negative, and positive). The functional groups of some side chains can 
also be neutral or charged, which adds further chemical complexity. 
Excess amino acids that are not used for protein synthesis or other 
biological processes (e.g., neurotransmitter synthesis) are metabolized into 
intermediates that can directly enter the TCA cycle (Figure 1-3). While most amino 
acid catalysis pathways result in the formation of acetyl-CoA, succinyl-CoA, 
fumarate, oxaloacetate, and a-ketoglutarate are also produced. In rapidly dividing 
cells (e.g., cancer cells and proliferating lymphocytes), the breakdown of the amino 
acid glutamine via glutaminolysis is a major energy production pathway (Figure 
1-4) (Newsholme, 2001; Yang et al., 2017). In addition, several amino acids can be 
readily converted to others through the action of transaminases such as the 




































Figure 1-4. The reactions of glutaminolysis 
GDH, glutamate dehydrogenase; GPT, glutamate pyruvate transaminase; GOT, 
glutamate oxaloacetate transaminase. 
 
Like glycolysis, the TCA cycle integrates metabolites from other metabolic 
pathways and as such, functions as a metabolic hub within the cell (Berg et al., 
2002; Voet and Voet, 2011). A notable export is citrate, which can be shuttled out 
of mitochondria for fatty acid synthesis. Additionally, oxaloacetate can be used in 
a number of pathways including amino acid and fatty acid synthesis. Imports 
include fumarate, which is produced by the urea cycle, and as noted above, the 
final products of amino acid catabolism. 
The TCA cycle is regulated by allosteric regulation in response to cellular 
energy charge (Berg et al., 2002; Voet and Voet, 2011). As such, ATP and NADH 
are negative regulators, while ADP is a positive regulator. In addition, NAD+ and 
FAD are key substrates for several reactions that are readily available during times 












limiting step of the TCA cycle. Unlike glycolysis, the TCA cycle is not carbon 
sparing as two carbons are lost as CO2 during each cycle, however the NADH and 
FADH2 produced are used in the synthesis of substantial amounts of ATP via 
oxidative phosphorylation. 
1.2.2. Oxidative phosphorylation 
Oxidative phosphorylation (OXPHOS) is facilitated by the large, multi-
subunit protein complexes of electron transport chain (ETC), which are integrated 
into the inner mitochondrial membrane (Berg et al., 2002; Voet and Voet, 2011). 
Through a series of coordinated redox reactions, the ETC ultimately transfers 
electrons from NADH and FADH2 to oxygen, which is the final electron acceptor 
in mammals. In the process, protons are pumped across in the inner mitochondrial 





Figure 1-5. Reactions and complexes of the electron transport chain 
Adapted from Sazanov (2015).  
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Complex I (NADH : ubiquinone oxidoreductase) is the largest of the ETC 
complexes at ~970 kDa and transfers the electrons from NADH to Coenzyme Q10 
(CoQ). In the process, four protons are translocated from the matrix to the IMS. 
The quaternary structure of Complex I is L-shaped and consists of 45 individual 
subunits in mammals (Sazanov, 2015). It is organized as a core of 14 subunits that 
are conserved from bacteria surrounded by a shell of 31 supernumerary subunits. 
A notable example is NDUFv1, which serves as the NADH binding site (Deng et 
al., 1990). 
While the structure of Complex I has been studied for decades, it  generally 
the least understood as only partial structures were known until the recent 
publication of the nearly complete ovine Complex I at high resolution (3.9 Å) 
(Fiedorczuk et al., 2016). Complex I has been shown to exist in two distinct 
conformations – the catalytically active (A) form and the inactive dormant (D) 
form (Babot et al., 2014). It is still unclear, however, what regulates the transition 
between the A and D forms as well as the specific mechanism(s) connecting proton 
translocation and electron transfer. 
Since Complex I catalyzes the first set of ETC reactions, deficiencies can lead 
to severe dysfunction in mitochondrial metabolism and cause significant 
pathology (Scheffler, 2015). Tissues that are most sensitive to Complex I 
dysregulation are the liver, kidney, muscle (both skeletal and cardiac), and those 
of the nervous system. As such, patients experience a myriad of symptoms such 
as lactic acidosis, myalgia, ataxia, epilepsy, and vision problems (Scheffler, 2015). 
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In addition to overall deficiencies in mitochondrial respiration, defects in or 
dysregulation of Complex I activity result in increased levels of mitochondrial 
reactive oxygen species (ROS) (Vinogradov and Grivennikova, 2016; Wirth et al., 
2016). Excess ROS production can lead to a breakdown in cellular redox potential 
and is a major source of oxidative stress (Schieber and Chandel, 2014). In disease 
states such as ischemia reperfusion injury, Complex I plays a predominant role in 
ROS production via reverse electron transport (RET) (Chouchani et al., 2014; Scialo 
et al., 2017). 
Complex II (succinate dehydrogenase) is the smallest ETC complex at ~120 
kDa and is comprised of four subunits (Sun et al., 2005). Complex II reduces CoQ 
via the oxidation of FADH2. Unlike the other members of the ETC, Complex II 
does not translocate protons into the IMS. Additionally, it catalyzes the conversion 
of succinate to fumarate and thus plays a direct role in the TCA cycle. Deficiencies 
in Complex II can also lead to mitochondrial disorders and have been implicated 
in disease pathology (Jain-Ghai et al., 2013). 
The lipid soluble CoQ formed by Complexes I and II travels through the 
inner mitochondrial membrane to Complex III (Coenzyme Q : cytochrome c 
oxidoreductase). Complex III is an ~240 kDa dimer of two identical monomers that 
are each comprised of 11 subunits each and catalyzes the transfer of electrons from 
CoQ to cytochrome c (Iwata et al., 1998). Each electron transferred to cytochrome 
c results in one proton being translocated into the IMS. Complex III is also a major 
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site of mitochondrial ROS production, and deficiencies are common causes of 
mitochondrial disorders (Benit et al., 2009). 
Reduced cytochrome c migrates to Complex IV (cytochrome c oxidase), 
which catalyzes the final redox reactions of the ETC. Complex IV is a homodimer 
and is ~400 kDa in size (Tsukihara et al., 1996). There are 13 subunits in each 
monomer. Complex IV transfers two electrons from cytochrome c to oxygen, 
producing water. In the process, two protons are translocated into the IMS. Similar 
to the other complexes, deficiencies in Complex IV activity can result in ROS 
production and mitochondrial disorders (Rak et al., 2016). 
The protons transferred to the IMS cannot freely diffuse back into the 
matrix. As such, an electrochemical gradient is produced across the inner 
membrane as the IMS and matrix become positively and negatively charged, 
respectively. According to the chemiosmotic theory (Mitchell, 1961), the potential 
energy of this gradient – known as the proton motive force – is used by ATP 
Synthase (also known as Complex V) to facilitate the oxidative phosphorylation of 
ADP to ATP. 
1.2.3. Respiratory supercomplexes 
The macromolecular organization of the electron transport chain has been 
an intense area of research for decades. Two models of the supramolecular 
organization have been proposed that are effectively direct opposites of one 
another – the solid and fluid state models (Figure 1-6). The solid state model posits 
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that the respiratory complexes associate to form large aggregates that coordinate 
the reactions of the ETC (Keilin and Hartree, 1947). The aggregates are proposed 
to contain pathways that direct the movement of CoQ and cytochrome c between 
the individual complexes. In contrast, the fluid state model posits that individual 
complexes freely diffuse throughout the inner mitochondrial membrane and that 
CoQ and cytochrome c are not restrained to specific paths (Hackenbrock et al., 
1986). 
The fluid model was generally accepted until analyses of mitochondrial 
extracts using blue native gel electrophoresis (BNE) showed that the complexes of 
the ETC can organize into supramolecular structures known as respiratory 
supercomplexes (Schagger and Pfeiffer, 2000). It was originally thought that 
supercomplexes were simply artifacts of the mild detergent solubilization 
employed by BNE, however their presence has been confirmed using other 
experimental methods (Acin-Perez et al., 2008; Dudkina et al., 2005). In addition, 
crystal structures of mammalian respiratory supercomplexes were recently solved 







Figure 1-6. Structural models of the electron transport chain 
Adapted from Schon and Dencher (2009). 
 
There is still debate in the literature over the specific purpose(s) served by 
supercomplexes (Milenkovic et al., 2017). Several proposed benefits to cells have 
been suggested including decreased production of ROS, regulation of ETC 
activity, and prevention of protein aggregation in the mitochondrial matrix 
(Milenkovic et al., 2017). Despite a lack of definitive evidence for these proposals, 
there have been several reports showing a significant correlation between 
supercomplex abundance and increased mitochondrial respiration. Additionally, 
increased ROS production has been detected after chemical disruption of 
supercomplexes containing Complexes I and III (Maranzana et al., 2013). Future 
studies are needed to elucidate the mechanistic role of respiratory supercomplexes 
in the regulation of mitochondrial metabolism. 
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1.3. Urea cycle 
In addition to the production of usable energy, mitochondria are vital to the 
removal of ammonia from cells (Berg et al., 2002; Voet and Voet, 2011). Ammonia 
is a toxic byproduct of amino acid breakdown that is ultimately excreted as urea 
in ureotelic organisms. The conversion of ammonia to urea is facilitated by the 
urea cycle, which primarily occurs in the liver and kidneys and is regulated by 
substrate availability. The urea cycle is a highly energy demanding process as it 
requires the hydrolysis of three ATP molecules, one of which is fully hydrolyzed 
to AMP. This cyclic set of five reactions starts in the mitochondria and also has 
cytosolic components (Figure 1-7). 
Like other pathways, the urea cycle produces intermediates that can be 
shuttled to other pathways (Berg et al., 2002; Voet and Voet, 2011). Citrulline is 
used in the synthesis of polyamines, while arginine has multiple fates including 
protein synthesis, production of the signaling and immune effector molecule nitric 
oxide (NO), and the synthesis of other amino acids. Additionally, fumarate can be 
oxidized in the TCA cycle. The final step of the cycle yields urea, which is 







Figure 1-7. The reactions of the urea cycle 
CPS1, carbamoyl phosphate synthetase 1; OTC, ornithine transcarbamylase; AS, 
argininosuccinate synthetase; ASL, argininosuccinate lyase. 
 
 
2. Introduction to cancer biology 
Cancer is a disease characterized by abnormal cell growth that can disrupt 
the normal functions of the healthy tissues and cells of the body. In addition, the 
process of metastasis induces the spread of these altered cells from their site of 
development to other regions of the body. Cancer is currently the second leading 
cause of death in the U.S., and approximately of 40 % of Americans will experience 
a cancer diagnosis during their lifetime according to the National Cancer Institute. 
While nearly all tissues and cells of the body can become cancerous, certain tissues 

















Table 1-1. Incidence and death rates of the most common cancers in the 
U.S. 
 
Cancer Incidence Deaths 
Breast 123.6 20.9 
Prostate 114.9 19.5 
Lung 61.5 43.4 
Colorectal 39.8 14.5 
Uterine 25.9 4.6 
 
Rates are per 100,000 individuals according to the American Cancer Society. 
 
Cancer diagnoses are graded based on disease progression and are staged 
according to criteria defined by the American Joint Committee on Cancer. The 
scale used varies by cancer type, however they are all based on the extent to which 
healthy tissue has been affected. The breast cancer system starts with Stage 0, 
where a benign growth is localized and not yet considered cancerous. Tumors that 
have invaded healthy breast tissue or local lymph nodes are considered cancerous 
and graded as Stage I, II, or III depending on the extent of spread. Stage IV breast 
cancer has metastasized to other parts of the body, represents the most progressed 
form of the disease, and is often the most difficult to treat. Other examples of 
grading schemes are the Ann Arbor staging system for lymphomas and the 
Gleason Score for prostate cancer. 
While treatment of the initial manifestation of low grade cancer is often 
effective, patients can relapse as the treatment may not clear all cancerous cells. 
While all cancer cells generally have an increased ability to proliferate compared 
to their nontransformed counterparts, certain cells within a tumor have an 
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enhanced self-renewal capacity. These are known as cancer stem cells and have 
the ability to differentiate into all of the cells that comprise a tumor. Cancer stem 
cells are often highly resistant to treatment and can be left behind while the bulk 
of the tumor is eliminated. As such, they are thought to be a major cause of relapse 
and are also implicated in metastasis (Carnero et al., 2016; Li et al., 2015; Owens 
and Naylor, 2013; Schwarz-Cruz et al., 2016). 
2.1. Cancer treatment strategies 
Several treatments for cancer have been devised, however the specific 
regimen used varies for each patient due to numerous factors. These include the 
type of cancer, location within the body, size of the tumor(s), and the age and 
medical history of the patient. The most commonly used treatment is 
chemotherapy. This treatment consists of the administration of one or more 
chemotherapeutic agents, many of which are natural products originally 
discovered in bacteria and plants. While these drugs are toxic to all cells of the 
body, their mechanisms of action are designed to target rapidly dividing cells. As 
such, several classes of chemotherapy agents are used in the clinic that effectively 
target different mechanisms that regulate the cell cycle. 
The most effective overall in terms of the number of cancers that respond 
are the anthracyclines, which are derivatives of compounds discovered in 
Streptomyces bacteria (e.g., daunorubicin, doxorubicin). Anthracyclines work by 
intercalating into DNA, thereby inhibiting the activity of topoisomerase II and the 
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synthesis of new DNA molecules. Nucleotide analogs (e.g., fluorouracil) also 
inhibit DNA synthesis either directly or by interfering with nucleotide production. 
Platinum based drugs (e.g., cisplatin) covalently crosslink DNA to prevent 
synthesis and repair of DNA damage. Chemotherapeutic agents can also interfere 
with the cytoskeletal machinery, thereby restricting cell division. Examples are the 
vinca alkaloids (e.g., vincristine) that were originally discovered in the rosy 
periwinkle (Catharanthus roseus) and interact with tubulin to inhibit microtubule 
polymerization. In contrast, taxanes (e.g., paclitaxel) prevent depolymerization by 
stabilizing microtubules. Taxanes originate from trees of the Taxus genus (yews). 
Other classes of chemotherapeutic agents include inhibitors of kinases (e.g., 
erlotinib), histone deacetylases (e.g., vorinostat), and transcription (e.g., 
actinomycin D). 
While many cancers initially respond to treatment, the development of 
chemoresistance is a major cause of poor patient outcomes. There are several 
mechanisms of chemoresistance including modifications to the drug target, 
changes in the metabolism or cellular distribution of the drug, and increased DNA 
repair capacity, however the most common mechanism is through activity of ATP 
binding cassette (ABC) transporters (Fodale et al., 2011; Kathawala et al., 2015). 
These efflux pumps normally function to export xenobiotics from cells, 
however in the case of cancer cells they remove chemotherapeutic agents. While 
ABC transporters came into existence well before the use of chemotherapy as they 
are found in all domains of life, chemotherapeutic agents are often biological 
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products and consequently are substrates for multiple ABC transporters (Dlugosz 
and Janecka, 2016; Pan et al., 2016; Ween et al., 2015). Due to this, chemoresistance 
often manifests as multidrug resistance, a phenomenon that is characterized by 
resistance to multiple drugs simultaneously (Gillet and Gottesman, 2010). 
Multidrug resistance often renders several classes of chemotherapeutic agents 
ineffective, thereby significantly limiting treatment options. 
ABC transporters comprise a large family of diverse membrane bound 
efflux pumps that use the energy of ATP hydrolysis to actively transport 
substrates across membranes (Ambudkar et al., 2003). There are currently 48 
known in humans, and the family is subdivided into seven groups based on 
structure (ABCA, B, C, D, E, F, and G) (Dean et al., 2001). ABC transporters are 
generally dimers that consist of two nucleotide binding domains and several 
membrane spanning regions that form a channel in the membrane (Figure 1-8) 
(Linton and Higgins, 2007). Up to two ATP molecules are needed for efflux of one 
substrate molecule, therefore the activity of ABC transporters is highly energy 
demanding (Linton and Higgins, 2007; Patzlaff et al., 2003; Poolman et al., 2005). 
The role of metabolism in the function of ABC transporters is a later focus of this 







Figure 1-8. Structure of the murine ABC transporter ABCB1 
Protein Data Bank ID: 3G5U (Aller et al., 2009). 
 
The first family member discovered was ABCB1, which is also known as 
P-glycoprotein 1 (P-gp) and multidrug resistance protein 1 (MRP1), while other 
notable examples commonly involved in chemoresistance are ABCG2 and ABCC1 
(Allikmets et al., 1998; Cole et al., 1992; Doyle et al., 1998; Miyake et al., 1999; 
Roninson et al., 1984; Ueda et al., 1987). Despite the correlation of ABC transporter 
expression and the development of chemoresistance, there are currently no 
approved therapies directly targeting these efflux pumps. All three generations of 
inhibitors that have been tested in clinical trials have failed to show efficacy, with 
the majority of failures due to off target effects and toxicity (Robey et al., 2018). In 
addition to these pharmacological effects, it has been shown that genetic variation 
in ABC transporters, specifically shown for ABCB1, can affect the outcome of 
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treatment (Chaturvedi et al., 2013; Reed and Parissenti, 2011; Tulsyan et al., 2016). 
Therefore, novel therapies for inhibiting ABC transporter function represent a 
significant medical need in the treatment of chemoresistance. Later in this 
dissertation it will be shown that reducing mitochondrial respiration in cancer 
cells can effectively reverse ABC transporter mediated chemoresistance, a finding 
that may lead to the development of novel metabolism-based therapies 
(CHAPTER 3). 
Surgery is also used in the treatment of cancer. While many solid tumors 
can be physically removed, not all cancers are treatable by this method due to the 
extensive normal tissue damage that would occur during their removal (e.g., brain 
cancers). Surgery can also be combined with chemotherapy to increase efficacy. 
Chemotherapy administered prior to surgery is known as neoadjuvant therapy 
and has the goal of shrinking a tumor for more efficient removal and to allow for 
less normal tissue damage. Administration after surgery is known as adjuvant 
therapy and targets cancer cells that were not removed or those that may have not 
been detected during screening assays. The primary goal of adjuvant therapy is to 
lessen the risk of relapse. 
Radiation therapy (also known as radiotherapy) is also used to treat cancer 
and has the goal of inducing sufficient DNA damage such that cell death occurs. 
Rapidly dividing cells are the most sensitive to radiation treatment, however 
normal tissue is also affected. External beam radiation is used for many types of 
cancer and is a localized treatment that directs high energy beams of photons, 
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protons, or electrons to the site of a tumor. In contrast, internal radiation is the 
administration of radioactive nuclides into the body. This can occur via systemic 
administration or as brachytherapy where a sealed radiation source is implanted 
near the tumor. 
While chemotherapy, radiotherapy, and surgery have been used and 
refined for decades, there is still a need for new types of therapy as many patients 
do not respond to these treatments. The latest advances in cancer treatment are 
based on immunotherapy, which employs the tools of the immune system to treat 
cancer. One strategy is through the use of monoclonal antibodies that target cells 
of the immune system (Apetoh et al., 2015; Wargo et al., 2015). As described later 
(§3.2), mechanisms exist that negatively regulate immune responses. These can be 
exploited by cancer cells, thereby downmodulating immune responses and 
protecting tumor cells from clearance. These regulatory mechanisms are known as 
checkpoint inhibitors, and a notable example is programmed cell death protein 1 
(PD-1) ligand (PD-1L), which blocks T cell immunity by engaging PD-1 on T cells 
(Sharpe and Pauken, 2018). Blocking antibodies (e.g., pembrolizumab) can 
effectively prevent this interaction and have been shown to effectively improve 
treatment outcomes. In addition, bispecific antibodies have been generated that 
target antigens on cancer cells and immune cells simultaneously, increasing the 
likelihood of their interaction (e.g., catumaxomab) (Brinkmann and Kontermann, 
2017; Kontermann and Brinkmann, 2015). 
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In addition, immune cells from patients can be genetically altered ex vivo to 
improve their cancer immunity function and then administered back to the 
patient. A notable example is the addition of a chimeric antigen receptor to T cells, 
which was recently approved for the treatment of certain types of leukemia. The 
engineered cells, known as CAR-T cells, are induced to express a TCR/antibody 
chimera that allows for specific targeting of cancer cells (Kochenderfer et al., 2010). 
Cellular immunotherapy is currently an intense area of research and numerous 
clinical trials are ongoing. 
2.2. Tumor metabolism 
There are six acquired capabilities of cancer that have been described as the 
“hallmarks” of cancer (Hanahan and Weinberg, 2000). These characteristics are 
common to all cancers, and their acquisition is facilitated by the inherent genomic 
instability and genetic diversity of cancer cells (Figure 1-9). As such, these 
hallmarks have been targets of intense research for decades. This paradigm was 
recently revisited, and alterations to cellular energetics was proposed as an 
“emerging hallmark” of cancer (Hanahan and Weinberg, 2011). It has since been 
demonstrated that dysregulated metabolism is not just a hallmark of cancer, but it 







Figure 1-9. Biological hallmarks of cancer cells 
Adapted from Hanahan and Weinberg (2011). 
 
The metabolism of cells has been studied for over a century, and discoveries 
of its role in cancer were pioneered by Otto Warburg in the early 1920s (Warburg 
et al., 1927). Under normal oxygen conditions (normoxia), mammalian cells 
typically convert pyruvate derived from glycolysis to acetyl-CoA for further 
oxidation in mitochondria. However, the reduction of pyruvate to lactate and the 
corresponding oxidation of NADH to NAD+ can also occur under normoxic 
conditions and is often detected in rapidly dividing cells. Warburg noted that even 
in conditions where oxygen concentrations were sufficient for oxidation to occur, 
glucose was still fermented to lactate (Warburg et al., 1927). This metabolic state 
was later termed aerobic glycolysis and is generally known as the Warburg effect.  
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The altered metabolism of cancer cells serves to promote anabolic processes 
(Liberti and Locasale, 2016; Vander Heiden et al., 2009). While glycolysis is 
generally considered a catabolic pathway, it produces metabolic intermediates 
that support the biosynthesis needed for cell growth and proliferation. A number 
of signaling and transcription factors have been shown to induce aerobic 
glycolysis in cancer (Figure 1-10). A notable example is the well-known tumor 
suppressor p53, which is commonly mutated in cancer cells (Ozaki and 
Nakagawara, 2011). While most famous for its role in DNA repair, p53 also 
negatively regulates flux through glycolysis (Zhang et al., 2014). Activation of 
phosphatidylinositol-3 kinase (PI3K) also plays a major role in upregulating 
glycolysis through regulation of the downstream modulators protein kinase B 
(Akt) and the mammalian target of rapamycin complex (mTORC) (DeBerardinis 
and Chandel, 2016). The combined effects of these and other regulators leads to an 







Figure 1-10. Signaling pathways regulating cancer metabolism. 
Adapted from DeBerardinis and Chandel (2016).  
 
The abnormal accumulation of some metabolic intermediates can have a 
significant effect on the metabolism and growth of tumor cells. Termed 
oncometabolites, these intermediates can alter DNA and histone methylation in 
ways that promote tumor growth and progression (Sciacovelli and Frezza, 2016; 
Yang et al., 2013). A notable example is D-2-hydroxyglutarate, which has been 
shown to have substantial impacts on the epigenetic landscape of cancer cells 
(Figure 1-11). In addition, common products of mitochondrial respiration (e.g., 
acetyl-CoA, a-ketoglutarate) have also been shown to affect epigenetic markers of 
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Figure 1-11. Biological changes induced by D-2-hydroxyglurate 
Adapted from Yang et al. (2013). 
 
Several changes in mitochondrial metabolism in cancer have been shown 
to promote cancer progression (Wallace, 2012; Zong et al., 2016). Mutations in key 
enzymes of the TCA cycle, including succinate dehydrogenase (Complex II), lead 
to increased levels of intermediates (e.g., succinate, fumarate) that serve as 
feedback inhibitors and promote aerobic glycolysis (Kurelac et al., 2011). 
Activation of the MYC pathway promotes glutaminolysis, which provides a 
supplemental carbon source to the TCA cycle (a process known as anaplerosis) in 
order to produce citrate and support fatty acid synthesis (DeBerardinis et al., 2008). 
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In addition, it has been shown that reduced Ca2+ flux into mitochondria occurs in 
cancer, which has been proposed to play a role in preventing apoptosis (Wallace, 
2012). These examples, along with others not mentioned, all promote 
tumorigenesis and cancer progression via alterations to mitochondrial function. 
Additionally, the metabolism of cancer cells serves not only to promote 
tumor development, but it can also modulate immune responses. Due to the high 
utilization of glucose, cancer cell metabolism results in “deserts” of low glucose in 
the tumor microenvironment that effectively starve tumor infiltrating 
lymphocytes (Lyssiotis and Kimmelman, 2017). Furthermore, waste products of 
cancer metabolism can alter immune responses as it has been shown that lactate 
excreted by cancer cells negatively affects the glycolytic activity of T cells, which 
suppresses cytotoxic T cell function (Fischer et al., 2007). 
 
3. Overview of the immune system 
An important characteristic of life is the ability to discern between what 
components constitute the body and those of other organisms (self versus nonself). 
The need to protect the self from nonself threats led to the evolution of the immune 
system, which is a complex suite of tissues, cells, and molecules that defend an 
organism from disease. The human immune system is capable of detecting and 
eradicating a wide variety of pathogens, including many different types of viruses, 
bacteria, parasites, and fungi. It is also capable of neutralizing internal threats, 
such as eliminating cancerous cells and tumors. 
 
31 
The complex responses of the immune system are heavily regulated to 
prevent autoimmunity, which occurs when the immune system attacks the normal 
cells and tissues of the body. In addition, allergic responses to normally harmless 
substances can result in severe, life-threatening conditions (e.g., anaphylaxis). 
Thus, a balance must be maintained such that immune responses occur while 
damaging effects to the body are limited. 
The human immune system can be broadly separated into two major arms, 
the innate and adaptive immune systems. The immune system can also be further 
divided into humoral immunity, which is due to the immune effector functions of 
proteins and other soluble components (e.g., the complement system and 
antibodies), and cell mediated immunity, which is immunity due to the actions of 






Figure 1-12. Mediators of the immune system 
Adapted from Dranoff (2004). 
 
3.1. Innate immunity 
The innate immune system is comprised of physical and chemical barriers, 
proteins such as the complement system and inflammatory mediators, and innate 
immune cells. Innate immunity is fast-acting and is often the first to encounter and 
respond to an invader. In addition to pathogens, it is also activated by endogenous 
signals from damaged or stressed cells. 
Several barriers exist that separate or differentiate the body into different 
compartments, and innate immunity is crucial for their protection (Owen et al., 
2013). Physical barriers are present where the body encounters the environment. 
These barriers are generally lined with epithelial cells that are protected by a layer 
of mucus, which is a thick secretion of glycoproteins, antimicrobial peptides, 
 
33 
antibodies, and other factors. This is known as a mucosal layer and protects areas 
such as the linings of the lungs and gastrointestinal tract. As living systems require 
constant transport of nutrients and waste products, none of these barriers are 
completely impermeable and are therefore armed with multiple defenses from 
pathogens. 
Chemical barriers are another line of defense against invading pathogens. 
These exist in several forms including broadly acting antibiotics in the form of 
antimicrobial peptides (e.g., b-defensins) and enzymes (e.g., lysozyme). 
Additionally, the pH of the stomach is chemical barrier that acts against ingested 
pathogens. The specific defenses present depend on the nature of the barrier and 
vary by location in the body. 
Innate immune responses to pathogens are generally initiated by the 
engagement of pattern recognition receptors (Brubaker et al., 2015; Takeuchi and 
Akira, 2010). These innate receptors recognize conserved molecular patterns 
known as pathogen associated molecular patterns. A classic example from bacteria 
is lipopolysaccharide (LPS), which activates Toll-like receptor 4 (TLR4) (Park and 
Lee, 2013). Pattern recognition receptors also detect damage associated molecular 
patterns, which are endogenous cues of cellular stress and tissue damage 
(Schaefer, 2014). The release of mitochondria DNA is one such example and is 
recognized by TLR9 (Kumagai et al., 2008). A major effect of signals downstream 
of TLR engagement is the activation of the inflammasome, which is a multi-
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subunit protein scaffold that facilitates the production and release of inflammatory 
mediators (e.g., IL-1b) (Broz and Dixit, 2016). 
The induction of an acute inflammatory response is the first line of defense 
when the innate immune system is activated (Owen et al., 2013). Acute 
inflammation is characterized by five classic symptoms - heat, pain, redness, 
swelling, and loss of function. It can be caused by responses to pathogens, but it 
can also manifest after an injury that results in tissue damage. These responses are 
initiated by the release of inflammatory mediators that activate downstream 
signaling cascades. Proinflammatory cytokines such as IL-1, IL-6, and TNF are key 
components of the inflammatory cascade. A subset of cytokines known as 
chemokines are also released and function to recruit other immune cells to the site 
of infection or injury. Whether from pathogens or tissue damage, the responses 
initiated are facilitated by innate immune cells. 
The most abundant cells of the innate immune system are macrophages, 
neutrophils, natural killer cells, and dendritic cells. When a pathogen enters the 
body, it is typically first engaged by tissue resident macrophages (Davies et al., 
2013). These cells serve as “vacuum cleaners” for the body as they endocytose and 
break down invading microbes and debris in a process known as phagocytosis. 
Macrophages also release cytokines and other mediators that direct and further 
activate immune responses (e.g., IL-1b, TNF). Additionally, macrophages can 
serve as antigen presenting cells to directly activate the adaptive immune system.  
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Macrophages are found throughout the body and exist in two major 
phenotypes – classic (M1) and alternative (M2) macrophages (Shapouri-
Moghaddam et al., 2018). M1 macrophages are proinflammatory cells that secrete 
inflammatory cytokines (e.g., IL-1b, IFNg). These macrophages are highly 
phagocytic and effectively clear bacteria and cell debris. In contrast, M2 
macrophages are anti-inflammatory and serve roles in dampening immune 
responses and in wound healing. Most tissue resident macrophages are of the M2 
phenotype, however the molecular mechanisms that induce their differentiation 
are not clear.  
Neutrophils are also phagocytic cells, but they generally reside in the blood, 
bone marrow, or vascular bed until activated (Kolaczkowska and Kubes, 2013). 
Neutrophils enter the tissue at the site of inflammation via a process called 
chemotaxis in response to chemokines released during the inflammatory response 
(e.g., IL-8). In addition to phagocytosis, neutrophils eliminate pathogens by 
releasing granules filled with antimicrobial peptides and enzymes (e.g., defensins, 
lysozyme) in a process known as degranulation. They can also release neutrophil 
extracellular traps (NETs), which are primarily composed of DNA and effectively 
bind and trap pathogens (Papayannopoulos, 2018). Activation and release of NETs 
occurs by NETosis, which is a specialized form of programmed cell death 
(Zawrotniak and Rapala-Kozik, 2013). 
Natural killer cells are cytotoxic lymphocytes that are critical for immunity 
to intracellular bacteria and viruses (Vivier et al., 2008). Unlike extracellular 
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bacteria and parasites, intracellular pathogens are not easily engaged by immune 
cells. Therefore, the most effective method of clearance is to induce death of the 
infected cell. NK cells recognize changes induced by infection – the so called state 
of “altered self” – and induce programmed cell death in the target cell. One 
mechanism employed is through the detection of decreased cell surface expression 
of major histocompatibility complex (MHC) molecules by infected cells, which is 
often induced by viral infections. Nearly all nucleated cells express MHC 
molecules, and NK cells are sensitive to differences in their expression. NK cells 
are also crucial for the elimination of transformed cells and tumors. NK cells 
induce cell death by releasing granules containing death mediators (e.g., perforin, 
granzymes). NK cells also secrete cytokines that further direct the immune system 
(e.g., recruitment of macrophages to phagocytose dead cell debris). 
Dendritic cells are phagocytic antigen presenting cells that reside in tissues 
along with tissue resident macrophages (Mildner and Jung, 2014; Sato and Fujita, 
2007). They function to processes pathogens and present antigens to the adaptive 
immune system. As such, they serve as messengers of the innate immune system 
that activate adaptive immune responses. Dendritic cells migrate from the site of 
infection to the lymph nodes, where they present whole and processed antigen to 
the cells of the adaptive immune system. Dendritic cells also secrete cytokines that 
direct and further activate immune responses (e.g., TNF, IL-10, IL-12). 
Other less common cells of the innate immune system are eosinophils, 
basophils, and mast cells (Rosenberg et al., 2013; Siracusa et al., 2010; Wernersson 
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and Pejler, 2014). These, along with neutrophils, are known as granulocytes due 
the abundance of granules containing antimicrobial factors in their cytoplasm. 
Unlike neutrophils, however, eosinophils, basophils, and mast cells are involved 
in allergic responses and are important for the clearance of parasites. Due to the 
decreased parasite burdens found in the developed world, these cells are mainly 
associated with excessive allergic responses and inflammatory diseases (e.g., 
asthma) and are the key mediators of extreme allergic response symptoms (e.g., 
anaphylaxis) (Fulkerson and Rothenberg, 2013; Sharma and Bayry, 2015; 
Voehringer, 2013). 
3.1.1. Complement system 
In addition to the cell mediated immunity described above, the innate 
immune system also has humoral components. A notable example is the 
complement system, which is comprised of serum proteins that are activated in a 
catalytic cascade that ultimately leads to the breakdown of the membrane integrity 
of invading pathogens (Ricklin et al., 2010). Complement components can also 
induce the opsonization of pathogens, thereby enhancing innate immune cell 
function. Complement activation also releases proinflammatory mediators that 
direct and recruit other components of the immune system. Complement 
components are synthesized in the liver as inactive precursors that can be 
activated by three distinct pathways, all of which lead to the formation of the 
membrane attack complex (MAC) on the surface of an invading pathogen. The 
 
38 
MAC leads to the release of cytosolic components and eventual death of the 
invading cell. 
3.2. Adaptive immunity 
While the innate immune system is generally effective against most threats, 
the receptors used to detect pathogens are static and limited in diversity. Due to 
the constant evolution of pathogens, they can adapt such that detection by the 
innate immune system is avoided or rendered less effective. To combat this, jawed 
vertebrates evolved the adaptive immune system. Adaptive immune responses 
are mediated by T and B cells and are highly specific due to the diverse nature of 
their antigen receptors. T cell receptors (TCRs) and B cell receptors (BCRs) are 
produced by a process known as V(D)J recombination that through genetic 
rearrangement forms enormous numbers of unique receptors (Figure 1-13) (Schatz 
and Ji, 2011). In this way, the adaptive immune system can adapt to changes in 







Figure 1-13. T cell receptor gene rearrangement 
Adapted from Turner et al. (2006). 
 
3.2.1. T cells 
T cells are the facilitators of cell-mediated immunity within the adaptive 
immune system. They develop from common lymphoid precursors derived from 
the bone marrow, and the majority mature in the thymus (Owen et al., 2013). There 
are several subsets of T cells, however all are characterized by the presence of a 
T cell receptor (TCR) on the cell surface. TCRs recognize peptide antigens 
presented on MHC molecules and are highly diverse in nature. There are two 
major types of T cells, which are defined by the expression of the glycoproteins 
CD4 or CD8. These cell surface molecules enhance the binding of the TCR to MHC 
molecules and also functionally differentiate T cells into the major subsets. CD4+ 
T cells are generally known as helper T cells as they direct the immune responses 
of other cells, and their TCR recognizes peptides presented by MHC class II 
molecules. CD8+ T cells are distinguished by cytotoxic activity and are restricted 
to peptides presented by MHC class I molecules. 
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TCRs are heterodimers formed by the association of two peptide chains 
(Reinherz et al., 1999). The most common type of T cell bears a TCR formed by the 
association of a and b chains. These are known as ab T cells and can effectively 
respond to all pathogens. The other type of TCR is a combination of g and d chains, 
which marks the less understood gd T cells that are often found in mucosal linings 
(e.g., intestinal barriers) (Chien et al., 2014; Vantourout and Hayday, 2013). 
The development of T cells begins in the bone marrow and is completed in 
the thymus (Figure 1-14). Common lymphoid progenitor cells destined to become 
T cells migrate from the bone marrow to the thymus where they differentiate into 
double negative (DN) thymocytes, defined by a lack of both CD4 and CD8 
expression. During the DN stages of development thymocytes proliferate, lose the 
potential to become B cells, and rearrange the TCRb chain genes. They then 
transition to the double positive (DP) stage, characterized by expression of both 
CD4 and CD8 and formation of the TCRa chain. 
The binding of the complete TCR to self peptide expressing MHC molecules 
is then tested in a process known as positive selection (Klein et al., 2009). If the TCR 
does not bind any MHC molecules, the thymocyte will die by apoptosis. Proper 
engagement of an MHC molecule will activate a signaling cascade through the 
TCR that induces lineage commitment and the transition to the single positive (SP) 
stage. Mature T cells only express CD8 or CD4, and this depends on whether their 
TCR engaged MHC class I or II molecules, respectively. Thymocytes also undergo 
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negative selection in the SP stage, a process which is vital to preventing 
autoimmunity (Klein et al., 2014). If a TCR strongly engages the MHC molecule, it 
has a high chance of being autoreactive (specific for self peptides). Therefore, 






Figure 1-14. Stages of T cell development 




MHC molecules are cell surface proteins that are essential for adaptive 
immunity (Owen et al., 2013). MHC molecules are broadly characterized into two 
major classes. MHC class I are expressed by nearly all cells (including platelets), 
however red blood cells are a notable exception. MHC class I molecules present 
self-derived peptides and mainly function in immunity to intracellular pathogens 
(e.g., viruses) and transformed cells. MHC class II are expressed by professional 
antigen presenting cells (APCs; comprised of dendritic cells, macrophages, and B 
cells) and present peptides derived from processed antigens. Professional APCs 
can also present processed antigen on MHC class I via a process known as cross 
presentation. 
After maturation in the thymus, T cells enter the circulation as naïve cells. 
In this state, they are relatively quiescent and exhibit low levels of DNA 
transcription and protein translation. They can be found in the blood and in 
tissues, however most are found in the secondary lymphoid organs (e.g., lymph 
nodes, spleen). Due to the enormous energy demands of an immune response, 
T cells remain in the naïve state until activated. 
T cell activation requires engagement of the TCR with cognate peptide 
presented by an MHC molecule, however the TCR itself does not contain a 
signaling component. Signal transduction requires the T cell coreceptor CD3 and 
the z chain (CD247) (Gaud et al., 2018; Smith-Garvin et al., 2009). Complete 
activation of naïve T cells also requires signaling from co-stimulatory molecules 
(Gaud et al., 2018; Smith-Garvin et al., 2009). The is primarily due to CD28, however 
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other molecules such as inducible costimulatory (ICOS) can serve this function 
(Chen and Flies, 2013). In addition, there are regulatory molecules such as 
cytotoxic T lymphocyte associated protein 4 (CTLA4) and programmed cell death 






Figure 1-15. Regulation of T cell activation 
Adapted from Chen and Flies (2013). 
 
3.2.1.1. CD4+ T cells 
When naïve CD4+ T cells become activated, they differentiate into helper 
T cells (Owen et al., 2013). These cells direct the immune responses of other 
leukocytes and play a central role in the progression, strength, restriction, and 
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conclusion of immune responses. Helper T cells perform this function by 
producing cytokines that act on other immune cells and by fully activating B cells 
to produce antibodies and induce class switching. Helper T cells are activated by 
professional antigen presenting cells, and they differentiate into several types with 
specialized effector functions depending on the cytokine environment and nature 





Figure 1-16. Helper T cell subsets 
Adapted from O'Shea and Paul (2010). 
 
The majority of activated CD4+ T cells are classified at type 1 helper (TH1) 
or TH2 effector cells (Mosmann et al., 1986; Romagnani, 1991). Immunity driven by 
TH1 cells is most effective against intracellular pathogens. These cells are 
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characterized by high production of IFNg and expression of the transcription 
factors STAT4 and T-bet (Farrar et al., 2002; Luckheeram et al., 2012; Romagnani, 
1994). In contrast, TH2 cells are most effective against extracellular pathogens 
(Walker and McKenzie, 2018). They are induced by IL-4 and IL-6 signaling and 
predominantly produce cytokines involved in allergic responses (e.g., IL-4, IL-5, 
IL-13) (Luckheeram et al., 2012; Romagnani, 1994). TH2 cells activate a number of 
innate immune cells including eosinophils, basophils, and mast cells as well as IgE 
and IgG antibody producing B cells (Annunziato et al., 2015). 
Follicular B helper T (TFH) cells are a subset of helper T cells that are 
localized to the periphery of B cell follicles in secondary lymphoid organs (Crotty, 
2014). TFH cells mediate the generation of germinal centers, in which B cells 
proliferate, differentiate, and undergo antibody class switching and affinity 
maturation. TFH cells are therefore crucial to the production of antibodies that 
effectively target pathogens. The cytokine IL-21 and the immune checkpoint 
protein ICOS induce TFH cell differentiation (Luckheeram et al., 2012).  
Another subset is comprised of T helper 17 (TH17) cells, which are 
proinflammatory cells that produce significant amounts of IL-17 (Acosta-
Rodriguez et al., 2007; Annunziato et al., 2007; Harrington et al., 2005). These cells 
are important mediators of immune responses at mucosal sites and are enriched 
in the linings of the lungs and intestinal tract. The differentiation of TH17 cells is 
induced by transforming growth factor b (TGFb) and IL-6 signaling and the 
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transcription factors STAT3 and RORgt (Luckheeram et al., 2012; Yang et al., 2007). 
Excessive inflammation caused by TH17 cells has been shown to exacerbate 
diseases (e.g., psoriasis) (Tesmer et al., 2008), which may be due (at least in part) to 
the signals that induce TH17 differentiation competing with those that induce 
regulatory T (Treg) cells. 
Treg cells are immunosuppressive T cells that are important for the 
maintenance of tolerance and the prevention of autoimmunity. The transcription 
factor forkhead box P3 (FOXP3) directs the differentiation of Treg cells, expression 
of which begins in the thymus during the later stages of T cells development 
(Luckheeram et al., 2012; Ohkura et al., 2013). The TCR of Treg cells is often specific 
to self peptides, however activation of these cells leads to dampened immune 
responses (Josefowicz et al., 2012). Treg cells restrict immune responses by 
producing anti-inflammatory cytokines (e.g., IL-10, IL-35) and by releasing 
cytolytic mediators (e.g., granzyme B) that induce apoptosis of effector immune 
cells (Josefowicz et al., 2012). Treg cells also alter the cytokine environment by 
rapidly absorbing cytokines released by other cells (Pandiyan et al., 2007). Defects 
in the number and/or function of Treg cells have been implicated in the pathology 
of several diseases (e.g., cancer, autoimmunity), however the exact mechanisms 
involved are unclear. 
In addition to these commonly known subsets, other T helper cell subsets 
have been reported that are less understood. A subset characterized by high 
production of IL-9 was recently described and termed T helper 9 (TH9) cells 
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(Kaplan et al., 2015). This subset currently lacks specific biomarkers, but TH9 cells 
are thought to be involved in allergy responses. Similarly, T helper 22 (TH22) cells 
are characterized by substantial production of IL-22. Originally thought to related 
to TH17 cells, TH22 cells have also been shown to produce IL-13 and granzymes 
and are implicated in the pathology of asthma and atopic dermatitis (Plank et al., 
2017). In addition, functionally unique CD4+ T cells with cytotoxic activity have 
been described (Takeuchi and Saito, 2017), contrasting with the dogma of 
immunology that only CD8+ T cells have cytolytic activity. 
3.2.1.2. CD8+ T cells 
The other major class of effector T cells are cytotoxic T (TC) cells, which 
develop from naïve CD8+ T cells (Owen et al., 2013). Similar to NK cells, TC cells 
provide immunity to intracellular pathogens and eliminate transformed cells 
through the production and release of cytolytic granules. A key difference from 
NK cells, however, is that TC cells are specifically activated as their TCR is 
restricted to a unique peptide presented on an MHC class I molecule. 
The main function of TC cells is to induce cell death. Engagement of their 
TCR with an infected or transformed cell triggers the release of the components of 
cytotoxic granules (mainly perforin and granzymes), which induce programmed 
cell death in the target cell. TC cells can also induce cell death through expression 
of other effector proteins such as first apoptosis signal receptor (Fas) ligand (FasL), 
which binds to Fas expressed on target cells (Owen et al., 2013). 
 
48 
Another major function of TC is to produce cytokines, including significant 
amounts of IFNg. There are currently three defined subtypes of cytotoxic T cells 
based on their cytokine secretion profile (Annunziato et al., 2015; Kondo et al., 2009; 
Mosmann et al., 1995). T cytotoxic 1 (TC1) cells are the most common type of 
effector cytotoxic cell and produce significant amounts of IFNg (Mosmann et al., 
1995). The transcription factors T-bet and Eomes are critical for both their 
production of IFNg and cytolytic activity (Glimcher et al., 2004). Similar to TH2 
cells, T cytotoxic 2 (TC2) cells produce IL-4, IL-5, and IL-13 and are involved in 
immunity to parasites and in allergy responses (Mosmann et al., 1995). Lastly, T 
cytotoxic 17 (TC17) cells are proinflammatory cells characterized by production of 
IL-17 (Kondo et al., 2009). Activation of STAT3 and signaling through RORgt are 
required for their differentiation (Annunziato et al., 2015). 
In addition to these subsets, a functionally unique type of TC cells was 
recently described. In response to IL-6, a subset of TC cells can produce IL-21 
during an influenza infection, which is sufficient to support B cell antibody 
production and class switching (Yang et al., 2016). These “helper” cytotoxic T cells, 
along with the “cytotoxic” helper T cells described previously (§3.2.1.1) are 




3.2.2. B cells 
B cells function to produce and secrete antibodies (Owen et al., 2013). B cells 
mainly reside in the lymph nodes and spleen and are activated through direct 
interaction with antigens from pathogens, which engage the B cell receptor on the 
cell membrane. B cells also function as antigen presenting cells, and, along with 
dendritic cells and activated macrophages, are known as professional antigen 
presenting cells as they express MHC class II molecules and can effectively activate 
CD4+ T cells. B cells also secrete cytokines and chemokines when activated. Like T 
cells, B cells also develop from common lymphoid progenitor cells, however they 
develop and mature in the bone marrow. 
B cells are characterized by the cell surface expression of the B cell receptor 
(BCR), which, like the TCR, is formed through the process of V(D)J recombination 
(Schatz and Ji, 2011). Naïve B cells are activated by binding of the cognate ligand 
to the BCR. This leads to endocytosis of the antigen, which is then processed and 
presented to helper T cells via MHC class II molecules. B cells that receive T cell 
help undergo a rapid proliferation and begin secreting antibodies, which are 
soluble versions of the BCR.  
There are five major types of antibodies that can be produced by B cells – 
immunoglobulin M (IgM), IgD, IgA, IgG, and IgE (Owen et al., 2013). The BCR of 
naïve B cells is in the form of IgM or IgD. To produce the other types of antibodies, 
germinal center B cells undergo a process known as class switching (Stavnezer et 
al., 2008). The specific type of antibody induced depends on the cytokine 
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environment and the type of pathogen that initiated the immune response. 
Additionally, antibody specificity for antigen increases over time as B cells 
introduce mutations in antibody genes via somatic hypermutation (Teng and 
Papavasiliou, 2007). B cells that produce higher affinity antibodies preferentially 
receive help from TFH cells, which leads to their selection over time. The combined 
effects of somatic hypermutation and TFH cell selection are known as affinity 
maturation. 
3.3. Immunologic memory 
After the stimulus that initially activated the immune response is 
eliminated, the cells of the immune system undergo a process known as 
contraction during which the majority of the activated leukocytes die (Marrack et 
al., 2010). Unlike innate immune cells, however, some activated T and B cells 
differentiate into long lived memory cells (Owen et al., 2013). These cells serve as 
sentinels in the event of another infection with the same pathogen and can persist 
for decades. Due to the individual nature of the pathogens and other threats that 
each organism experiences, the memory cell repertoire of every individual is 
unique. Unlike a primary immune response, activation of memory cells occurs 
quickly, is less dependent on costimulatory molecules, and leads to rapid 
protection from secondary infections. 
Both CD4+ and CD8+ memory T cells form and have been classified into 
three subsets (Mahnke et al., 2013; Mueller et al., 2013; Sallusto et al., 1999). Central 
 
51 
memory T (TCM) cells circulate between the blood and secondary lymphoid organs 
(e.g., spleen, lymph nodes). TCM cells exhibit self-renewal, have a large proliferative 
capacity, can differentiate into effector cells, and produce significant amounts of 
IL-2. Effector memory T (TEM) cells can be found migrating between the blood and 
nonlymphoid peripheral tissues. TEM cells have a lower proliferative capacity 
compared to TCM cells but are potent cytotoxic cells that can rapidly produce 
substantial amounts of effector cytokines (e.g., IFNg). Tissue resident memory 
(TRM) cells do not circulate and therefore permanently remain in the tissue in 
which they develop (Gebhardt et al., 2009; Masopust et al., 2010). These cells serve 
as immediate responders to invading pathogens and are especially effective 
against recurrent, localized challenges from the same pathogen. 
In contrast to these “classically” derived memory cells that develop after 
antigen exposure, a subset of memory cells that are antigen naïve have been 
recently described. These cells, known as virtual memory T (TVM) cells (White et 
al., 2017) have been shown to comprise a substantial portion of the pool of all CD8+ 
T cells in naïve mice (15 – 20 %) (Dobber et al., 1992; Le Campion et al., 2002). 
Instead of foreign antigen, it is thought that cytokine signaling leads to their 
development (Haluszczak et al., 2009). Future studies are needed to characterize 




In recent years, the metabolism of immune cells has become an intense area 
of research. Unlike the majority of cells in the body, those of the immune system 
experience rapid and drastic changes in nutrient availability and oxygen 
concentrations during the normal course of their function. Accordingly, the 
metabolic state of immune cells has been shown to directly correlate with immune 





Figure 1-17. Metabolism of T cells 




Naïve and certain memory cells (e.g., TCM cells) are commonly found in 
relatively resource rich compartments such as the blood, spleen, and lymph nodes 
(McNamee et al., 2013). In contrast, activated effector cells that traffic to the 
nutrient and oxygen poor environments of infected and/or inflamed tissues 
experience extracellular signals and cues are exceedingly different from those of 
nutrient replete compartments (Eltzschig and Carmeliet, 2011). As such, the 
metabolic demands of effector cells are significantly different from those of resting 
cells. In order to survive and function in these vastly different niches, cells of the 
immune system have the ability to substantially reprogram their metabolism 
(Buck et al., 2015; Pearce et al., 2013).  
Naïve and resting memory T cells are small and relatively quiescent, 
however they require ATP for the cytoskeletal rearrangements necessary to 
navigate the blood and lymphatic vessels. To maintain this state, they primarily 
utilize oxidative phosphorylation fueled by glucose and fatty acids to produce 
ATP (van der Windt and Pearce, 2012; Wang et al., 2011). In contrast, effector T 
cells are large, highly proliferative, and secrete substantial amounts of cytokines 
and other effector molecules. Since glycolytic pathways are more supportive of 







Figure 1-18. Metabolic changes T cells over time 
Adapted from Pearce et al. (2013). 
 
Signaling pathways activated via engagement of the TCR, costimulatory 
molecules, and cytokines initiate the upregulation of glucose and amino acid 
transporters (Carr et al., 2010; Frauwirth et al., 2002; Sinclair et al., 2013) and 
promote the metabolic switch from OXPHOS to aerobic metabolism (Frauwirth et 
al., 2002). For example, CD28 ligation leads to increased PI3K activity, which 
activates Akt and mTORC. The combined effect of these integrated promotes the 
differentiation and proliferation of effector T cells (Buck et al., 2015; Delgoffe et al., 
2011; Pollizzi et al., 2015; Pollizzi and Powell, 2015). In addition, metabolic changes 
induced by these pathways during activation have lasting effects as memory cell 
development requires CD28 signaling during the initial stages of naïve T cell 
activation (Klein Geltink et al., 2017).  
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Consistent with the switch to aerobic glycolysis, b-oxidation of fatty acids 
is downregulated during T cell activation (Wang et al., 2011). While effector cells 
primarily utilize aerobic glycolysis, OXPHOS is still utilized by these cells (Wang 
et al., 2011). However, the paradigm of effector T cells primarily using aerobic 
glycolysis is not universal as Treg cells have been shown to depend on b-oxidation 
and OXPHOS (Michalek et al., 2011). Consistent with this, mTORC signaling 
represses FoxP3+ Treg cell differentiation, while the conventional effector subsets 
(TH1, TH2, TH17)  are promoted (Delgoffe et al., 2009; Kopf et al., 2007). In addition, 
while the metabolism of TFH cells is currently unclear, the transcription factor Bcl6 
(which defines the lineage) suppresses glycolysis (Oestreich et al., 2014), indicating 
that these cells may also rely more on OXPHOS. 
As effector cells undergo contraction and become memory T cells, their 
metabolism undergoes additional reprogramming. Like naïve cells, memory T 
cells primarily rely on OXPHOS for their metabolic needs. However, they have 
increased mitochondrial mass, which instills these cells with a significantly higher 
spare respiratory capacity (van der Windt et al., 2012). The cytokine IL-15, which 
is critical to the differentiation of memory T cells, is important for the generation 
of this phenotype (van der Windt et al., 2012). It has also been shown that memory 
T cells heavily rely on the oxidation of fatty acids, which they produce and store 
in membrane bound compartments in the cytosol (Araki et al., 2009; O'Sullivan et 
al., 2014; Pearce et al., 2009; van der Windt and Pearce, 2012). 
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The morphology of mitochondrial networks has also been shown to vary 
between T cell activation states, and the patterns are consistent with their 
metabolic phenotypes. In effector T cells, mitochondria exhibit a punctate, fissed 
morphology, while those of memory T cells appear as a fused and connected 
network (Buck et al., 2016). Fused mitochondrial networks are thought to promote 
mitochondrial function, including the generation of respiratory supercomplexes 
(Cogliati et al., 2013; Mishra et al., 2014).  
Metabolic changes have also been shown to affect cells of the innate 
immune system (O'Neill and Pearce, 2016). Like activated T cells, M1 macrophages 
heavily rely on aerobic glycolysis. They also exhibit a “broken” TCA cycle, 
whereby succinate and citrate accumulate, and this ultimately facilitates the 
effective secretion of IL-1b (Mills et al., 2017). In contrast, the TCA cycle is fully 
functional in M2 macrophages as they primarily utilize OXPHOS for ATP 
synthesis. In addition, a unique requirement of glycogen as a fuel source for 
dendritic cell activation and effector function was recently described (Thwe and 
Amiel, 2018; Thwe et al., 2017). 
Taken together, these studies indicate that the metabolic state of immune 
cells is adapted to promote effector functions, and more detailed analyses of the 
metabolic requirements of specific effector functions are currently areas of intense 
research. Later in this dissertation, the effects of increased mitochondrial 
respiration on the effector functions of CD8+ T cells in the context of viral 




4. Methylation controlled J protein 
4.1. Discovery 
Methylation controlled J protein (MCJ) was originally discovered as a gene 
expressed in normal ovarian epithelial cells, but little to no expression was 
detected in several ovarian cancer cell lines (Shridhar et al., 2001). MCJ is a small 
protein of ~150 amino acids in length that is encoded by the DNAJC15 gene 
(Kampinga et al., 2009). In humans, the DNAJC15 gene locus spans approximately 
86,000 base pairs on chromosome 13 and encodes a 2792 base pair transcript 
containing 6 exons and 5 introns (Shridhar et al., 2001). The MCJ protein contains 
a short N-terminal sequence (35 amino acids) followed by a single transmembrane 
domain (Hatle et al., 2007; Shridhar et al., 2001). The C-terminus contains a 
canonical J domain, defining MCJ as a member of the large DNAJ family of protein 
co-chaperones (Hatle et al., 2007; Shridhar et al., 2001).  
4.2. Classification 
DNAJ family members (also called J proteins) are homologous to heat shock 
protein 40 (Hsp40) of Escherichia coli. There are currently 49 identified human 
DNAJ proteins that all contain a highly conserved J domain, but their specific 
function is determined by non-conserved domains (e.g., the N-terminus of MCJ) 
(Qiu et al., 2006). The current nomenclature divides DNAJ proteins into three 
subfamilies based on the location of the J domain and the presence of other 
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conserved protein motifs (Kampinga et al., 2009). Type A members contain a J 
domain in the N-terminus, a glycine/phenylalanine rich region, a cysteine rich 
region, and a C-terminus that varies in structure. Type B members also contain an 
N-terminal J domain and a glycine/phenylalanine rich region, but they lack a 
cysteine rich region. Type C members are the most numerous and are defined by 
only having a J domain, which can be present in either the N- or C-terminus. MCJ 
contains a J domain in the C-terminus but does not have a glycine/phenylalanine 
or cysteine rich region, therefore it is a type C DNAJ protein (Hatle et al., 2007; 
Shridhar et al., 2001). 
4.3. Evolutionary history 
MCJ is proposed to have evolved after a gene duplication event involving 
the mitochondrial import inner membrane translocase subunit 14 (TIM14) gene of 
yeast (Hatle et al., 2007), a vital component of the inner membrane translocase in 
mitochondria (Mokranjac et al., 2003). TIM14 is also a DNAJC family member and 
is designated as DNAJC19. In humans and other vertebrates, MCJ and DNAJC19 
are both paralogs of yeast TIM14 that are found in mitochondria. Both have a 
highly conserved J domain in the C-terminus and a predicted transmembrane 
domain, however MCJ also contains a unique N-terminal sequence (Hatle et al., 






Figure 1-19: Comparison of MCJ and DNAJC19 
Non-conversed amino acid residues of DNAJC19 isoforms relative to MCJ are 
indicated by bold lettering and dashes. 
 
To date, there has only been one phylogenetic analysis of the origin of MCJ 
(Hatle et al., 2007). It suggests that MCJ coalesced prior to the divergence of 
ecdysozoans and vertebrates, however MCJ homologs are only detectable in 
extant vertebrate lineages (Hatle et al., 2007). The absence of homologs in other 
animal clades indicates that it was likely lost during the course of their further 
divergence from vertebrates over time (Hatle et al., 2007). Interestingly, the amino 
acid sequence of MCJ is conserved among a diverse number of vertebrate 
populations (Table 1-2), indicating that unknown selective pressure(s) may be 
present. Future studies are needed to clarify the origin and evolutionary history of 










DNAJC15   RVMILNHPDKGGSPYVAAKINEAKDLLETTTKH
DNAJC19 iso 1   RIMLLNHPDKGGSPYIAAKINEAKDLLEGQAKK


























































































































































































































































































4.4. Regulation of DNAJC15 expression 
The expression of MCJ mRNA and protein has been detected in a variety of 
cell types. In primary tissues, high expression of MCJ has been shown in several 
metabolically active tissues (e.g., heart, liver), while other active tissues (e.g., brain, 
skeletal muscle) show substantially less expression (Hatle et al., 2013). MCJ 
expression also significantly varies by cell type, including those that are quite 
similar. For example, naïve CD8+ T cells highly express MCJ, while CD4+ T cells 
do not express MCJ (Hatle et al., 2013). MCJ has also been detected in a number of 
cancer cell types as described below. The mechanisms that promote MCJ 
expression in most tissues and cells are largely unknown, however DNA 
methylation is a known mechanism of silencing expression. 
4.4.1. DNA methylation 
The first report of MCJ identified it as a gene that is negatively regulated by 
DNA methylation (Shridhar et al., 2001). Treatment of ovarian cancer cells with a 
methyltransferase inhibitor resulted in the expression of MCJ mRNA in a dose 
dependent manner, therefore the gene was named methylation controlled J 
protein (Shridhar et al., 2001). The effect of methyltransferase inhibitors resulting 
in increased MCJ expression has also been seen in several cancer cell lines 
including gastric cancer (Mikata et al., 2006), melanoma (Muthusamy et al., 2006), 
and by a different group in ovarian cancer (Menendez et al., 2007), which indicates 
that DNA methylation is likely a common regulatory mechanism. Correlations 
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between increased methylation of DNAJC15 and low to no MCJ expression have 
been reported in brain cancer (Lindsey et al., 2006), breast cancer (Boettcher et al., 
2010), and non-transformed human peripheral blood mononuclear cells (PBMCs) 
(Zimmermann et al., 2016). 
Interestingly, differences have been found for the specific region of the 
DNAJC15 gene that must be methylated in order to silence expression. In ovarian 
cancer cells, reduced MCJ expression correlated with increased methylation of a 
CpG island in exon 1, however expression was independent of the methylation 
status of the promoter (Strathdee et al., 2004). A similar pattern was found in brain 
cancer and melanoma, where methylation within the exon 1 CpG island strongly 
correlated with lower MCJ expression (Lindsey et al., 2006; Muthusamy et al., 
2006). However, an analysis of transcriptomic data of tumors from a large number 
of breast cancer patients showed a strong correlation of increased DNA 
methylation at three sites in the proximal promoter region with decreased MCJ 
expression (Fernandez-Cabezudo et al., 2016). Additionally, reduced acetylation of 
histone markers in both the promoter and exon 1 has been associated with 
increased methylation of the exon 1 CpG island in ovarian cancer, indicating that 
alterations to overall chromatin structure likely play a role in the regulation of MCJ 
expression (Strathdee et al., 2004). Therefore, cell and/or tissue specific differences 
in the methylation status of DNAJC15 contribute to the regulation of MCJ 
expression, at least in cancer cells. 
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It is possible that heterogeneity in DNA methylation within tissues also 
leads to differential MCJ expression. Variability in MCJ expression among the 
tumor cells of breast cancer patients has been reported, however the mechanism 
responsible for this heterogeneity was not addressed (Fernandez-Cabezudo et al., 
2016). Compared to normal kidney tissue, Wilm’s tumors from the same patient 
show hypermethylation of DNAJC15 (Ehrlich et al., 2002). Differences in the 
degree of DNA methylation between grades of ovarian cancer have been shown 
(Houshdaran et al., 2010). Validation of this proposal and whether the regulation 
of MCJ expression by DNA methylation can be extended to nontransformed 
tissues are topics for future studies. 
DNAJC15 methylation has also been shown to vary among individuals and 
exhibits a pattern of heritability. An analysis of twins with Dutch ancestry showed 
that the DNA methylation pattern of DNAJC15 is significantly heritable (Boks et 
al., 2009). This was also seen in a cohort of individuals of Mexican American 
descent (Carless et al., 2013). Lower DNAJC15 methylation rates have been 
reported in the breast tumors of African American versus non-African American 
patients (Conway et al., 2015). In addition, variable expression of MCJ alleles 
between European and African populations has been attributed to a single 
nucleotide polymorphism in exon 1 (Tian et al., 2018). Therefore, the regulation of 




4.4.2. Signaling molecules and transcription factors 
Little is known of regulatory factors that control MCJ expression as there 
have been only a few studies on the signaling molecules and pathways involved. 
The cytokine IL-6 has been shown to downregulate MCJ expression in breast and 
liver cancer cell lines, however the mechanistic connection IL-6 signaling and MCJ 
expression is currently unknown (Hatle et al., 2007; Navasa, Martin-Ruiz, et al., 
2015). IL-6 has been shown to upregulate DNA methyltransferase 1 (DMNT1) 
activity (Li et al., 2012), therefore alterations in DNA methylation may be involved. 
In addition, the cytokine IFN-g reduces MCJ expression in macrophages through 
a mechanism dependent on the transcription factor Ikaros family zinc finger 
protein 1 (Ikaros) (Navasa, Martin-Ruiz, et al., 2015). IFN-g signaling activates 
casein kinase 2 (CK2), which regulates Ikaros activity via phosphorylation 
(Navasa, Martin-Ruiz, et al., 2015). The activation of this pathway may be specific 
to macrophages, however, as no changes in MCJ were detected in a liver cancer 
cell line or primary CD8+ T cells after incubation with IFN-g (Navasa, Martin-Ruiz, 
et al., 2015).  
Ikaros has been shown to regulates the development of several types of 
immune cells, including macrophages, T cells, and B cells (Westman et al., 2002). 
Two potential binding sites for Ikaros have been identified that are upstream of 
the transcriptional start site in the mouse MCJ promoter (Navasa, Martin-Ruiz, et 
al., 2015). Binding of Ikaros to the site proximal to the promoter was confirmed in 
macrophages (Navasa, Martin-Ruiz, et al., 2015) and as shown later in this thesis, 
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in CD8+ T cells (CHAPTER 2). Ikaros directed downregulation of MCJ was also 
shown to be independent of DNA methylation (Navasa, Martin-Ruiz, et al., 2015). 
4.5. Localization to mitochondria 
Initial studies investigating MCJ expression were performed using an 
overexpression system, which led to the conclusion that MCJ localized to the Golgi 
apparatus and other nonidentifiable vesicles (Hatle et al., 2007). It was later 
determined that overexpression of MCJ causes mitochondrial dysfunction and 
swelling that substantially alters mitochondrial morphology (Hatle et al., 2013). 
Several reports have since established that endogenously derived MCJ localizes to 
the mitochondria (Calvo et al., 2016; Hatle et al., 2013; Navasa, Martin, et al., 2015; 
Pagliarini et al., 2008; Schusdziarra et al., 2013). 
The first indication that MCJ is in a mitochondrial compartment was a 
large-scale mitochondrial proteome analysis that detected MCJ in the 
mitochondria of several different tissues (MitoCarta) (Pagliarini et al., 2008). A 
follow up to this report (MitoCarta2.0) confirmed these results (Calvo et al., 2016). 
This finding was also shown in biochemical analyses of murine MCJ in the heart 
and CD8+ T cells (Hatle et al., 2013). The localization of MCJ is not affected by 
cellular transformation as it has also detected in the mitochondria of several cancer 
cell lines (Hatle et al., 2013; Navasa, Martin, et al., 2015; Schusdziarra et al., 2013). 
An in silico analysis of the MCJ amino acid sequence indicated that it does 
not contain any currently known mitochondrial targeting sequences (Schusdziarra 
 
68 
et al., 2013). MCJ is, however, predicted to contain a transmembrane domain, 
indicating that it is an integral membrane protein (Hatle et al., 2007; Schusdziarra 
et al., 2013). Within mitochondria, MCJ localizes to the inner mitochondrial 
membrane (Hatle et al., 2013; Schusdziarra et al., 2013; Sinha et al., 2014), which has 
been shown in both mouse (heart and CD8+ T cells) and human cells (HeLa and 
HEK 293T cells) (Hatle et al., 2013; Schusdziarra et al., 2013; Sinha et al., 2014). MCJ 
contains a single putative transmembrane domain (Hatle et al., 2007; Schusdziarra 
et al., 2013), indicating that the N- and C-termini face opposite sides of the inner 
mitochondrial membrane, however the precise orientation of the termini is 
currently unclear as conflicting results have been published in the literature. 
Using a Hidden Markov model that predicts protein topology, the 
N-terminus of MCJ was predicted to be in an intracellular compartment, while the 
C-terminus was predicted to be in an extracellular compartment (Hatle et al., 2007). 
Therefore based on the results of this prediction algorithm, MCJ is a single pass 
transmembrane protein with its N-terminus in the inner membrane space and C-
terminus in the matrix (Hatle et al., 2007). 
A biochemical analysis of mitochondria and mitoplasts did not agree with 
this prediction (Schusdziarra et al., 2013). Mitoplasts are generated by removing 
the outer mitochondrial membrane, while the inner membrane is left intact. 
Proteinase treatment induced the loss of the N-terminus of MCJ in mitoplasts, 
indicating it resides in the inner membrane space (Schusdziarra et al., 2013). A 
major limitation, however, is that untreated mitoplasts were not shown or 
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indicated, therefore it cannot be excluded that MCJ loss may have occurred during 
mitoplast generation. 
In contrast, other studies have reported results that agree with the above 
topology prediction. Phage display analysis using the N-terminal sequence of MCJ 
as bait indicated that MCJ likely interacts with the Complex I subunit NDUFv1 
(Hatle et al., 2013), which is found in the matrix. Additionally, later in this 
dissertation (CHAPTER 3) it will be shown that a mimetic of MCJ that is targeted 
to the matrix can restore the function of MCJ in deficient cells. Future studies will 
clarify these apparent discrepancies in the orientation of MCJ in the inner 
mitochondrial membrane. 
4.6. Function 
As stated above, MCJ is member of the DNAJ family of co-chaperones that 
is found in mitochondria. All members of this family contain a canonical DNAJ 
domain, however their specific function(s) are mediated by non-conserved 
regions. For MCJ, the functional domain is thought to be in the N-terminus as it 
has no significant homology to any other known eukaryotic protein. 
4.6.1. Negative regulation of mitochondrial metabolism 
Biochemical analyses have shown that MCJ is a negative regulator of 
Complex I (Hatle et al., 2013). As a consequence of increased Complex I activity in 
the absence of MCJ, cells experience significantly higher mitochondrial membrane 
potential and ATP production rates (Barbier-Torres et al., 2017; Champagne et al., 
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2016; Hatle et al., 2013). A concomitant increase in mitochondrial oxygen 
consumption after MCJ loss has also been shown (Barbier-Torres et al., 2017; 
Champagne et al., 2016; Navasa, Martin, et al., 2015). These effects of MCJ 
deficiency have been shown in a number of tissues and cell types, including the 
heart, liver, macrophages, T cells, and breast cancer cells (Barbier-Torres et al., 
2017; Hatle et al., 2013; Navasa, Martin, et al., 2015). Later in this dissertation, the 
negative regulation of mitochondrial metabolism in CD8+ T cells (CHAPTER 2) 
and other types of cancer (CHAPTER 3) will be described. 
As described previously (§1.2.3), the complexes of the ETC can associated 
into supramolecular structures known as respiratory supercomplexes. MCJ 
deficiency increases the abundance of supercomplexes in the heart, indicating that 
it is refractory to their formation (Hatle et al., 2013). Additionally, biochemical 
analyses have revealed that MCJ only associates with Complex I in its monomeric 
form and that it does not bind Complex I in supercomplexes (Hatle et al., 2013). 
This dissertation will also describe the regulation of supercomplexes by MCJ in 
CD8+ T cells (CHAPTER 2).  
4.6.2. Regulation of liver metabolism 
MCJ is highly expressed in the liver of both mice and humans, however no 
obvious differences are observed between the livers of wild-type and MCJ 
deficient mice under normal physiological conditions (Hatle et al., 2013). This 
indicates that MCJ is not essential for normal liver function. In contrast, substantial 
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differences are seen in response to fasting conditions. During a fast, the liver 
releases glucose derived from its stores of glycogen for use as an energy source by 
other cells of the body. If glycogen becomes limited, adipocytes begin to release 
fatty acids. Hepatocytes then import these released fatty acids for repackaging and 
release in a form usable by other cells (Berg et al., 2002; Voet and Voet, 2011). In 
extreme conditions, such as prolonged fasting, fatty acids build up beyond the 
capacity for efficient repackaging producing a condition known as steatosis (fatty 
liver). 
Using a mouse model of steatosis, it was shown that MCJ deficiency 
prevents steatosis as hepatocytes have an increased capacity to metabolize fatty 
acids (Hatle et al., 2013). Loss of MCJ also reduced the levels of free fatty acids and 
triglycerides in the serum, indicating a systemic overall improvement (Hatle et al., 
2013). In humans, nonalcoholic fatty liver disease (NAFLD) is a spectrum disorder 
of the liver (Rinella, 2015). Mild cases present as chronic steatosis, while liver 
inflammation and fibrosis are symptoms of progressed disease. While MCJ 
significantly affects the development of steatosis in mice, it remains to be 
determined whether MCJ plays a role in NAFLD. 
A number of therapeutic drugs have off-target effects on mitochondria, 
with a notable example being acetaminophen. Overdose is currently the primary 
cause of acute liver failure (AFL) and a major cause of drug induced liver injury 
(DILI). Furthermore, a significant proportion of liver transplants are secondary to 
acetaminophen overdose induced AFL. Hepatotoxicity due to acetaminophen 
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overdose is complex and not fully understood (McGill and Jaeschke, 2013; Yoon et 
al., 2016), however it is correlated with impaired mitochondrial respiration and 
increased oxidative stress due to the production of reactive intermediates (notably 
NAPQI) and ROS. N-acetylcysteine (NAC), the only available treatment, mitigates 
liver damage by supplementing the cellular antioxidant pool, however treatment 
is only effective within the first 8 – 10 hours of the overdose. Thus, there is a 
significant need for other therapies for acetaminophen poisoning. 
In a mouse model of acetaminophen overdose, MCJ deficiency lead to lower 
levels of hepatocyte death, liver damage, serum transaminase levels, and liver 
inflammation (Barbier-Torres et al., 2017). This protective effect was correlated to 
lower ROS production, reduced oxidative stress, and increased Complex I activity 
(Barbier-Torres et al., 2017). Importantly, treatment with an siRNA targeting MCJ 
up to 24 hours post drug exposure significantly attenuated liver toxicity and 
inflammation (Barbier-Torres et al., 2017), indicating that MCJ is a viable 
therapeutic target for drug induced liver toxicity. This was further supported by 
the detection of increased levels of MCJ in the liver of patients experiencing DILI 
relative to healthy controls (Barbier-Torres et al., 2017). Additionally, MCJ 
expression was highest in DILI patients overdosing on drugs known to be 
mitotoxic compared to overdoses due to drugs that are not classified as hazardous 
to mitochondria (Barbier-Torres et al., 2017). 
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4.6.3. Regulation of immune cell metabolism 
CD8+ T cells play a significant role in protection from intracellular 
pathogens. Compared to naïve CD4+ T cells, CD8+ T cells abundantly express MCJ 
(Hatle et al., 2013). As expected, this leads to lower mitochondrial membrane 
potential and Complex I activity in these cells (Hatle et al., 2013). The role of MCJ 
in CD8+ T cell immune effector responses is a later focus of this dissertation 
(CHAPTER 2). 
MCJ is also expressed by macrophages and has a profound effect on their 
immune effector functions. Loss of MCJ in macrophages decreases production of 
TNF after engagement of multiple TLR ligands, including LPS (Navasa, Martin, et 
al., 2015). Interestingly, the decrease in TNF secretion was due to reduced activity 
of the metalloprotease tumor necrosis factor α converting enzyme (TACE) rather 
than decreased Tnf gene expression or TNF protein production (Navasa, Martin, 
et al., 2015). Using a mouse model of fulminant acute liver failure, it was shown 
that reduced TNF production in the absence of MCJ is protective (Navasa, Martin, 
et al., 2015). MCJ loss in macrophages is therefore beneficial to protection from 
inflammatory insults. 
4.6.4. Role in chemoresistance 
The loss of MCJ expression, however, is not always beneficial. As described 
previously, increased methylation of the DNAJC15 gene and/or reduced MCJ 
expression has been shown in a number of different cancers (§4.4), however only 
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a few studies have shown functional consequences of these differences. The first 
report of MCJ showed that restoration of its expression induced sensitivity to 
commonly used chemotherapeutic agents in ovarian cancer cell lines, indicating 
that loss of MCJ had conferred resistance to these drugs (Shridhar et al., 2001). This 
correlation has also been seen in breast cancer as a chemoresistant derivative of 
MCF7 cells exhibited increased DNAJC15 methylation and lower MCJ expression 
relative to the parental cell line (Boettcher et al., 2010). The ability to prevent 
doxorubicin accumulation, thereby mediating chemoresistance, was also 
increased in MCJ deficient breast cancer cells (Hatle et al., 2007). These findings 
were supported using mouse models as the tumor cells of MCJ deficient mouse 
mammary tumor virus (MMTV-PyMT) mice were also highly resistant to 
chemotherapy (Fernandez-Cabezudo et al., 2016).  
A retrospective study of breast cancer patients indicated that the levels of 
MCJ expression in tumors was predictive of relapse free survival after 
chemotherapy treatment (Fernandez-Cabezudo et al., 2016). Furthermore, a 
prospective analysis of breast cancer patients revealed that MCJ expression 
correlated with increased responses to neoadjuvant therapy (Fernandez-
Cabezudo et al., 2016). In addition, higher levels of DNAJC15 methylation 
correlated with poor responses to chemotherapy and reduced long term survival 
in ovarian cancer patients (Strathdee et al., 2005). While the exact mechanism(s) are 
unclear, loss of MCJ correlates with increased expression of ATP binding cassette 
(ABC) transporters (Hatle et al., 2007). The mechanistic connection between the 
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regulation of mitochondrial metabolism by MCJ and ABC transporter mediated 
chemoresistance is addressed later in this dissertation (CHAPTER 3). 
4.6.5. Other potential functions 
MCJ has been reported to affect the import of mitochondrial proteins 
(Schusdziarra et al., 2013; Sinha et al., 2014). The import of nuclear encoded 
proteins into mitochondria is facilitated by the translocase of the inner membrane 
(TIM), formed by the association of the TIM22 complex at the inner membrane and 
TIM23 complex in the matrix (Dudek et al., 2013). Protein transport requires the 
function of DNAJC19 in yeast (Mokranjac et al., 2003), therefore a potential role for 
MCJ was investigated as they share similar evolutionary origins as described 
previously (§4.3). MCJ was shown to interact with and stimulate regulators of the 
TIM23 complex in cell free assays, however the loss of MCJ was dispensable for 
import in whole cells (Schusdziarra et al., 2013; Sinha et al., 2014). MCJ is therefore 
nonessential for mitochondrial protein import in intact cells. 
MCJ has also been reported to influence the activity of the mitochondrial 
permeability transition pore (MPTP) (Sinha and D'Silva, 2014). Mitochondria have 
a significant role in the induction of apoptosis via the release of factors through 
the MPTP complex, of which expression and increased activity are promoted by 
cell death stimuli (Bonora and Pinton, 2014). While the molecular components and 
regulators of the MPTP complex are still a matter of debate, peptidylprolyl 
isomerase D (also called cyclophilin D or CypD) is a known essential activator 
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(Baines and Gutierrez-Aguilar, 2018). MCJ have been shown to directly interact 
with CypD and recruits it to the MPTP complex, which thereby enhances MPTP 
activity in response to cisplatin treatment (Schusdziarra et al., 2013). However, 
these studies were performed using overexpression systems that, as described 
previously (§4.5), can dysregulate the localization of MCJ and mitochondrial 
morphology. Thus, further studies on the potential role of MCJ in the MPTP 
complex are needed. 
 
5. Specific aims of this dissertation 
5.1. Aim 1 
Determine the role of MCJ in CD8+ T cell immune responses. MCJ is a negative 
regulator of Complex I activity that is abundantly expressed by CD8+ T cells 
relative to other leukocytes (Hatle et al., 2013; Navasa, Martin, et al., 2015). As such, 
loss of MCJ expression in these cells leads to increased mitochondrial respiration, 
including higher membrane potential (Hatle et al., 2013). However, the impact of 
these changes on the immune function of CD8+ T cells was unknown. The goal of 
this aim was to determine how the regulation of mitochondria by MCJ influences 
the development, activation, proliferation, and effector functions of CD8+ T cells 
in the context of viral immunity. 
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5.2. Aim 2 
Determine the role of MCJ in maintenance or induction of chemoresistance. 
Decreased MCJ expression in cancer cells is correlated with a chemoresistant 
phenotype and poor patient responses to chemotherapy (Fernandez-Cabezudo et 
al., 2016; Hatle et al., 2007; Strathdee et al., 2005). This has been attributed to 
increased ABC transporter expression in the absence of MCJ (Hatle et al., 2007), 
however the mechanistic connection to chemoresistance was unclear. The goal of 
this aim was to address how increased mitochondrial respiration due to MCJ 
deficiency in cancer leads to chemoresistance. 
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Mitochondrial respiration is regulated in CD8+ T cells during the transition 
from naive to effector and memory cells, but mechanisms controlling this process 
have not been defined. Here we show that MCJ (methylation-controlled J protein) 
acted as an endogenous break for mitochondrial respiration in CD8+ T cells by 
interfering with the formation of electron transport chain respiratory 
supercomplexes. Metabolic profiling revealed enhanced mitochondrial 
metabolism in MCJ-deficient CD8+ T cells. Increased oxidative phosphorylation 
and subcellular ATP accumulation caused by MCJ deficiency selectively increased 
the secretion, but not expression, of interferon-g. MCJ also adapted effector CD8+ 
T cell metabolism during the contraction phase. Consequently, memory CD8+ 
T cells lacking MCJ provided superior protection against influenza virus infection. 
Thus, MCJ offers a mechanism for fine-tuning CD8+ T cell mitochondrial 
metabolism as an alternative to modulating mitochondrial mass, an energetically 




Metabolism is emerging as a major factor that regulates the function and 
differentiation of immune cells and influences the course of an immune response 
(Pearce et al., 2013; van der Windt and Pearce, 2012; Wang and Green, 2012). Naive, 
effector, and memory T cell subsets have distinct metabolic profiles to provide the 
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energy and bioenergetic precursors required for cell growth and expansion. Naive 
cells use glucose and free fatty acids (FFA) as sources of ATP through 
mitochondrial oxidative phosphorylation (OXPHOS) (van der Windt et al., 2012; 
Wang et al., 2011). After activation, CD8+ T cells undergo a metabolic 
reprograming and switch to glycolysis as a source of ATP. Effector T cells can also 
use glutamine to generate ATP through glutaminolysis, which can further fuel 
OXPHOS (Carr et al., 2010; Wang et al., 2011). Proliferation of effector CD8+ T cells 
appears to be more dependent on glucose than effector CD4+ T cells (Frauwirth et 
al., 2002; Macintyre et al., 2011). In contrast, production of some cytokines by 
effector CD8+ T cells is not affected by a strong inhibition of glycolysis (Cham et 
al., 2008), and cytotoxic activity can occur in the absence of glucose (MacDonald 
and Koch, 1977). 
Effector CD8+ T cells further reprogram metabolism during memory cell 
generation in response to antigen and cytokine withdrawal. Memory CD8+ T cells 
primarily use FFA oxidation in mitochondria as the main energy pathway (Araki 
et al., 2009; Pearce et al., 2009; van der Windt et al., 2012). Additionally, memory 
CD8+ T cells manifest a greater increase in both OXPHOS and aerobic glycolysis 
following activation compared with naive cells, and the induction of glycolysis is 
dependent on mitochondrial ATP (van der Windt et al., 2013). Importantly, 
intervention of metabolism with metformin (AMPK activator) or rapamycin 
(mTOR inhibitor) to promote FFA oxidation enhances the generation of memory 
CD8+ T cells and protection against viral infection (Araki et al., 2009; Pearce et al., 
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2009). A recent study revealed that memory CD8+ T cells have developed their 
own intrinsic pathways to mobilize fatty acids for oxidation (Pearce et al., 2009). 
Considering this highly dynamic metabolic reprogramming, CD8+ T cells likely 
utilize specific checkpoints to regulate these transitions and their effector 
functions. However, while a number of studies have addressed the effect of 
different metabolic substrates that fuel the mitochondrial electron transport chain 
(ETC), little is known about endogenous mechanisms that control mitochondrial 
respiration and, thereby, the immune response.  
Methylation controlled J protein (MCJ), a protein encoded by the DNAJC15 
gene, is a member of the DnaJ family of chaperones. MCJ is a small protein with 
features that distinguish it from other DnaJ family members. While most DnaJ 
family members are soluble proteins, MCJ contains a transmembrane domain and 
has a unique N-terminal domain that shares no significant sequence similarity 
with any other known protein. MCJ was first reported in ovarian cancer cells as a 
gene negatively regulated by methylation (Shridhar et al., 2001; Strathdee et al., 
2004). Loss of MCJ is associated with chemoresistance of human breast and 
ovarian cancer cell lines (Hatle et al., 2007; Shridhar et al., 2001; Strathdee et al., 
2005). We recently showed that MCJ is abundantly expressed primarily in tissues 
with a highly active mitochondrial metabolism, including heart and liver (Hatle et 
al., 2013). Within the immune system, MCJ is highly expressed in CD8+ T cells, but 
not in CD4+ T and B cells (Hatle et al., 2013), and less in macrophages (Navasa, 
Martin, et al., 2015). Importantly, MCJ localizes to the inner membrane of 
 
101 
mitochondria (Hatle et al., 2013; Schusdziarra et al., 2013) and acts as a negative 
regulator of the ETC. MCJ deficiency in vivo results in increased complex I activity 
and mitochondrial membrane potential (MMP) without affecting mitochondrial 
mass (Hatle et al., 2013). Endogenous MCJ in primary tissues associates with 
complex I and acts as a natural inhibitor, making MCJ one of the first described 
endogenous negative regulators of complex I. The activity of complex I is 
enhanced by assembly in ‘‘respirasomes,’’ which are mitochondrial ETC 
supercomplexes containing complexes I, III, and IV (Acin-Perez et al., 2008). 
Supercomplexes facilitate efficient transfer of electrons to enhance complex I 
activity and minimize electron ‘‘leak’’ that results in ROS production (Moreno-
Lastres et al., 2012). We have shown that MCJ interferes with the formation of these 
supercomplexes in heart (Hatle et al., 2013), a mechanism to inhibit complex I 
activity and MMP. 
Although MCJ is abundantly present in CD8+ T cells, its role in regulating 
mitochondrial metabolism and function of these cells is unknown. Here, we show 
that MCJ acts a negative regulator of mitochondrial respiration in CD8+ T cells. 
MCJ deficiency did not affect proliferation of naive CD8+ T cells upon activation, 
nor activation marker or cytokine gene expression. However, increased OXPHOS 
in MCJ-deficient CD8+ T cells enhanced the secretion of cytokines and sustained 
the metabolic state of effector CD8+ T cells during the contraction phase. MCJ-
deficient memory CD8+ T cells had greater protective capacity against influenza 
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virus infection. Therefore, MCJ is emerging as an important negative regulator of 
mitochondrial activity of CD8+ T cells. 
 
3. Results 
3.1. Loss of MCJ Promotes Respiratory Supercomplexes and Mitochondrial 
Metabolism in Naive CD8+ T cells 
To investigate the role of MCJ in CD8+ T cell development and function, we 
used MCJ-deficient mice previously described to have no obvious phenotypic 
alterations under physiological conditions (Hatle et al., 2013). Although CD8+ T 
cells freshly isolated from MCJ-deficient mice display higher mitochondrial 
membrane potential (MMP) (Supplementary Figure 2-1A), there was no difference 
in the percentage (Supplementary Figure 2-1B) or number (data not shown) of 
CD8+ or CD4+ T cells in the spleen and lymph nodes (LN) of WT and MCJ-deficient 
mice. No difference in the expression of activation markers such as CD44 was 
observed (Supplementary Figure 2-1C). The percentage (Supplementary Figure 
2-1B) and number (data not shown) of single-positive, double-positive (DP), or 
double-negative (DN) populations in the thymus were also comparable. Thus, 
MCJ deficiency does not affect the development of CD8+ and CD4+ T cells in the 
thymus or homeostasis in the periphery. 
MMP is the driver for oxidative phosphorylation (OXPHOS), generation of 
ATP, and oxygen consumption. To investigate the impact that increased MMP in 
MCJ-deficient CD8+ T cells has on mitochondrial respiration, we examined the 
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oxygen consumption rate (OCR) in freshly isolated CD8+ T cells using the Seahorse 
MitoStress assay. Correlating with the increased MMP, OCR was also elevated in 
MCJ-deficient CD8+ T cells compared with WT CD8+ T cells (Figure 2-1A). In 
contrast, the extracellular acidification rate (ECAR), a parameter for glycolysis, 
was not affected in MCJ-deficient CD8+ T cells (Figure 2-1B). Mitochondrial ATP 
production, determined by subtracting the OCR in the presence of oligomycin 
(Complex V/ATP Synthase inhibitor) from the OCR at baseline, was also higher 
in MCJ-deficient CD8+ T cells (Figure 2-1C). Thus, MCJ is a negative regulator of 
mitochondrial respiration in CD8+ T cells. 
To identify the impact of MCJ on the overall metabolism of naive CD8+ 
T cells, we performed nonbiased high-throughput metabolic profiling. 
Metabolome analysis of CD8+ T cells freshly isolated from WT and MCJ-deficient 
mice showed a large number of metabolic intermediates from different pathways 
equally present in both (Supplementary Table 2-1). However, there was a 
significant increase in the amounts of several amino acids in MCJ-deficient CD8+ 
T cells (Figure 2-1D). Most of the amino acids that were significantly elevated 
belonged to the essential amino acid group (Figure 2-1D). In contrast, only tyrosine 
in the conditionally essential amino acid group and asparagine in the non-essential 
group were significantly increased (Figure 2-1D). 
The preferential accumulation of amino acids that need to be imported 
suggested a greater amino acid transport occurred in the absence of MCJ. Since 
amino acid transport is highly dependent on ATP, increased mitochondrial 
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OXPHOS due to MCJ deficiency could be responsible for this transport. To 
investigate this, we incubated freshly isolated CD8+ T cells in culture medium. 
After 16 hours, the metabolic profile of the culture supernatants was analyzed to 
determine the amino acid consumption. The amounts of amino acids were 
significantly reduced in the culture supernatant of MCJ-deficient CD8+ T cells 
(Figure 2-1E). In addition, metabolic flux analyses with 13C- and 15N-labeled amino 
acids showed increased uptake of extracellular [13C, 15N]-glutamine (Figure 2-1D). 
Thus, the increased mitochondrial respiration resulting from MCJ deficiency in 
naive CD8+ T cells in vivo promotes amino acid uptake. 
The other metabolite significantly increased in MCJ-deficient CD8+ T cells 
was succinate (Figure 2-1F and Supplementary Table 2-1), which is oxidized to 
fumarate by succinate dehydrogenase (ETC complex II) in the TCA cycle. 
However, the amounts of fumarate and the other components of the TCA cycle 
were not different (Figure 2-1F). These results suggested that elevated succinate in 
MCJ-deficient CD8+ T cells was the result of impaired complex II activity. Indeed, 
reduced complex II activity was found in freshly isolated MCJ-deficient CD8+ 
T cells as measured by OCR in response to succinate using a Seahorse Extracellular 
Flux analyzer (Figure 2-1G). In addition, metabolic flux analyses of freshly isolated 
CD8+ T cells incubated with 13C- and 15N-labeled amino acids revealed an increase 
in newly synthesized succinate, but not fumarate (the product of complex II), in 
MCJ-deficient CD8+ T cells (Figure 2-1H). Thus, complex II appears to be 
uncoupled from the rest of the ETC in MCJ-deficient CD8+ T cells. 
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We have shown that the absence of MCJ in heart favors the accumulation 
of mitochondrial respiratory supercomplexes (Hatle et al., 2013), composed of 
complexes I, III, and IV, but not complex II. To investigate whether 
supercomplexes were increased in naive MCJ-deficient CD8+ T cells, we generated 
mitochondrial extracts with digitonin to preserve supercomplexes and resolved 
them by blue native electrophoresis (BNE) as previously described (Yang et al., 
2015). The supercomplex region was excised, resolved by SDS-PAGE, and 
analyzed by Western blot for subunits of complexes I (NDUFA9) and IV (CoxIV). 
The amount of supercomplexes were higher in MCJ-deficient CD8+ T cells (Figure 
2-1I). Monomeric complex IV analyzed as a control and was not different (Figure 
2-1I). To further support the accumulation of supercomplexes in MCJ-deficient 
CD8+ T cells, we resolved mitochondrial extracts by BNE, followed by immunoblot 
analysis for subunits of complexes I (NDUFA9) and III (Core1). Increased 
NDUFA9 amounts were present in the supercomplex region in MCJ-deficient 
CD8+ T cells, while the amounts of NDUFA9 in the monomeric complex I region 
were comparable between MCJ-deficient and WT cells (Figure 2-1J). Similar results 
were obtained for Core1 (Figure 2-1J). Thus, loss of MCJ promotes the formation 
of respiratory supercomplexes in naive CD8+ T cells. Uncoupling complex III from 
complex II could compromise complex II activity and cause the observed 
accumulation of succinate. Together, these results indicate that the function of MCJ 
in naive CD8+ T cells is to restrict mitochondrial metabolism, and a deficiency in 






Figure 2-1. MCJ Restrains Mitochondrial Respiration in Naive 





































Champagne et al. Figure 1




































































































































































































a ** * * * * * *






















(A) Baseline OCR, (B) ECAR, and (C) OCR linked to mitochondrial ATP 
production (baseline OCR minus OCR in the presence of oligomycin) of freshly 
isolated cells as determined by MitoStress (A and C) or Glycolysis Stress assays 
(B). (D and F) Metabolic profiles of cells were determined by UPLC-MS analysis. 
Relative amounts of (D) amino acids and (F) TCA cycle metabolites. (E) Equal 
numbers of cells were incubated in culture medium for 16 hours, and metabolic 
profiles of the culture supernatants were determined. (G) Complex II activity was 
determined by examining OCR at baseline and in the response to succinate with 
rotenone (Succ + Rote) and malonate. (H) Cells were cultured with 13C- and 
15N-labeled amino acids, and metabolic flux was determined by UPLC-MS 
analysis. 13C-succinate and 13C-fumarate peak areas shown. (I and J) Mitochondrial 
extracts were resolved by BNE. (I) Bands corresponding to supercomplexes (SC) 
or monomeric complex IV were excised, resolved by SDS-PAGE, and examined by 
Western blot analysis for NDUFA9 (complex I) and CoxIV (complex IV). (J) 
Proteins separated by BNE were examined by Western blot analysis for NDUFA9 
and Core1 (complex III). Bands corresponding to supercomplexes (SC) and 
monomeric complexes I (CI) and III (CIII) regions of the Western blot shown. 
*p < 0.05 by unpaired t test. Avg ± SD (n ³ 3) shown. Results are representative of 
2 - 3 experiments. See also Supplementary Figure 2-1 and Supplementary Table 
2-1.  
 
3.2. MCJ Deficiency Does Not Affect Proliferation, but Enhances the Secretion 
of Cytokines in Activated CD8+ T cells 
We investigated whether the enhanced mitochondrial metabolism found in 
MCJ-deficient CD8+ T cells could alter proliferation. Freshly isolated CD8+ T cells 
were stained with CFSE and activated with anti-CD3 and anti-CD28 antibodies, 
and proliferation was analyzed by flow cytometry. No differences were observed 
in the frequency of proliferating cells or number of cell divisions (Figure 2-2A), the 
survival of cells after 2 days of activation (Figure 2-2B), or expression of the cell 
surface activation markers CD69 and CD25 (Figure 2-2C). In contrast, greater 
IFN-g (Figure 2-2D) and IL-2 (Figure 2-2E) production was detected in activated 
MCJ-deficient CD8+ T cells as determined by ELISA. Thus, loss of MCJ does not 
interfere with activation or expansion of CD8+ T cells, but results in a greater 
production of cytokines. 
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Production of cytokines by CD8+ T cells upon activation is primarily 
regulated at the level of gene expression either by transcription or mRNA stability. 
However, analysis of cytokine mRNA by quantitative RT-PCR showed no 
difference in the amounts of IFN-g and IL-2 mRNA between activated MCJ-
deficient and WT CD8+ T cells (Figure 2-2F). Thus, MCJ had no effect on cytokine 
gene expression in CD8+ T cells. A recent study reported that aerobic glycolysis 
promotes IFN-g production at the translational level in effector CD4+ T cells 
(Chang et al., 2013). However, intracellular staining analysis for IFN-g showed no 
difference between WT and MCJ-deficient CD8+ T cells (Figure 2-2G). Similarly, 
there was no difference in IL-2 intracellular staining (Figure 2-2G). Thus, the 
increased amounts of cytokines in MCJ-deficient CD8+ T cell supernatants were 
not due to increased gene or protein expression. 
Secretion of cytokines is another mechanism that regulates the overall 
amount of cytokines being produced, although little is known about the pathways 
involved. To investigate whether the increased IFN-g in the supernatants of MCJ-
deficient CD8+ T cells was caused by enhanced secretion, we activated CD8+ T cells 
with anti-CD3 and anti-CD28 antibodies for 2 days, washed, and then incubated 
equal numbers of cells in medium alone without any additional stimuli for 
different periods of time. IFN-g in the supernatants from MCJ-deficient CD8+ 
T cells after 2 hours was higher than WT CD8+ T cells (Figure 2-2H). IFN-g in MCJ-
deficient CD8+ T cell supernatants continued increasing for at least 4 hours and 
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then remained constant, while the amount secreted by WT CD8+ T cells did not 
increase (Figure 2-2H). Treatment with cycloheximide (CHX), an inhibitor of 
protein synthesis, did not affect the IFN-g produced during this period 
(Supplementary Figure 2-2A), although CHX prevented new protein synthesis 
triggered by the activation of naive CD8+ T cells (Supplementary Figure 2-2B). 
These results further support the conclusion that increased protein translation was 
most likely not the primary cause of enhanced IFN-g production by MCJ-deficient 
CD8+ T cells. IL-2 and GM-CSF were also elevated in the supernatant of MCJ-
deficient CD8+ T cells after 4 hours (Supplementary Figure 2-2C), indicating that 
the effect of MCJ on secretion is not restricted to IFN-g. To further confirm the 
enhanced capacity of secretion by MCJ-deficient CD8+ T cells, we performed 
ELISpot assays for IFN-g. The number of spots with a larger area (high IFN-g 
producers) was increased in MCJ-deficient CD8+ T cells (Figure 2-2I). Enhanced 
secretion should result in lower accumulation of intracellular IFN-g if no 
additional synthesis takes place. Intracellular staining for IFN-g after activated 
cells were washed and incubated in medium alone showed lower IFN-g in MCJ-
deficient CD8+ T cells after 1 hour (Supplementary Figure 2-2D). Together these 
results indicate that MCJ deficiency augments cytokine production primarily by 






Figure 2-2. MCJ Deficiency Does Not Affect Effector CD8+ T Cell 
Proliferation but Increases the Secretion of Cytokines 
 
WT (blue) and MCJ-deficient CD8+ T cells (MCJ def, red) were activated for 2 days 
with anti-CD3 and anti-CD28 antibodies. (A) Proliferation determined by CFSE 
staining. Grey histograms show unstimulated cells. (B) Cell survival determined 
by Live Dead staining. (C) Cell surface expression of CD69 and CD25. Grey 
histograms show unstained cells. (D and E) Culture supernatants of activated cells 
were examined for (D) IFN-g and (E) IL-2 by ELISA. (F) IL-2 and IFN-g mRNA 
expression determined by qRT-PCR. (G) Intracellular staining for IFN-g and IL-2. 
Grey histograms show unstained cells. (H) Activated cells were washed and 
replated at equal numbers in medium alone. IFN-g in the culture supernatants over 
time was determined by ELISA. (I) Number of IFN-g producing cells determined 
by ELISpot assay. *p < 0.05 by unpaired t test. Avg ± SD (n ³ 3) shown. Results are 
representative of 2 – 3 experiments. See also Supplementary Figure 2-2. 
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3.3. Localized Mitochondrial Production of ATP in the Absence of MCJ 
Promotes Cytokine Secretion 
We used an unbiased metabolomics approach to investigate which 
metabolic pathways were regulated by MCJ in effector CD8+ T cells. Metabolic 
profiling was obtained from equal numbers of WT and MCJ-deficient CD8+ T cells 
after 2 days of activation and 4 hours of resting. Although no obvious phenotypic 
differences in terms of size or activation markers could be detected between the 
cell types, MCJ deficiency caused well-defined metabolic changes (Supplementary 
Table 2-2). Similar to naive CD8+ T cells, the absence of MCJ in activated CD8+ 
T cells resulted in increased amounts of amino acids, but this increase was not 
restricted to essential amino acids (Figure 2-3A). In addition, a number of 
intermediate metabolites of the TCA and urea cycle pathways, two of the main 
mitochondrial pathways, were among the most elevated components in activated 
MCJ-deficient CD8+ T cells relative to WT CD8+ T cells (Supplementary Table 2-2). 
Similar to naive CD8+ T cells, succinate was also drastically increased in activated 
MCJ-deficient CD8+ T cells, but fumarate, malate, and 2-hydroxyglutarate were 
also higher (Figure 2-3B). Citrulline and arginosuccinate, components of the urea 
cycle, were also increased (Figure 2-3C). Although there was no difference in 
proliferation, nucleotide pathways were also upregulated in the absence of MCJ 
(Figure 2-3D). Nucleotide synthesis is primarily cytosolic, however mitochondrial 
metabolic pathways feed into these pathways, as purine salvage reactions 
consume aspartate to produce fumarate and recover AMP upon deamination to 
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IMP. Thus, an unbiased metabolic screening revealed increased mitochondrial 
activity in MCJ-deficient effector CD8+ T cells.  
Effector CD8+ T cells are primarily glycolytic and use ATP from glycolysis 
instead of mitochondrial OXPHOS as the major source of energy. Because the 
absence of MCJ enhances overall mitochondrial activity, we examined 
intracellular ATP. Higher amounts of total ATP were present in MCJ-deficient 
CD8+ T cells that were activated for 2 days and rested for 4 hours (Figure 2-4A). 
To determine whether this increased production of ATP resulted from increased 
mitochondrial respiration, we performed Seahorse MitoStress analysis. OCR was 
higher in activated MCJ-deficient CD8+ T cells, as shown by the effect of 
oligomycin on baseline OCR (Figure 2-4B). These data indicate that the rate of ATP 
synthesis by mitochondria was increased in the absence of MCJ. In contrast, 
analysis of ECAR in response to glucose showed no difference between the two 
cell types (Figure 2-4C). Thus, loss of MCJ promotes mitochondrial respiration 
without altering the glycolytic rate of effector CD8+ T cells. 
The normal rate of glycolysis as determined by ECAR analysis correlated 
with the normal rate of proliferation and gene expression observed in MCJ-
deficient CD8+ T cells. While glycolysis-derived ATP represents the predominant 
source of energy and is sufficient for these processes in activated cells, 
mitochondrial derived ATP could be essential for other CD8+ T cell functions such 
as cytokine secretion. Due to the dynamic characteristics of mitochondria, this 
organelle could provide a subcellular microenvironment rich in ATP without the 
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need to raise total cytosolic ATP. We investigated the presence of ATP-rich 
microdomains within activated CD8+ T cells using a fluorescent probe used to 
identify ATP and ADP intracellular accumulation. Confocal microscopy of live 
cells showed only a few punctate ATP probe accumulations in activated WT CD8+ 
T cells, while ATP puncta were abundant and prominent in MCJ-deficient CD8+ 
T cells (Figure 2-4D). The subcellular ATP accumulation in MCJ-deficient CD8+ 
T cells represented the mitochondrial derived ATP pool since treatment with 
oligomycin prevented their formation (Supplementary Figure 2-3A). Moreover, 
costaining with the ATP probe and Mitotracker, a mitochondrial marker, revealed 
colocalization of the ATP puncta with mitochondria in activated MCJ-deficient 
CD8+ T cells (Figure 2-4E). Thus, MCJ deficiency facilitates the formation of ATP-
rich microdomains within activated CD8+ T cells. 
To address whether the increased secretion of IFN-g found in MCJ-deficient 
CD8+ T cells was mediated by increased mitochondrial ATP production, we 
activated CD8+ T cells for 2 days and treated them with oligomycin during the last 
4 hours of activation. Cells were then washed and incubated at equal numbers in 
medium alone for 4 hours. IFN-g in the supernatants was determined by ELISA. 
Inhibition of mitochondrial ATP synthesis by oligomycin suppressed the 
enhanced secretion of IFN-g by MCJ-deficient CD8+ T cells (Figure 2-4F). In 
contrast, oligomycin did not reduce intracellular IFN-g (Supplementary Figure 
2-3B). Thus, MCJ acts as an endogenous negative regulator of mitochondrial 
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respiration, restricting the production of mitochondrial ATP and secretion of 





Figure 2-3. MCJ Deficiency Enhances Mitochondrial Metabolism in 
Effector CD8+ T Cells 
 
(A – D) WT (blue) and MCJ-deficient (MCJ def, red) CD8+ T cells were activated 
for 2 days with anti-CD3 and anti-CD28 antibodies, and metabolic profiles were 
determined by UPLC-MS. Relative peak areas of (A) amino acids and metabolites 
of the (B) TCA cycle, (C) urea cycle, and (D) nucleotide pathways shown. *p < 0.05 
by unpaired t test. Avg ± SD shown (n = 3 mice). See also Supplementary Table 
2-2. 
Champagne et al. Figure 3

























































































































































































































































































































































Figure 2-4 Increased Oxidative Phosphorylation in MCJ-Deficient 
Effector CD8+ T Cells Facilitates IFN-g Secretion 
 
WT (blue) and MCJ-deficient CD8+ T cells (MCJ def, red) were activated with anti-
CD3 and anti-CD28 antibodies for 2 days. (A) ATP concentration in cells rested in 
medium without stimuli for 4 hours. (B) OCR of cells rested for 12 hours at baseline 
and in response to oligomycin (O), FCCP (F), and rotenone with antimycin (R+A) 
by Seahorse MitoStress assay. (C) ECAR in cells after addition of glucose by 
Seahorse Glycolysis Stress assay. (D) Live cells stained with ATP probe (green) 
were visualized by confocal microscopy. Right panels show a magnification of the 
cells indicated by the white arrows. (E) Live cells costained with ATP probe (green) 
and Mitotracker (red) were visualized by confocal microscopy. (F) Cells were 
incubated with oligomycin during the last 4 hour of activation and then rested for 
4 hours. IFN-g in the supernatants was determined by ELISA. *p < 0.05 by 
unpaired t test. Avg ± SD (n ³ 3) shown. Scale bar represents 10 nm. Results are 
representative of 2–3 experiments. See also Supplementary Figure 2-3. 
 
3.4. MCJ Attenuates Mitochondrial Metabolism during the Contraction Phase 
of Effector CD8+ T cells In Vivo 
CD8+ T cells reprogram their mitochondrial metabolism during the 
differentiation from naive to effector and from effector to memory stages. Memory 
CD8+ T cells also have greater mitochondrial mass and maximum respiratory 






























































































capacity (van der Windt et al., 2012). Because MCJ acts as an internal break for 
mitochondrial function in tissues with a high content of active mitochondria, we 
investigated MCJ expression during the contraction phase of effector CD8+ T cells. 
To examine MCJ expression in individual cells, we used MCJ-deficient mice 
because they contain a b-galactosidase reporter gene inserted in the MCJ locus, 
while WT CD8+ T cells served as negative controls (Supplementary Figure 2-3C). 
We performed  b-galactosidase activity assays by flow cytometry analysis in CD8+ 
T cells that were freshly isolated, activated (effector), and rested in medium alone 
after activation (rested effector) to mimic the contraction phase of effector cells and 
development of memory cells. The frequency of MCJ expressing cells was 
dramatically decreased in effector cells relative to naive cells (Figure 2-5A). We 
recently showed that Ikaros, a transcriptional repressor known to attenuate gene 
expression (John and Ward, 2011), binds the DNAJC15 gene (encodes MCJ) 
promoter in macrophages to silence MCJ expression (Navasa, Martin-Ruiz, et al., 
2015). Because Ikaros has been previously reported in CD8+ T cells (O'Brien et al., 
2014), we performed chromatin immunoprecipitation analysis (ChIP) to determine 
whether Ikaros also binds the DNAJC15 promoter in CD8+ T cells. Relative to 
naive CD8+ T cells, greater Ikaros binding to the DNAJC15 promoter was found in 
activated CD8+ T cells (Figure 2-5B). Thus, MCJ is present in naive CD8+ T cells as 
an additional checkpoint to restrict potential effector function. 
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The frequency of CD8+ T cells expressing MCJ increased again when 
effector cells were rested in the presence of medium without additional stimuli 
(Figure 2-5A). During the contraction phase, effector CD8+ T cells modulate their 
metabolism, become smaller and less active, and most die except for a few that 
survive to become memory cells (D'Cruz et al., 2009). We examined whether the 
observed reacquisition of MCJ in resting effector CD8+ T cells contributed to the 
attenuation of metabolism or cell survival in vitro during the contraction phase. 
CD8+ T cells were activated for 2 days, washed, and then incubated in medium 
alone (without addition of cytokines). After 24 hours of resting, most WT and MCJ-
deficient CD8+ T cells remained alive (Figure 2-5C). However, after 48 hours only 
a few WT CD8+ T cells remained alive, whereas many MCJ-deficient CD8+ T cells 
were still viable even at 72 hours (Figure 2-5C). In addition, the surviving MCJ-
deficient CD8+ T cells maintain the ‘‘blastic cell stage’’ (large) reminiscent of 
effector cells (data not shown). Analysis of MMP in live cells after 48 hours of 
resting showed that a high proportion of WT CD8+ T cells had low MMP (Figure 
2-5D), similar to naive CD8+ T cells (Supplementary Figure 2-1A). In contrast, a 
large fraction of rested effector MCJ-deficient CD8+ T cells displayed high MMP 
(Figure 2-5D). To determine whether the increased survival in rested MCJ-
deficient CD8+ T cells in vitro was due to their intrinsic metabolic state (high MMP) 
or due to increased IL-2 production that can promote cell expansion, a blocking 
anti-IL-2 antibody was added during the resting period. No differences were 
detected in the survival of MCJ-deficient CD8+ T cells after blocking IL-2 
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(Supplementary Figure 2-3D). Furthermore, the addition of small amounts of 
recombinant IL-2 during the resting period resulted in increased expansion of both 
WT and MCJ-deficient CD8+ T cells (Supplementary Figure 2-3E). Thus, 
reacquisition of MCJ in rested effector CD8+ T cells contributes to the reduction of 
mitochondrial activity, restoration of a quiescent metabolic state and fitness 
impairment of effector CD8+ T cells during the contraction phase in vitro. 
To address the role of MCJ in the contraction phase of antigen specific 
effector CD8+ T cells in vivo, we crossed MCJ-deficient mice with OT-I TCR 
transgenic mice, which express a TCR that recognizes ovalbumin. MCJ deficiency 
did not affect the development of OT-I CD8+ T cells (Supplementary Figure 2-4A). 
Similar to polyclonal CD8+ T cells, naive MCJ-deficient OT-I CD8+ T cells also 
displayed high MMP relative to WT CD8+ T cells (Figure 2-5E). CD8+ T cells were 
purified from OT-I and MCJ-deficient OT-I mice, activated for 2 days in vitro, and 
then further expanded for 3 days. An equal number of cells from each genotype 
were combined and cotransferred into the same WT recipient mice (Figure 2-5F). 
After 2 weeks, donor cells present in LN and spleen of host mice were examined 
by flow cytometry using CD90.1 and CD90.2 markers (Supplementary Figure 2-4B 
and C). Phenotypic characterization of the cells based on CD44 and CD62L 
(memory and homing markers) as well as KLRG1 and CD127 (markers that define 
subsets of long lived effector and memory T cells (Jameson and Masopust, 2009; 
Kaech and Wherry, 2007; Sarkar et al., 2008)) did not show differences between WT 
and MCJ-deficient CD8+ OT-I T cells (Supplementary Figure 2-4B and C). The 
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overall percentage of cell recovery in both donors was comparable (data not 
shown). However, as determined by forward scatter (Figure 2-5G), only a few WT 
OT-I CD8+ T cells showed a large blastic phenotype (Figure 2-5H). In contrast, a 
greater fraction of MCJ-deficient OT-I CD8+ T cells displayed the large blastic 
phenotype (Figure 2-5H). Thus, in vivo MCJ does not seem to contribute to cell 
survival but does participate in the attenuation of metabolism during the 







Figure 2-5. MCJ Deficiency Sustains the Metabolic Activity of 
Effector CD8+ T Cells during the Contraction Phase 
 
WT (blue) and MCJ-deficient CD8+ T cells (MCJ def, red). (A) Frequency of 
b-galactosidase+ MCJ-deficient CD8+ T cells that were naive, activated for 2 days 
with anti-CD3 and anti-CD28 antibodies, or activated for 2 days and then rested 
in medium without stimuli for 48 hours (2 d + 48 h) or 72 hours (2 d + 72 h) as 
determined by flow cytometry analysis. (B) Ikaros binding to the DNAJC15 gene 
(encodes MCJ) promoter in naive and activated (2 days) cells by ChIP assay. Fold 
increase over rabbit IgG immunoprecipitates relative to input shown. (C) Cells 
were activated for 2 days, washed, and rested in medium. The number of live cells 
recovered relative to the initial number is shown. (D) MMP was examined by 
TMRE staining in cells activated for 2 days and rested for 48 hours. (E) MMP in 
freshly isolated OT-I and MCJ-deficient OT-I CD8+ T cells. (F – H) OT-I (CD90.1+) 
and MCJ-deficient OT-I (CD90.1+ CD90.2+) CD8+ T cells were activated for 2 days 
and then expanded with IL-2 for 3 days. Equal numbers of each cell type were then 
adoptively transferred into WT (CD90.2+) recipient mice. LN and spleen of 





































































































































































recipients were harvested after 2 weeks and analyzed for donor cells. (G and H) 
Forward scatter of CD8+ OT-I T cells as determined by flow cytometry analysis. 
*p <  0.05 by unpaired t test. Avg ± SD (n ³ 3) shown. Results are representative of 
2 – 3 experiments. See also Supplementary Figure 2-3 and Supplementary Figure 
2-4. 
 
3.5. MCJ Deficiency Enhances the Antiviral Protective Activity of Memory CD8+ 
T cells 
Memory CD8+ T cells are believed to play an important role in protection 
against influenza viral infection (La Gruta and Turner, 2014). Recent studies 
indicate that increased mitochondrial respiration in CD8+ T cells results in 
increased memory activity (van der Windt et al., 2013). We investigated the role of 
MCJ in protective memory CD8+ T cell responses using an influenza virus 
infection model. WT and MCJ-deficient mice were intranasally infected with a 
sublethal dose of influenza A/Puerto Rico/8/34 (PR8) H1N1 virus. As expected, 
based on the predominant role of innate immunity in primary infection with 
influenza virus, no significant differences were observed in weight loss and 
recovery or survival between infected WT and MCJ-deficient mice during primary 
infection (Figure 2-6A). Analysis of influenza NP-tetramer+ CD8+ T cells 2 weeks 
post-infection also showed a similar frequency between infected WT and MCJ-
deficient mice (Figure 2-6B), indicating that the loss of MCJ did not affect the 
expansion of effector CD8+ T cells in vivo, consistent with the in vitro studies. 
However, ex vivo analysis of IFN-g production by CD8+ T cells showed higher 
IFN-g in the supernatants of MCJ-deficient CD8+ T cells (Figure 2-6C). Thus, MCJ 
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deficiency results in increased IFN-g production by effector CD8+ T cells in vivo 
during virus infection. 
We then addressed whether the lack of MCJ could affect memory CD8+ 
T cell development. Analysis of influenza NP-tetramer+ CD8+ T cells 3 and 5 weeks 
post-infection showed a lower percentage relative to 2 weeks post-infection as 
expected, but there was no difference in the frequency between WT and MCJ-
deficient mice (Figure 2-6B and Supplementary Figure 2-5A). This further 
supported the finding that lack of MCJ does not affect cell survival during the 
generation of memory CD8+ T cells from effector cells in vivo. Phenotypic analysis 
of NP-tetramer+ CD8+ T cells for CD44, CD62L, KLRG1, and CD127 showed no 
substantial difference between WT and MCJ-deficient CD8+ T cells 
(Supplementary Figure 2-5B and data not shown). Lower CD27 expression was 
found in the MCJ-deficient CD8+ T cell memory population (Supplementary 
Figure 2-5B). CD27low memory cells mediate rapid protective immunity against 
acute infection and manifest high cytolytic activity (Olson et al., 2013). 
To investigate the protective capacity of memory MCJ-deficient CD8+ 
T cells, we performed adoptive transfer of equal numbers WT and MCJ-deficient 
CD8+ T cells obtained 5 weeks post-infection separately into WT recipient mice. 
Recipient mice were then infected with a lethal dose of PR8 virus. As expected, 
recipient mice that received cells from infected WT mice were not protected, did 
not recover their weight, and died between 8 and 9 days post lethal infection 
(Figure 2-6E and F). In contrast, most recipient mice that received cells from 
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infected MCJ-deficient mice were protected and survived (Figure 2-6E). Mice 
receiving MCJ-deficient CD8+ T cells lost weight initially, indicating that they had 
been infected, but they recovered to a healthy state (Figure 2-6F). Thus, the absence 
of MCJ in memory CD8+ T cells confers greater protective capacity against 
influenza virus infection. 
Death caused by some of the highly pathogenic influenza viruses (such as 
H5N1 influenza) is often associated with a strong systemic immune response and 
cytokine storm. To rule out that the death of the recipients of WT CD8+ T cells was 
caused by an exuberant immune response, we examined cytokine production 6 
days post-infection with the lethal dose. The concentration of inflammatory 
cytokines (IL-6, KC) and chemokines (CXCL10) in brochoalveolar lavage fluid 
(Figure 2-6G) and serum (Supplementary Figure 2-6A) were comparable. These 
results indicate that the protection found in mice that received MCJ-deficient CD8+ 
T cells was not due to an attenuated immune response relative to mice that 
received WT CD8+ T cells. 
To investigate whether the protective capacity of memory MCJ-deficient 
CD8+ T cells was due to an improved effector function to clear virus, we examined 
PR8 virus titers in the lung of recipient mice 6 days post-infection with the lethal 
dose. Higher virus titers were present in host mice that received WT CD8+ T cells 
(Figure 2-6H), indicating that memory MCJ-deficient CD8+ T cells were more 
efficient in clearing influenza virus. To examine the effector function of memory 
MCJ-deficient CD8+ T cells, we isolated CD8+ T cells from the mediastinal LN 
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(MLN) 6 days after the lethal infection and determined ex vivo IFN-g production 
by culturing cells in medium without stimuli. IFN-g was higher in MCJ-deficient 
CD8+ T cells (Figure 2-6I); however, the NP-tetramer+ cell frequency was not 
different (Supplementary Figure 2-6B). Ex vivo IFN-g production by MCJ-deficient 
CD8+ T cells isolated from the lung was also increased (Supplementary Figure 
2-6C), as was the number of IFN-g secreting cells as determined by ELISpot assay 
(Figure 2-6J). However, the frequency of NP-tetramer+ CD8+ T cells in the lung 
was comparable (Supplementary Figure 2-6D), showing a great secretory capacity 
of memory MCJ-deficient CD8+ T cells.  
Secretion of granules by exocytosis is dependent on both Ca2+ and ATP. We 
investigated whether increased mitochondrial ATP production in MCJ-deficient 
CD8+ T cells could also facilitate an increase in exocytosis of cytotoxic granules 
present in effector cells by CD107a mobilization assay. CD8+ T cells were isolated 
from the MLN 6 days after lethal infection and incubated in medium containing 
monensin with or without ionomycin to provide the Ca2+ signal. The frequency of 
CD107a+ MCJ-deficient CD8+ T cells treated with ionomycin was significantly 
higher than WT CD8+ T cells (Figure 2-6K), indicating that MCJ-deficient CD8+ 
T cells have a greater capacity to function as cytotoxic cells. Thus, increased 
mitochondrial respiration caused by the loss of MCJ in CD8+ T cells results in 
increased antiviral protective activity during memory responses by enhancing the 






Figure 2-6. Loss of MCJ Confers Viral Protective Activity to 
Memory CD8+ T Cells 
 
WT (blue) and MCJ-deficient CD8+ T cells (MCJ def, red). (A – D) Mice were 
infected with a sublethal dose of PR8 virus (primary infection). (A) Percent weight 
loss over time. (B) Percentage of NP-tetramer+ cells in the spleen 2 weeks post 
infection. (C) Ex vivo IFN-g production of cells isolated from the spleen and MLN 
2 weeks post infection by ELISA. (D) Percentage of NP-tetramer+ cells from the 
spleen and MLN of mice 5 weeks post infection. (E – K) Mice were infected with a 
sublethal dose of PR8 virus (primary infections). CD8+ T cells were isolated 5 
weeks post infection and adoptively transferred into naive WT recipients, which 
were then infected with a lethal dose of PR8 virus. (E) Survival and (F) percent 
weight loss over time. (G–K) Recipients were sacrificed 6 days post lethal infection. 
(G) BALF cytokines and chemokines. (H) Lung PR8 virus titer by quantitative RT-
PCR. (I) Ex vivo production of IFN-g by MLN CD8+ T cells by ELISA. (J) IFN-g 
secretion by lung CD8+ T cells by ELISpot assay. (K) CD107a mobilization assay of 
MLN CD8+ T cells cultured with (Iono) or without (Med) ionomycin. *p < 0.05 by 
log-rank test for Kaplan-Meier survival curve and by unpaired t test for all others. 
Avg ± SD (n ³ 3) shown. Results are representative of 2 – 3 experiments. See also 
Supplementary Figure 2-5 and Supplementary Figure 2-6. 
Champagne et al. Figure 6






















































































































































































































































Mitochondria play a key role in balancing cellular metabolism primarily as 
the site for OXPHOS through the ETC and as a source of ATP. Recently, it has 
become clear that tight regulation of mitochondrial metabolism occurs during the 
reprograming of CD8+ T cells. A number of molecules have been shown to be 
required for maximum efficiency of the ETC and OXPHOS. However, very little is 
known about negative regulatory mechanisms that restrict mitochondrial 
respiration. We have recently identified MCJ as one of the first known negative 
regulators of complex I activity through its effect on the formation of respiratory 
supercomplexes (Hatle et al., 2013). Our earlier studies demonstrated that the 
absence of MCJ prevents the development of steatosis by accelerating fatty acid 
metabolism within the liver (Hatle et al., 2013). Here we have shown that MCJ 
restrains mitochondrial respiration in CD8+ T cells. In the absence of this natural 
break, CD8+ T cells have enhanced OXPHOS leading to increased secretion of 
cytokines by effector CD8+ T cells. In addition, MCJ deficiency interferes with the 
metabolic adaptation during the contraction phase of effector CD8+ T cells and 
results in greater antiviral protective activity of memory CD8+ T cells. 
Effector and memory CD8+ T cells need ATP for effector functions in 
addition to cell growth and expansion. While CD8+ T cells primarily use glycolysis 
instead of OXPHOS for proliferation (Frauwirth et al., 2002; Macintyre et al., 2011) 
other sources might provide the ATP required for processes with high ATP 
consumption. Production of some cytokines by effector CD8+ T cells is not affected 
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by strong inhibition of glycolysis (Cham et al., 2008), and cytotoxic activity can take 
place in the absence of glucose (MacDonald and Koch, 1977). Considering the 
dynamic aspect of mitochondria as organelles that can rapidly relocate in the 
cytosol, it is quite possible that mitochondria can create a microenvironment that 
is highly rich in ATP in specific locations without elevating overall cytosolic ATP. 
Mitochondria have been shown to relocate to the edge of lamellipodia and are 
critical for providing the energy for migration of cells (Morlino et al., 2014). Our 
studies revealed the presence of microenvironments where ATP and ADP 
accumulate in CD8+ T cells located in the proximity of mitochondria. Here we have 
shown that increased mitochondrial respiration in CD8+ T cells lacking MCJ had 
no effect on CD8+ T cell proliferation or cytokine gene expression, but it enhanced 
the secretion of cytokines such as IFN-g. Little is known about the mechanisms of 
cytokine secretion in T cells; however, secretion of intracellular components often 
is dependent on ATP (Jena, 2013; Monteleone et al., 2015) and the source of this 
ATP, whether mitochondrial or cytosolic, has yet to be determined. Secretion of 
IFN-g by CD8+ T cells in the absence of MCJ is dependent on ATP derived from 
mitochondria. Thus, through OXPHOS mitochondria can regulate effector 
function of CD8+ T cells independently of cell expansion. 
The presence of respiratory supercomplexes in mammalian cells has been 
demonstrated in tissues such as heart. Respirasomes bring the individual 
complexes together to facilitate the efficient transfer of electrons between 
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complexes while preventing electron leak and, thereby, production of ROS. Here 
we revealed the presence of supercomplexes in naive CD8+ T cells and increased 
supercomplex formation in the absence of MCJ. Naive CD8+ T cells primarily use 
mitochondria and OXPHOS relative to activated CD8+ T cells; however, 
mitochondrial ROS are almost undetectable (Hatle et al., 2013). It is possible that 
the presence of supercomplexes prevents the formation of ROS and enhances 
survival of naive cells. Although increased MMP is normally associated with 
increased ROS, in MCJ-deficient CD8+ T cells MMP is higher but ROS is not (Hatle 
et al., 2013). This is most likely due to abundance of supercomplexes in these cells. 
To date, there is no clear evidence that complex II (succinate dehydrogenase) is 
also recruited to supercomplexes. Because complex III receives electrons from both 
complex I and complex II, the recruitment of complex III to supercomplexes might 
cause an uncoupling of complex III from complex II. Therefore, the attenuation of 
complex II activity in the absence of MCJ could be a mechanism to prevent electron 
leakage since its corresponding acceptor, complex III, is sequestered, explaining 
the accumulation of succinate in MCJ-deficient CD8+ T cells.  
Memory CD8+ T cells utilize mitochondrial respiration for both their 
generation and effector function. However, instead of using glucose to feed 
mitochondrial respiration through pyruvate, memory CD8+ T cells perform 
b-oxidation of fatty acids. Recently, it has been shown that these cells utilize 
lipolysis to generate their own fuel (O'Sullivan et al., 2014). Pathways leading to 
increased mitochondrial respiration are associated with a superior memory CD8+ 
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T cell response. In our study, we have identified MCJ as an endogenous negative 
regulator of OXPHOS in CD8+ T cells. Lack of MCJ sustained the active 
metabolism of effector CD8+ T cells during the contraction phase and resulted in 
greater effector memory CD8+ T cell responses to influenza virus. Although MCJ 
deficiency had an impact in the metabolic adaptation during the contraction phase 
of effector CD8+ T cells, it did not seem to have a substantial effect on overall 
survival of those effector cells in vivo. MCJ deficiency appeared to provide a 
survival advantage to effector cells when these cells were rested in medium alone 
without additional cytokines in vitro. This is most likely due to the fact that during 
in vitro resting effector WT CD8+ T cells undergo cytokine withdrawal. We also 
show here that WT memory CD8+ T cells alone failed to provide protection against 
a lethal dose of influenza virus. Strikingly, MCJ-deficient memory CD8+ T cells 
were highly protective against lethal infection with influenza. Using the LCMV 
infection model, it has been shown that CD4+ T cells can rescue exhausted CD8+ T 
cells during chronic viral infection (Aubert et al., 2011). We also observed that a 
small frequency of CD4+ T cells was sufficient for WT memory CD8+ T cells to 
provide protection against influenza virus infection (data not shown). Because 
MCJ deficiency results in enhanced CD8+ T cell responses, it is not evolutionarily 
clear why MCJ is expressed in CD8+ T cells. While CD8+ T cells are key for 
protection, an exaggerated cytotoxic CD8+ T cell response could cause non-specific 
tissue damage. We propose that MCJ was acquired in CD8+ T cells as a strategy to 
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restrain their metabolism and prevent a prolonged effector function that could be 
harmful. 
 
5. Experimental Procedures 
5.1. Mice 
Mouse strains used were C57BL/6J (WT), MCJ-deficient C57BL/6 (Hatle et 
al., 2013), OT-I TCR transgenic, and MCJ-deficient OT-I. All mice were maintained 
at the University of Vermont animal care facility and used under procedures 
approved by the University of Vermont Institutional Animal Care and Use 
Committee (IACUC). 
5.2. Cell Preparation and Culture 
Cells were purified by negative selection or positive selection using the 
MACS Cell Separation System (Miltenyi). Cytokine production was determined 
by ELISA. Detailed protocols are described in Supplemental Experimental 
Procedures.  
5.3. Extracellular Flux Analysis 
Oxygen consumption (OCR) and extracellular acidification rates (ECAR) 
were analyzed using a XF24 Extracellular Flux analyzer (Seahorse Bioscience). 
Detailed protocols are described in Supplemental Experimental Procedures. 
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5.4. Intracellular ATP Concentration 
ATP concentration was determined using the ATPlite Luminescence Assay 
System and a TD-20/20 Luminometer. Detailed protocols are described in 
Supplemental Experimental Procedures. 
5.5. Flow Cytometry Analyses 
Flow cytometry analyses were performed using an LSRII Flow Cytometer 
(BD Biosciences). Cell proliferation, survival, and MMP were determined using 
CFSE, Live Dead Cell Viability Assay, and TMRE (Molecular Probes). 
b-galactosidase activity was determined using the FACS Fluorescent Blue lacZ 
b-Galactosidase Detection Kit (Marker Gene Technologies). Intracellular cytokine 
staining was performed without brefeldin A or monensin. CD107a mobilization 
assay was performed using monensin and an anti-CD107a PE antibody 
(Biolegend) with or without ionomycin. Detailed protocols are described in 
Supplemental Experimental Procedures.  
5.6. Chromatin Immunoprecipitation 
ChIP assays were performed using the SimpleChip Enzymatic Chromatin 
IP Kit (Cell Signaling) with anti-Ikaros or rabbit IgG. Detailed protocols are 
described in Supplemental Experimental Procedures. 
5.7. Influenza Infection and Analyses 
Mice were infected intranasally with a sublethal dose of PR8 virus. CD8+ 
T cells were isolated after 5 weeks, equal numbers of NP-tetramer+ cells were 
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transferred to naive WT mice. Recipients were infected with a lethal dose and 
sacrificed 6 days later. CD8+ T cells from the MLN and lung were examined for 
ex vivo IFN-g production by ELISA and/or ELISpot assay and for effector and 
memory cell surface markers, NP-tetramer+ cell frequency, and/or CD107a 
mobilization by flow cytometry. BALF and serum were analyzed by Luminex 
assay (Millipore). Lung was examined for PR8 virus titer by quantitative RT-PCR 
for acid polymerase. Detailed protocols are described in Supplemental 
Experimental Procedures.  
5.8. Confocal Microscopy 
Cells were examined by confocal microscopy using ATP probe and/or 
Mitotracker and a Zeiss LSM 510 Meta Confocal Laser Scanning microscope (Carl 
Zeiss Microscopy). Detailed protocols are described in Supplemental 
Experimental Procedures.  
5.9. Statistical Analyses 
Statistical significance was determined by t test or long-rank test as 
indicated. Bars represent average ± SD or SEM as indicated. p < 0.05 was 
considered statistically significant. 
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7. Supplementary Information 




Supplementary Figure 2-1. MCJ does not affect T cell development 
in the thymus or homeostasis in the peripheral immune system but 
increases amino acid import 
 
WT, blue; MCJ-deficient (MCJ def), red. (A) Mitochondrial membrane potential 
(MMP) of freshly isolated CD8+ T cells from the spleen and LN was determined 
by TMRE staining and flow cytometry analysis. (B) CD4 and CD8 expression by 
thymocytes, splenocytes, and lymph node (LN) cells was examined by flow 
cytometry analyses. Numbers indicate the percentage of cells in each gate. (C) 
CD44 expression by CD4+ and CD8+ T cells from the spleen and LN was 
determined by flow cytometry analysis. (D) Freshly isolated CD8+ T cells were 
cultured in the presence of 13C- and 15N-labeled amino acids for the indicated 
times, and [13C, 15N]-glutamine was determined by UPLC-MS analysis. *p < 0.05 
by paired t test. Avg ± SEM (n = 3) shown. See also Figure 2-1 and Figure 2-5. 
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Supplementary Figure S1. MCJ does not affect T cell development in the thymus or homeostasis
in the peripheral immune syst m but increases amino acid import. W , blue; MCJ-deficient (MCJ
def), red. (A) Mitochondrial membrane potential (MMP) of freshly isolated CD8+ T cells from the spleen
and LN was determined by TMRE staining and flow cytometry analysis. (B) CD4 and CD8 expression by
thymocytes, splenocytes, and lymph node (LN) cells was examined by flow cytometry analyses. Numbers
indicate the percentage of cells in each gate. (C) CD44 expression by CD4+ and CD8+ T cells from the
spleen and LN was determined by flow cytometry analysis. (D) Freshly isolated CD8+ T cells were
cultured in the presence of 13C and 15N labeled amino acids for the indicated times, and [13C, 15N]-
glutamine was determined by UPLC-MS analysis. *, p<0.05 by paired t test (n=3). Avg ± SEM. See also






Supplementary Figure 2-2. MCJ deficiency increases the secretion, 
but not production, of cytokines by CD8+ T cells 
 
(A) MCJ-deficient CD8+ T cells were activated for 2 day with anti-CD3 and anti- 
CD28 antibodies. Cells were then washed and rested in medium (Med) or in the 
presence of cycloheximide (CHX, 5 µg/ml) for 12 hours. IFN-g in the culture 
supernatants was determined by ELISA. (B) Total protein content in 5 x 105 freshly 
isolated CD8+ T cells prior to (unstim) and 20 hours after activation with anti-CD3 
and anti-CD28 antibodies in the absence (-) or presence (CHX) of cycloheximide. 
(C and D) WT (blue) and MCJ-deficient (MCJ def, red) CD8+ T cells were activated 
for 2 days with anti-CD3 and anti-CD28 antibodies. (C) Cells were then washed 
and incubated without stimuli for 4 hours. IL-2 and GM-CSF in the culture 
supernatants were then determined by ELISA. (D) Cells were then washed and 
rested for 1 hour, and intracellular IFN-g was determined by intracellular cytokine 
staining and flow cytometry analysis. *p < 0.05 by unpaired t test. Avg ± SD (n ≥ 3) 
shown. See also Figure 2-2. 
Supplementary Figure S2. MCJ deficiency increases the secretion, but not production, of
cytokines by CD8+ T cells. (A) MCJ-deficient CD8+ T cells were activated for 2 d with anti-CD3 and anti-
CD28. Cells were then washed and rested in medium (Med) or in the presence of cycloheximide (CHX, 5
µg/ml) for 12 h. IFN-g in the culture supernatants was determined by ELISA. (B) Total protein content in 5
x 105 freshly isolated CD8+ T cells prior to (unstim) and 20 h after activation with anti-CD3 and -CD28 in
the absence (-) or pres nce (CHX) of cycloheximide. (C, D) WT (blu ) and MCJ- eficient CJ def, red)
CD8+ T cells were activated for 2 d with anti-CD3 and -CD28. (C) Cells were then washed and incubated
without stimuli for 4 h. IL-2 and GM-CSF in the culture supernatants were determined by ELISA. (D) Cells
were then washed and r sted for 1 h, and intracellular IFN-g was determined by intracellular cytokine


































































Supplementary Figure 2-3. MCJ deficiency in CD8+ T cells 
increases mitochondrial ATP production, IFN-g secretion, and cell 
survival 
 
(A) Confocal microscopy images in combination with bright field of live MCJ-
deficient CD8+ T cells activated for 2 days with anti-CD3 and anti-CD28 antibodies 
followed by incubation with or without oligomycin for 2 hours. Left, cells cultured 
in medium alone (unstained). Middle, cells in medium with ATP probe. Right, 
cells incubated with oligomycin and ATP probe. (B) MCJ-deficient CD8+ T cells 
were activated for 2 days, and oligomycin was added during the last hour of 
activation. Cells were then washed and replated with oligomycin for 4 hours. 
Intracellular IFN-g was determined by intracellular cytokine staining and flow 
cytometry analysis. Red, medium alone; green, oligomycin. The percentage of cells 
in each gate is indicated. (C) Freshly isolated WT (blue) and MCJ-deficient (red) 











Supplementary Figure S3. MCJ deficiency in CD8+ T cells increases mitochondrial ATP production,
IFN-g secretion, and cell survival. (A) Confocal microscopy images in combination with bright field of live
MCJ-deficient CD8+ T cells activated for 2 d with anti-CD3 and anti-CD28 followed by incubation with or
without oligomycin for 2 h. Left, cells cultured in medium alone (unstained). Middle, cells in medium with
ATP probe. Right, cells incubated with oligomycin and ATP probe. (B) MCJ-deficient CD8+ T cells were
activated for 2 d, and oligomycin was added during the last hour of activation. Cells were then washed and
replated with oligomycin for 4 h. Intracellular IFN-g was determined by intracellular cytokine staining and
flow cytometry analysis. Red, medium alone; green, oligomycin. The percentage of cells in each gate is
indicated. (C) Freshly isolated WT (blue) and MCJ-deficient (red) CD8+ T cells were analyzed for b-
galactosidase activity by flow cytometry. The percentage of b-galactosidase positive cells in MCJ-deficient
cells is shown. WT cells are shown as a negative control. (D, E) WT (blue) and MCJ-deficient (MCJ def,
red) CD8+ T cells were activated for 2 d, washed, and replated at eq al numbers in medi m without
stimulation. After 24 h, culture supernatants were supplemented with (D) anti-IL-2 or (E) recombinant IL-2.
The number of live cells was determined 24 h later (48 h after replating) by Trypan blue exclusion.
Columns indicate avg ± SD cell survival relative to the starting number of cells. *, p<0.05 by unpaired t test















































percentage of β-galactosidase+ MCJ-deficient cells is indicated. WT cells are shown 
as a negative control. (D and E) WT (blue) and MCJ-deficient (MCJ def, red) CD8+ 
T cells were activated for 2 days, washed, and replated at equal numbers in 
medium without stimulation. After 24 hours, culture supernatants were 
supplemented with (D) anti-IL-2 antibody or (E) recombinant IL-2. The number of 
live cells was determined 24 hours later (48 hours after replating) by Trypan blue 
exclusion. Bars indicate cell survival relative to the initial number of cells. *p < 0.05 






Supplementary Figure 2-4. MCJ-deficient CD8+ OT-I T cells 













OT-I OT-I MCJ def
Supplemental Figure 4. MCJ-deficient CD8+ OT-I T cells maintain their large blastic size during the
contraction phase in vivo. OT-I, blue; OT-I MCJ-deficient (MCJ def), red. (A) CD4 and CD8 expression
by splenocytes and lymph node (LN) cells was examined by flow cytometry analyses. Numbers indicate
the percentage of cells in each gate. (B, C) OT-I and OT-I MCJ-deficient CD8+ T cells were activated with
anti-CD3 and anti-CD28 for 2 d and then expanded with IL-2 for an additi nal 3 d. Equal numbers of OT-I
(CD90.1+) and OT-I MCJ-deficient (CD90.1+ CD90.2+) CD8+ T cells were combined and adoptively
transferred to C57BL/6 (CD90.2+) recipient mice (n=4). LN and spleen were harvested after 2 wks and
analyzed by flow cytometry. (B) Dot plots showing FSC and SSC of total spleen and LN cells from
recipients (upper panel) and CD90.1 and CD90.2 expression used to discriminate donor and recipient
cells (lower panel). (C) OT-I and OT-I MCJ-deficient CD8+ Vα2+ (OT-I TCR) T cells gated as shown in (B)
were examined for FSC and surface expression of CD44, CD62L, KLRG1, and CD127. Numbers indicate
the percentage of cells in each gate. Note the increased fraction of OT-I MCJ-deficient CD8+ T cells that


























































OT-I, blue; OT-I MCJ-deficient (MCJ def), red. (A) CD4 and CD8 expression by 
splenocytes and lymph node (LN) cells was examined by flow cytometry analyses. 
Numbers indicate the percentage of cells in each gate. (B and C) OT-I and OT-I 
MCJ-deficient CD8+ T cells were activated with anti-CD3 and anti-CD28 
antibodies for 2 days and then expanded with recombinant IL-2 for an additional 
3 days. Equal numbers of OT-I (CD90.1+) and OT-I MCJ-deficient (CD90.1+ 
CD90.2+) CD8+ T cells were combined and adoptively transferred to C57BL/6 
(CD90.2+) recipient mice (n = 4). LN and spleen were harvested after 2 weeks and 
analyzed by flow cytometry. (B) Dot plots showing FSC and SSC of total spleen 
and LN cells from recipients (upper panel) and CD90.1 and CD90.2 expression 
used to discriminate donor and recipient cells (lower panel). (C) OT-I and OT-I 
MCJ-deficient CD8+ Vα2+ (OT-I TCR) T cells gated as shown in (B) were examined 
for FSC and surface expression of CD44, CD62L, KLRG1, and CD127. Numbers 
indicate the percentage of cells in each gate. Note the increased fraction of OT-I 
MCJ-deficient CD8+ T cells that have a large, blastic size (higher FSC). See also 






Supplementary Figure 2-5. MCJ deficiency does not increase the 
number of influenza-specific CD8+ T cells or have a significant 
effect on memory cell populations 
 
(A and B) WT and MCJ-deficient (MCJ def) mice (n = 5) were infected with a 



























































Supplementary Figure 5. MCJ deficiency does not increase the number of influenza-specific CD8+
T c lls or have a significant effect on memory cell populations. (A, B) WT and MCJ-deficient (MCJ
def) mice (n=5) were infected with a sublethal dose of influenza virus and allowed to recover from this
primary infection. (A) The number of NP-tetramer+ CD8+ cells in the spleen was determined 3 weeks post-
infection by flow cytometry analysis. (B) Five weeks post-primary infection, CD8+ T cells were isolated
from the spleen and draining mediastinal lymph node and pooled for adoptive transfer into naïve WT
(C57 L/6) recipie t mice. Shown is the phenotype of the donor CD8+ T cells analyzed for CD8, NP
tetramer, KLRG1, CD127, CD62L, CD27, and CD44 surface expression by flow cytometry analysis. *,



























infection. (A) The number of NP-tetramer+ CD8+ cells in the spleen was 
determined 3 weeks postinfection by flow cytometry analysis. (B) Five weeks post 
primary infection, CD8+ T cells were isolated from the spleen and draining MLN 
and pooled for adoptive transfer into naïve WT (C57BL/6) recipient mice. Shown 
is the phenotype of the donor CD8+ T cells analyzed for CD8, NP-tetramer, 
KLRG1, CD127, CD62L, CD27, and CD44 surface expression by flow cytometry 






Supplementary Figure 2-6. Effector function of influenza-specific 
memory CD8+ T cells 
 
WT recipient mice were lethally infected with influenza after receiving either WT 
or MCJ-deficient (MCJ def) CD8+ T cells from donor mice that had recovered from 
a sublethal primary infection with influenza. Recipients were sacrificed 6 days 
post lethal infection. (A) Cytokines in the serum were analyzed by Luminex assay. 
(B) Influenza specific CD8+ T cells in the spleen were determined by staining with 
NP-tetramer and flow cytometry analysis. (C) CD8+ T cells from the lung were 
incubated in medium without stimulation for 11 hours, and IFN-g in the culture 
supernatant was determined by ELISA. (D) Influenza specific CD8+ T cells in the 
lung were determined as in (B). *p < 0.05 by unpaired t test. Avg ± SD (n ≥ 3) 





























































































































Supplementary Figure S6. Effector function of influenza-specific memory CD8+ T cells.WT recipient
mice were lethally infected with influenza after receiving either WT or MCJ-deficient (MCJ def) CD8+ T
cells from donor mice that had recovered from a sublethal primary infection with influenza. Recipients
were sacrificed 6 days post-lethal infection. (A) Cytokines in the serum were analyzed by Luminex assay.
(B) Influenza-specific CD8+ T cells in the spleen were determined by staining with NP tetramer and flow
cytometry analysis. (C) CD8+ T cells from the lung were incubated in medium without stimulation for 11h,
and IFN-g in the culture supernatant was determined by ELISA. (D) Influenza-specific CD8+ T cells in the
lung were determined as in (B). *, p<0.05 by unpaired t test. Avg ± SD (n≥3) shown. See also Fig. 6.
 
143 
7.2. Supplementary Tables 
Supplementary Table 2-1. Metabolome Analysis of Naive CD8+ T Cells 
 
Pathway Compound 





lysine 5.11E+05 9.69E+05 1.90 0.036 
methionine 5.06E+05 8.87E+05 1.75 0.006 
histidine 3.93E+05 6.66E+05 1.70 0.030 
asparagine 4.70E+05 7.51E+05 1.60 0.004 
tyrosine 1.04E+06 1.53E+06 1.47 0.012 
tryptophan 2.35E+05 3.41E+05 1.45 0.047 
leucine 4.69E+06 6.75E+06 1.44 0.018 
arginine 1.05E+06 1.51E+06 1.44 0.127 
serine 6.82E+05 9.54E+05 1.40 0.079 
valine 6.31E+06 8.69E+06 1.38 0.002 
cysteine 1.72E+05 2.35E+05 1.37 0.058 
threonine 8.59E+05 1.17E+06 1.36 0.051 
phenylalanine 1.12E+06 1.45E+06 1.30 0.032 
glutamine 1.36E+06 1.76E+06 1.29 0.115 
alanine 8.64E+06 1.05E+07 1.22 0.086 
proline 4.55E+06 5.45E+06 1.20 0.165 
glutamate 1.42E+07 1.58E+07 1.11 0.302 
glycine 7.14E+06 7.83E+06 1.10 0.086 
cystine 3.74E+03 3.73E+03 1.00 0.524 
aspartate 8.41E+06 7.65E+06 0.91 0.621 
Nucleotides 
inosine 7.37E+03 7.20E+04 9.78 0.399 
guanosine 1.42E+04 3.42E+04 2.40 0.400 
adenosine 2.32E+05 4.83E+05 2.08 0.129 
5-hydroxyisourate 1.14E+04 1.69E+04 1.49 0.459 
UMP 1.12E+05 1.50E+05 1.34 0.143 
cytidine 3.79E+04 5.07E+04 1.34 0.634 
guanine 6.37E+04 7.72E+04 1.21 0.675 
AMP 2.86E+06 3.42E+06 1.19 0.416 
nicotinamide 6.79E+06 7.97E+06 1.17 0.631 
uracil 6.15E+05 7.19E+05 1.17 0.155 
4-pyridoxate 1.12E+07 1.15E+07 1.03 0.991 
5-6-dihydrothymine 1.11E+06 1.12E+06 1.01 0.427 
hypoxanthine 3.98E+05 3.72E+05 0.93 0.370 
NAD+ 9.11E+04 6.93E+04 0.76 0.291 
adenine 3.63E+05 1.83E+05 0.50 0.329 
 
*Median value of 3 independent biological replicates. †Fold increase of median peak area calculated 
as KO/WT. ‡Determined by unpaired t test (n = 3).  
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Supplementary Table 2-1 (continued) 
 
Pathway Compound 
*Peak Area †Fold 
Increase 
‡p-value WT KO 
Glycolysis & Sugars 
D-glucose 6.22E+04 8.48E+04 1.36 0.508 
pyruvate 3.75E+06 3.89E+06 1.04 0.222 
mannitol 5.30E+05 5.46E+05 1.03 0.402 
lactate 1.24E+07 1.27E+07 1.02 0.508 
TCA Cycle 
succinate 3.39E+04 2.00E+05 5.89 0.014 
2-hydroxyglutarate 4.00E+04 6.50E+04 1.63 0.023 
oxaloacetate 9.54E+04 1.26E+05 1.32 0.166 
citrate 1.82E+05 2.23E+05 1.23 0.128 
malate 1.53E+05 1.62E+05 1.06 0.482 
2-oxoglutaramate 5.05E+05 4.91E+05 0.97 0.318 
cis-aconitate 4.03E+05 3.45E+05 0.86 0.269 
fumarate 1.24E+05 1.03E+05 0.83 0.106 
Pentose Phos. Pathway α-D-ribose 1-phosphate 9.01E+03 1.04E+04 1.15 0.550 
Glutathione 
Homeostasis 
glutathione 1.61E+07 2.00E+07 1.24 0.319 
5-oxoproline 4.74E+06 5.06E+06 1.07 0.386 
dehydroascorbate 4.03E+05 3.45E+05 0.86 0.269 
ascorbate 1.10E+06 8.20E+05 0.75 0.223 
Gamma-glutamyls γ-L-glutamyl-[acp] 8.73E+04 1.46E+05 1.68 0.119 γ-L-glutamyl-L-cysteine 4.86E+03 4.70E+03 0.97 0.727 
Serine Biosynthesis 
& 1C Metabolism 
D-O-phosphoserine 2.45E+04 3.13E+04 1.28 0.456 
N-N-dimethylglycine 2.57E+06 2.72E+06 1.06 0.360 
Urea cycle 
L-citrulline 6.67E+04 9.90E+04 1.48 0.015 
ornithine 9.93E+05 9.24E+05 0.93 0.464 
N-(L-rginino)succinate 9.52E+03 5.14E+03 0.54 0.975 
Aminosugars 
N-acetylneuraminate 3.09E+04 4.18E+04 1.35 0.015 
N-glycoloyl-neuraminate 2.64E+04 3.29E+04 1.25 0.116 
Arginine & 
Proline Metabolism 
creatinine 5.46E+05 5.71E+05 1.05 0.806 
creatine 2.97E+06 3.01E+06 1.02 0.680 
Sulfur metabolism 
L-selenomethionine 1.40E+04 2.10E+05 15.00 0.004 
L-cysteate 3.93E+04 4.71E+04 1.20 0.194 
hypotaurine 4.00E+04 4.20E+04 1.05 0.463 
taurine 3.05E+07 3.13E+07 1.02 0.604 





Supplementary Table 2-2. Metabolome Analysis of Activated CD8+ T Cells 
 
Pathway Compound 
*Peak Area †Fold 
Increase 
‡p-value WT KO 
Amino Acids 
alanine 2.00E+07 3.73E+07 1.86 0.211 
proline 9.84E+07 1.63E+08 1.66 0.418 
glycine 1.06E+07 1.75E+07 1.66 0.007 
serine 4.56E+06 7.24E+06 1.59 0.032 
cysteine 8.51E+05 1.34E+06 1.57 0.001 
glutamate 7.11E+07 1.11E+08 1.56 0.005 
glutamine 1.94E+07 2.95E+07 1.52 0.008 
asparagine 8.41E+06 1.25E+07 1.49 0.011 
histidine 2.97E+06 4.31E+06 1.45 0.000 
threonine 1.68E+07 2.44E+07 1.45 0.006 
tryptophan 2.91E+06 4.11E+06 1.41 0.000 
phenylalanine 2.34E+07 3.22E+07 1.38 0.001 
leucine 1.19E+08 1.60E+08 1.35 0.001 
tyrosine 2.69E+07 3.57E+07 1.33 0.228 
methionine 1.41E+07 1.85E+07 1.31 0.000 
arginine 7.92E+06 9.99E+06 1.26 0.004 
valine 6.28E+07 7.83E+07 1.25 0.000 
lysine 1.95E+06 2.19E+06 1.13 0.022 
aspartate 1.18E+07 1.24E+07 1.05 0.005 
cystine 4.07E+05 3.61E+05 0.89 0.223 
Nucleotides 
cytidine 4.07E+05 1.29E+06 3.17 0.271 
guanine 1.91E+06 4.11E+06 2.15 0.508 
adenosine 3.99E+05 7.46E+05 1.87 0.065 
AMP 2.80E+06 4.75E+06 1.70 0.010 
hypoxanthine 6.21E+05 1.02E+06 1.64 0.022 
5-hydroxyisourate 2.05E+06 3.24E+06 1.58 0.307 
UMP 9.04E+05 1.24E+06 1.37 0.003 
nicotinamide 1.38E+07 1.86E+07 1.35 0.516 
inosine 3.42E+05 4.55E+05 1.33 0.217 
4-pyridoxate 3.44E+07 4.34E+07 1.26 0.262 
5-6-dihydrothymine 1.02E+06 1.23E+06 1.20 0.295 
uracil 6.58E+05 7.88E+05 1.20 0.004 
guanosine 8.31E+05 9.64E+05 1.16 0.010 
NAD+ 1.68E+06 1.80E+06 1.07 0.784 
adenine 2.10E+05 1.62E+05 0.77 0.153 
 
*Median value of 3 independent biological replicates. †Fold increase of median peak area calculated 
as KO/WT. ‡Determined by unpaired t test (n = 3).  
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Supplementary Table 2-2 (continued) 
 
Pathway Compound 
*Peak Area †Fold 
Increase 
‡p-value WT KO 
Glycolysis & Sugars 
lactate 1.77E+07 2.42E+07 1.37 0.397 
pyruvate 3.43E+06 3.89E+06 1.13 0.008 
D-glucose 6.10E+05 4.59E+05 0.75 0.075 
mannitol 1.08E+06 7.74E+05 0.72 0.063 
TCA Cycle 
succinate 5.14E+05 1.39E+06 2.70 0.058 
2-hydroxyglutarate 1.70E+05 3.50E+05 2.06 0.314 
malate 1.98E+06 3.64E+06 1.84 0.711 
fumarate 2.35E+05 4.26E+05 1.81 0.306 
citrate 7.12E+05 8.68E+05 1.22 0.011 
2-oxoglutaramate 5.09E+05 5.11E+05 1.00 0.038 
cis-aconitate 1.80E+04 1.53E+04 0.85 0.033 
oxaloacetate 2.49E+05 2.01E+05 0.81 0.373 
Pentose Phos. Pathway α-D-ribose 1-phosphate 7.26E+04 6.92E+04 0.95 0.951 
Glutathione 
Homeostasis 
dehydroascorbate 4.63E+03 ND --- 0.340 
5-oxoproline 4.18E+07 5.45E+07 1.30 0.009 
glutathione 7.21E+07 9.00E+07 1.25 --- 
ascorbate 1.75E+04 2.02E+04 1.16 0.088 
Gamma-glutamyls γ-L-Glutamyl-L-cysteine 1.60E+05 2.25E+05 1.40 0.018 γ-L-Glutamyl-[acp] 2.03E+05 2.38E+05 1.17 0.906 
Serine Biosynthesis 
& 1C Metabolism 
D-O-phosphoserine 3.34E+05 5.95E+05 1.78 0.326 
N-N-dimethylglycine 2.40E+06 2.49E+06 1.04 0.071 
Urea cycle 
L-citrulline 1.77E+05 3.97E+05 2.24 0.051 
N-(L-arginino)succinate 2.33E+05 4.62E+05 1.98 0.134 
ornithine 9.32E+05 9.98E+05 1.07 0.000 
Aminosugars 
N-glycoloyl-neuraminate 5.43E+04 6.20E+04 1.14 0.564 
N-acetylneuraminate 7.21E+04 7.78E+04 1.08 0.082 
Arginine & 
Proline Metabolism 
creatine 4.83E+06 7.71E+06 1.60 0.039 
creatinine 6.31E+05 5.60E+05 0.89 0.134 
Sulfur metabolism 
L-selenomethionine 9.25E+03 2.00E+05 21.62 0.154 
L-cysteate 1.98E+05 2.89E+05 1.46 0.001 
taurine 2.56E+07 2.97E+07 1.16 0.030 
hypotaurine 1.10E+05 1.20E+05 1.09 0.685 





7.3. Supplemental Experimental Procedures 
7.3.1. Mice 
All mice were bred and maintained under sterile conditions at the 
University of Vermont animal care facility and used under procedures approved 
by the University of Vermont Institutional Animal Care and Use Committee 
(IACUC). Mouse strains used were WT C57BL/6J (Jackson Laboratories), MCJ-
deficient C57BL/6 (Hatle et al., 2013), OT-I TCR transgenic (Hogquist et al., 1994), 
and MCJ-deficient OT-I.  
7.3.2. Cell preparation and culture 
CD8+ T cells were purified from spleen and lymph nodes (LN) by negative 
selection as previously described (Farley et al., 2006) and by positive selection 
using the MACS Cell Separation System (Miltenyi) as recommended by the 
manufacturer. The purity of isolated cells was confirmed by flow cytometry. Cells 
were activated in vitro using plate bound anti–CD3 (5 µg/mL) and soluble anti–
CD28 (1 µg/mL) antibodies (BioXcell). For analysis of cytokine secretion during 
resting, cells were activated for 2 days, washed, and incubated at equal numbers 
in medium alone without additional stimuli for 4 – 12 hours. Culture supernatants 
of activated and rested cells were analyzed for IFN-g, IL-2, and/or GM-CSF by 
ELISA. Cells were also incubated with or without oligomycin (20 µM, Sigma) or 
cycloheximide (5 µg/ml, Sigma). For cell survival analysis, activated cells were 
washed and incubated at equal numbers in medium without further stimulation 
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or the presence of exogenous cytokines. In some cases, the culture medium was 
supplemented with a blocking anti-IL-2 antibody or recombinant IL-2 after 24 
hours. Live cells were determined by Trypan blue exclusion at 24, 48, and 72 hours 
after replating.  
7.3.3. Mitochondrial respiration and extracellular acidification 
Oxygen consumption rates (OCR) of CD8+ T cells were analyzed under 
basal conditions and in response to sequential injections of oligomycin, FCCP, and 
rotenone with antimycin A (1 µM each) using the Seahorse MitoStress Test Kit. 
Extracellular acidification rates (ECAR) were analyzed under basal conditions and 
in response to glucose (10 mM) using the Seahorse Glycolysis Stress Test Kit. OCR 
linked to mitochondrial ATP production (ATP linked OCR) was determined by 
subtracting OCR of CD8+ cells reached after treatment with oligomycin from OCR 
obtained at baseline. Complex II linked respiration was determined using a 
modified version of a previously described method (Salabei et al., 2014). Briefly, 
XF24 cell culture microplates were coated with Cell-Tak (50 uL at 22.4 µg/mL, 
Corning) and freshly isolated CD8+ T cells were plated in MAS-BSA assay solution 
(220 mM mannitol, 70 mM sucrose, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 
1 mM EGTA, 0.2% fatty acid free BSA) containing XF Plasma Membrane 
Permeabilizer (PMP, 1 nM, Seahorse Bioscience) and ADP (4 mM, Sigma). Oxygen 
consumption rates were measured at baseline and in response to sequential 
injections of succinate (10 mM, Sigma) with rotenone (2 µM, Seahorse Bioscience) 
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and malonate (500 µM, Sigma). All extracellular flux analyses were performed 
using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience) as recommended 
by the manufacturer. 
7.3.4. Mass spectrometry based metabolomics 
For metabolomics analyses, CD8+ T cells from WT and MCJ KO mice were 
purified and either left unstimulated or activated for 2 days prior to mass 
spectrometry analysis. For culture supernatants, unstimulated CD8+ T cells were 
incubated in medium without stimulation for 16 hours. For heavy isotope and flux 
analyses, unstimulated cells were incubated in medium supplemented with Cell 
Free Amino Acid Mixture - 13C, 15N (2 mM, Sigma) for 5 minutes or 5 hours. 
Metabolomics and flux analyses were performed as previously reported 
(D'Alessandro et al., 2015). Briefly, 2 x 106 cells and 20 µl of cell media were 
extracted in 1 ml and 980 µl of cold lysis and extraction buffer (methanol : 
acetonitrile : water at 5 : 3 : 2), respectively. After discarding protein pellets, 10 µl 
of water and methanol soluble fractions were run through a Kinetex C18 1.7 µm, 
100 x 2.1 mm reversed phase column (phase A: water, 0.1 % formic acid; phase B: 
acetonitrile, 0.1 % formic acid; Phenomenex) via an ultra high performance 
chromatographic system (UHPLC, Ultimate 3000, ThermoFisher). UHPLC was 
coupled in line with a high resolution quadrupole Orbitrap instrument run in both 
polarity modes (QExactive, ThermoFisher) at 140,000 resolution (at 200 m/z). 
Metabolite assignment, heavy isotopologue distributions and peak integration for 
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relative quantitation were performed using Maven software (Princeton) against 
the KEGG pathway database and an in house validated standard library (>650 
compounds, Sigma, IROATech). Integrated peak areas were exported to Excel 
(Microsoft) and elaborated for statistical analysis (t test, ANOVA) and hierarchical 
clustering analysis (HCA) through Prism (GraphPad Software) and GENE-E 
(Broad Institute), respectively. 
7.3.5. Mitochondrial respiratory supercomplexes 
Mitochondrial fractions were obtained by differential centrifugation, 
solubilized with 2 % digitonin (Sigma), and resolved by electrophoresis using 
NativePAGE Novex 4 – 16 % Bis-Tris protein gels (Invitrogen) as previously 
described (Hatle et al., 2013; Yang et al., 2015). Bands corresponding to respiratory 
supercomplexes and monomeric Complex IV were excised from the Blue Native 
gel, eluted, resolved by SDS-PAGE, and analyzed by Western blot for NDUFA9 
and CoxIV (MitoScience). Proteins were also transferred directly from the Blue 
Native gel to PVDF membrane for Western blot analysis for NDUFA9 and Core1 
(MitoScience). 
7.3.6. Intracellular ATP Concentration 
Intracellular ATP concentration in 104 CD8+ T cells was determined using 
the ATPlite Luminescence Assay System (PerkinElmer) and a TD-20/20 
Luminometer (Turner BioSystems) as recommended by the manufacturers. 
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7.3.7. Flow cytometry analyses 
For cell proliferation analysis, cells were stained with CFSE (5 µM, 
Molecular Probes), activated for 24 or 48 hours, and examined by flow cytometry 
analysis to determine proliferation. Control (unstimulated) cells were stained and 
incubated in medium alone for 16 hours before analysis. For cell survival analysis, 
cells were stained using the Live Dead Cell Viability Assay (Molecular Probes) as 
recommended by the manufacturer and examined by flow cytometry analysis. For 
expression of cell surface markers, cells were stained with antibodies for CD4, 
CD8, CD25, and CD69, and then analyzed by flow cytometry. For mitochondrial 
membrane potential analysis, cells were staining with TMRE (Molecular Probes) 
as previously described (Hatle et al., 2013) and examined by flow cytometry 
analysis. For β-galactosidase activity analysis, cells were incubated in 
β-galactosidase substrate (FACS Fluorescent Blue lacZ β-Galactosidase Detection 
Kit, Marker Gene Technologies) as recommended by the manufacturer and 
analyzed by flow cytometry. WT cells were used as negative controls. For 
intracellular cytokine staining analysis, cells were fixed after activation in 
paraformaldehyde, permeabilized with saponin and stained with the 
corresponding antibodies for IFN-g or IL-2 (BD Bioscience) as previously described 
(Yang et al., 1998). No preincubation with brefeldin A or monensin was used prior 
to intracellular staining. For CD107a mobilization assay, cells were cultured in the 
presence of monensin (1 µM, Sigma) and anti-CD107a (4 µL/ml, Biolegend) for 4 
hours using a modified version of a previously described method (McElroy et al., 
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2007). Additionally, cells were cultured with or without ionomycin (250 ng/ml). 
Cells cultured without anti-CD107a were used as negative controls. All flow 
cytometry analyses were performed using an LSRII Flow Cytometer (BD 
Biosciences) and FlowJo software. 
7.3.8. Cytokine Analyses 
For cytokine gene expression analysis, total RNA was isolated from 
activated cells using an RNeasy Mini Kit (Qiagen) as recommended by the 
manufacturer, cDNA was synthesized as previously described (Yang et al., 2015), 
and IL-2 and IFN-g mRNA were determined by qRT-PCR using Assays–on–
Demand TaqMan Gene Expression Assays (Applied Biosystems). Values were 
normalized to β2-microglobulin and analyzed by the comparative delta CT 
method. For cytokine production analysis, IFN-g and IL-2 in culture supernatants 
were determined by ELISA as previously described (Yang et al., 1998). For IFN-g 
ELISpot assays, cells were washed and plated in an ELISpot assay plate using 
capture and biotinylated anti-IFN-g antibodies (MabTech) as previously described 
(Dienz et al., 2009). Total and larger spots (high IFN-g producing cells) were 
quantified using an Axio Imager and software system (Zeiss). 
7.3.9. Chromatin immunoprecipitation. 
Ten to fifteen million purified CD8+ T cells were activated for 2 days or left 
unstimulated. ChIP assays were performed as previously described (Navasa, 
Martin-Ruiz, et al., 2015) using the SimpleChip Enzymatic Chromatin IP kit-
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Magnetic beads (Cell Signaling) following the manufacturer’s instructions using 
anti-Ikaros antibody or normal rabbit IgG as a negative control. 
Immunoprecipitated DNA was subjected to qPCR using primers encompassing 
the Ikaros binding site (5’ - TCA TTT GCT GTG AGC GCA AG - 3’ and 5’ - GCC 
TCC TTA GGT CTA CCT TGA - 3'). Results are presented as fold induction over 
rabbit IgG immunoprecipitates relative to input (percent input method). 
7.3.10. Influenza infection and analyses 
WT and MCJ-deficient mice were infected intranasally with a sublethal 
dose (3×103 EIU) of Puerto Rico A/PR/8/34 H1N1 influenza A (PR8) virus as 
previously described (Dienz et al., 2012). Mice were monitored for weight loss 
every other day. CD8+ T cells were isolated by positive selection from the draining 
mediastinal lymph node (MLN) and spleen 5 weeks later. Equal numbers of NP-
tetramer+ CD8+ T cells (2 - 2.5 x 106) were then transferred to WT mice, and a day 
later recipient mice were infected with a lethal dose of PR8 virus (104 EIU). Mice 
were monitored for weight loss every other day. Animals that lost >30% of their 
body weight at the day of infection or became grossly moribund were euthanized. 
BALF and serum were collected 6 days after the lethal dose. Cytokines and 
chemokines in BALF and serum were examined using Luminex Mouse Cytokine 
and Chemokine Panel I (Millipore) according to the manufacturer's protocol. Ex 
vivo production of IFN-g by CD8+ T cells from the MLN and lung were determined 
by ELISA and/or ELISpot assay as described above. CD8+ T cells were also stained 
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with NP366-374/Db tetramer containing peptide from the PR8 influenza virus 
(Powell et al., 2007) and antibodies for CD44, CD62L, KLRG1, CD127, and CD27 
(Biolegend) and analyzed by flow cytometry. For virus copy determination, total 
RNA extracted from whole lung tissue by RNeasy Kit (Qiagen) was used for 
cDNA synthesis (2 µg RNA) as previously described (Dienz et al., 2012). Viral titers 
were determined by quantitative RT-PCR for PR8 virus acid polymerase (PA) 
gene, a method validated as equivalent to PFU (Jelley-Gibbs et al., 2007). 
7.3.11. Confocal microscopy 
Cells were activated for 2 days, transferred to glass bottom plates (MatTek), 
and incubated at 37°C for 1 hour to sediment. Live cells were examined by confocal 
microscopy prior to staining (background). ATP probe (Rao et al., 2012) was then 
added (100 µM), cells were incubated for 5 minutes, washed, and visualized using 
a 405 nm laser. For costaining with Mitotracker, prior to incubation with the ATP 
probe cells were incubated with Mitotracker (Thermo Fisher) for 30 minutes. 
Confocal microscopy was performed using a Zeiss LSM 510 Meta Confocal Laser 
Scanning microscope (Carl Zeiss Microscopy). 
7.3.12. Statistical analyses 
Statistical significance was determined by t test or long-rank test as 
indicated. Bars represent the mean with the standard deviation (SD) or standard 
error of the mean (SEM). p < 0.05 was considered statistically significant. 
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Chemotherapy remains the standard of care for most cancers worldwide, 
however development of chemoresistance due to the presence of the drug-
effluxing ABC transporters remains a significant problem. The development of 
safe and effective means to overcome chemoresistance is critical for achieving 
durable remissions in many cancer patients. We have investigated the energetic 
demands of ABC transporters in the context of the metabolic adaptations of 
chemoresistant cancer cells. Here we show that mitochondrial-derived ATP, but 
not glycolysis-derived ATP, provides the energy needed for ABC transporters to 
efflux drugs out of cancer cells. We further demonstrate that the loss of MCJ 
(DNAJC15), an endogenous negative regulator of mitochondrial respiration, in 
chemoresistant cancer cells enhances their ability to produce ATP from 
mitochondria and fuel ABC transporters. We have developed novel MCJ mimetics 
that can attenuate mitochondrial respiration and safely overcome chemoresistance 
in vitro and in vivo. Administration of MCJ mimetics in combination with standard 
chemotherapeutic drugs could therefore become an affordable new strategy for 
treatment of multiple cancers.  
 
2. Introduction 
Despite the development of novel therapies, including immunotherapies, 
chemotherapy prior to or following surgery remains the most commonly used 
systemic treatment for most cancers. However, it is also evident that 
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chemotherapy treatment still faces major challenges as chemoresistance usually 
develops in cancer patients. In some cases, patients fail the initial chemotherapy 
course due to intrinsic properties of tumor cells. Frequently, following a successful 
response to the first-round chemotherapy, the cancer recurs following acquisition 
of adaptive mechanisms of chemoresistance, which can extend to families of drugs 
distinct from the chemotherapy used (i.e., multidrug resistance). Once 
chemoresistance is established, one of the approaches used to attempt to overcome 
this problem is increased drug dosing, but this approach is limited by increased 
toxicity, including off-target effects (e.g., cardio- or neurotoxicity) (Lyman, 2009; 
Pai and Nahata, 2000). The alternative use of different chemotherapeutic drugs is 
often hampered by multidrug resistance. Until now, the lack of a mechanistic 
understanding of the energetics of chemoresistance has hampered the 
development of effective strategies to overcome this major hurdle in cancer 
therapy. While there is growing interest in cancer cell metabolism as a novel 
approach to interfere with cancer growth, little is known about how metabolic 
changes contribute to the development of chemoresistance. 
Different mechanisms of chemoresistance have been identified (Fodale et 
al., 2011), but the most common mechanism is the upregulation of ATP binding 
cassette (ABC) transporters that mediate drug efflux and decrease intracellular 
accumulation of anti-cancer drugs (Kathawala et al., 2015). ABC transporters are a 
large family of proteins classified in seven subclasses (ABCA, B, C, D, E, F, and G) 
that use the energy of ATP hydrolysis to mediate the transport of substrates 
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(Ambudkar et al., 2003; Dean et al., 2001; Szakacs et al., 2006). In cancer cells, ABC 
transporters remove chemotherapeutic agents from cells, thereby reducing 
intracellular concentrations and thus drug efficacy. Several ABC transporters have 
been associated with the development of multidrug resistance in cancer (Dlugosz 
and Janecka, 2016). The most characterized ABC transporters associated with 
chemoresistance in cancer are ABCB1 (also known as P-gp or MDR1), ABCG2 
(BCRP), and ABCC1 (MRP1) (Allikmets et al., 1998; Cole et al., 1992; Doyle et al., 
1998; Miyake et al., 1999; Roninson et al., 1986; Ueda et al., 1987). A correlation 
between the expression of ABCB1 and ABCG2 and multidrug resistance in cancer 
cell lines in vitro is well established (Bugde et al., 2017; Doyle et al., 1998; Ozvegy et 
al., 2001; Riordan et al., 1985; Roninson et al., 1984), but the correlation between the 
expression of these transporters and chemoresistance in cancer patients is less 
clear, and therefore neither can be used as predictive markers for chemoresistance. 
The presence of ABC transporters therefore may not be sufficient to cause 
chemoresistance in cancer cells and other factors could be required for these efflux 
pumps to be active. 
ABC transporters are energy consuming pumps that require significant 
amounts of ATP as biochemical studies have indicated that up to two ATP 
molecules are required to efflux one molecule of substrate (Patzlaff et al., 2003; 
Poolman et al., 2005). Despite this energy demand and the distinct metabolism of 
cancer cells, little is known about the mechanisms that regulate their activity in the 
chemoresistant cancer cells other than substrate availability as well as how the 
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activity of these transporters is regulated by the metabolic state of the cell (Robey 
et al., 2018). Therefore, determining how the metabolic state of the cell affects ABC 
transporter activity could provide alternative pathways for the generation of novel 
inhibitors for these transporters to overcome chemoresistance. 
The two main pathways for ATP synthesis are glycolysis in the cytosol and 
oxidative phosphorylation in mitochondria. Cancer cells predominantly utilize 
aerobic glycolysis to generate ATP for proliferation and biosynthesis (Liberti and 
Locasale, 2016; Vander Heiden et al., 2009) (Koppenol et al., 2011; Warburg, 1956). 
While historically switching to a glycolytic metabolism at the expense of 
mitochondrial respiration was viewed as an approach to promote cancer 
progression, it is now clear that mitochondria contribute to a number of functions 
in cancer cells (DeBerardinis and Chandel, 2016; Wallace, 2012; Zong et al., 2016). 
Several studies have shown an upregulation of the mitochondrial respiratory 
machinery in slow-cycling, chemoresistant melanoma cells with a quiescent 
phenotype generated upon drug treatment (Cierlitza et al., 2015; Roesch et al., 
2013). This has also been reported in cancer stem cells, which are also more 
quiescent and resistant to therapy (Abdullah and Chow, 2013). Inhibition of the 
electron transport chain (ETC) with different pharmacological inhibitors in these 
slow-cycling resistant cells has been shown to restore drug sensitivity (Roesch et 
al., 2013). Interestingly, the increased response to drug treatment is not thought to 
be mediated by the reduction of mitochondrial metabolism but by increasing the 
production of reactive oxygen species that together with the drug effect promote 
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death of these quiescent cancer cells (Cierlitza et al., 2015). The regulation of 
mitochondrial respiration in normal-cycling chemoresistant cancer cells and the 
contribution of mitochondrial versus glycolytic ATP to ABC transporter mediated 
chemoresistance remain unclear. 
Here we show that mitochondrial ATP is essential for drug efflux mediated 
by ABC transporters in chemoresistant cancer cells. In contrast, ATP from 
glycolysis is dispensable, therefore upregulation of mitochondrial metabolism 
contributes to this mechanism of chemoresistance. Methylation controlled J 
protein (MCJ, encoded by DnaJC15) is an endogenous brake on mitochondrial 
respiration that negatively regulates Complex I activity (Barbier-Torres et al., 2017; 
Champagne et al., 2016; Hatle et al., 2013; Navasa, Martin, et al., 2015). 
Retrospective and prospective studies have shown that loss of MCJ expression in 
tumors correlates with chemotherapy resistance and poor prognosis in breast and 
ovarian cancer patients (Fernandez-Cabezudo et al., 2016; Strathdee et al., 2005). 
Here we show increased mitochondrial respiration due to the loss of MCJ in 
normal-cycling chemoresistant cancer cells. Importantly, we have developed 
therapeutic MCJ mimetics that attenuate mitochondrial respiration and ABC 
transporter activity in chemoresistant cancer cells both in vitro and in vivo. 
Restoring MCJ function is therefore a viable therapeutic strategy to inhibit ABC 







3.1. Cancer cells reprogram mitochondrial metabolism when acquiring 
multidrug resistance 
Increased mitochondrial respiration due to upregulation of the ETC 
machinery has been found in slow-cycling drug resistant cancer cells (e.g., stem 
cells, quiescent cells). However, it remains unclear whether mitochondrial 
respiration is also enhanced in normal-cycling cancer cells that are multidrug 
resistant due to mechanisms other than a slow-cycling rate. To examine differences 
in mitochondrial respiration between chemosensitive and chemoresistant normal-
cycling cancer cells, we used the well-known multidrug resistant NCI/ADR-RES 
ovarian cancer cell line and its chemosensitive parental OVCAR-8 cell line. The 
difference in drug response between the two cell lines was verified using 
doxorubicin, a standard clinical chemotherapeutic agent and the selective agent 
used to obtain NCI/ADR-RES cells. (Supplementary Figure 3-1A). 
Mitochondrial respiration was examined using the Seahorse Mito Stress test 
for mitochondrial oxygen consumption rates (OCR). NCI/ADR-RES cells had 
higher basal OCR than OVCAR-8 cells (Figure 3-1A and B), indicating that overall 
mitochondrial respiration is increased in NCI/ADR-RES cells. In contrast, baseline 
extracellular acidification (ECAR), a parameter for the rate of glycolysis, was 
comparable between NCI/ADR-RES cells and OVCAR-8 cells (Supplementary 
Figure 3-1B). The maximal respiratory capacity, determined by subtracting the 
OCR obtained after rotenone plus antimycin from OCR after the un-coupler FCCP, 
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was also higher in NCI/ADR-RES cells relative to OVCAR-8 cells (Figure 3-1B), 
indicating that the overall ability to employ mitochondrial respiration was higher 
in chemoresistant cells. We also determined the OCR linked to mitochondrial ATP 
production by subtracting OCR after oligomycin from baseline OCR. The levels of 
ATP-linked OCR were significantly higher in NCI/ADR-RES cells than OVCAR-8 
cells (Figure 3-1B), suggesting that production of mitochondrial ATP was 
increased in NCI/ADR-RES cells. To further investigate the fraction of total ATP 
production that was derived from mitochondrial respiration we used the Seahorse 
XF Real Time ATP Rate assay. The fraction of ATP production derived from 
mitochondria within the total ATP production was increased in NCI/ADR-RES 
cells compared with OVCAR-8 cells (Figure 3-1C). Thus, chemoresistant 
NCI/ADR-RES have an increased ability to undergo mitochondrial respiration 
and to produce ATP via OXPHOS. 
To show that increased mitochondrial respiration is also characteristic of 
other chemoresistant cells, we used the chemoresistant MES/Dox uterine cancer 
cell line and its chemosensitive parental MES-SA (MES) cell line. The difference in 
chemotherapy responses between the two cell lines was verified using 
doxorubicin (Supplementary Figure 3-1C). Using the Seahorse Mito Stress assay, 
MES/Dox cells were found to have higher basal OCR compared with MES cells 
(Figure 3-1D), while no differences were found in baseline ECAR (Supplementary 
Figure 3-1D). In addition, ATP-linked OCR and maximal respiratory capacity were 
also elevated in MES/Dox cells (Figure 3-1E). Furthermore, like NCI/ADR-RES 
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cells, the relative contribution of mitochondrial ATP production to the total ATP 
production was also higher in MES/Dox cells than in their chemosensitive 
parental cell line (Figure 3-1F). Therefore, enhanced mitochondrial respiration is a 
common phenotype in independently generated chemoresistant cancer cell lines 
from distinct origins (ovarian and uterine cancer). 
Since both chemoresistant NCI/ADR-RES and MES/Dox cancer cells were 
derived from their parental cell lines using doxorubicin as a selective agent, we 
examined MCF7/Tx400 breast cancer cells that were derived from the 
chemosensitive MCF7 cell line using paclitaxel as a selective agent. Increased 
resistance to doxorubicin in MCF7/Tx400 cells was validated (Supplementary 
Figure 3-1E). Relative to MCF7 cells, MCF7/Tx400 cells exhibited increased basal 
OCR (Figure 3-1G), but comparable baseline ECAR (Supplementary Figure 3-1F). 
ATP-linked OCR and maximal respiratory capacity were also higher in 
MCF7/Tx400 cells (Figure 3-1H). The relative contribution of mitochondrial ATP 
production to the total ATP production was more prominent in MCF7/Tx400 cells 
as well (Figure 3-1I). Thus, chemoresistant breast cancer cells also have greater 
capacity to produce mitochondrial ATP. 
To further demonstrate a prominent selective mitochondria component in 
the overall cell metabolism of chemoresistant cancer cells, we performed mass 
spectrometry-based, high-throughput metabolic profiling using chemoresistant 
NCI/ADR-RES cancer cells and their chemosensitive parental OVCAR-8 cells. The 
nonbiased metabolome analysis revealed distinct metabolic profiles for the two 
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cancer cell lines (Figure 3-1J and Supplementary Table 3-1). While the levels of 
some metabolites were decreased, the levels of other metabolites were increased 
in NCI/ADR-RES cells compared to OVCAR-8 cells (Figure 3-1J). Consistent with 
the increased mitochondrial respiration of NCI/ADR-RES described above, these 
cells exhibited (i) an enrichment for the products of substrates of mitochondrial 
metabolism (including several amino acids), (ii) decreases in glycolytic metabolites 
and byproducts (pyruvate, lactate) accompanied by increases in carboxylic acids 
from the TCA cycle (citrate, succinate), (iii) increases in products of amino acid 
catabolism (urea cycle intermediates and creatine/creatinine), (iv) increases in 
NADPH and pentose phosphate pathway intermediates (glucose 6-phosphate and 
sedoheptulose phosphate) as well as glutathione precursors (g-glutamyl cysteine) 
and metabolites (glutathione disulfide, ascorbate), (v) increases in high energy 
phosphate compounds (e.g. ATP) and nucleotide metabolism, and (vi) increased 
NAD+, the product of Complex I of the ETC  (Supplementary Figure 3-2). Taken 
together, these results show an enhanced mitochondrial metabolism and a 
predominant contribution of mitochondria to overall ATP synthesis in normal-







Figure 3-1. Chemoresistant cancer cells exhibit increased 
mitochondrial respiration and ATP production 
 
(A and B) OVCAR-8 and NCI/ADR-RES cells were analyzed by Seahorse 
MitoStress Assay for (A) oxygen consumption rates (OCR) at baseline and in 
response to sequential injections of oligomycin (O), FCCP (F), and rotenone with 
antimycin (RA) and for (B) basal, ATP linked (ATP), and maximal respiration rates 
(Max) relative to OVCAR-8 cells (n ≥ 5). (C) Rates of mitochondrial production of 
ATP relative to the total ATP production rate in OVCAR-8 and NCI/ADR-RES 
cells as determined by Seahorse ATP Production Rate Assay (n ≥ 7). (D and E) OCR 
of MES and MES/Dox cells were determined as in (A and B) (n ≥ 7). (F) 
Mitochondrial ATP production rates of MES and MES/Dox cells were determined 
as in (C) (n = 11). (G and H) OCR of MCF7 and MCF7/Tx400 cells were determined 
as in (A and B) (n ≥ 6). (I) Mitochondrial ATP production rates of MCF7 and 
MCF7/Tx400 cells were determined as in (C) (n = 9). (J) Relative abundances of 
metabolic intermediates in OVCAR-8 and NCI/ADR-RES cells as determined by 
mass spectrometry based metabolomics (n = 4). Mean ± SD provided. *denotes 
p < 0.05 by unpaired t test. Results are representative of 2 - 3 experiments.  


















































































































































































































































































































































3.2.  Mitochondrial respiration prevents drug accumulation in chemoresistant 
cancer cells 
NCI/ADR-RES cells are resistant to doxorubicin and other 
chemotherapeutic drugs because drugs fail to accumulate in the cells, and higher 
doses are needed to cause cell death. To investigate whether increased 
mitochondrial respiration could contribute to preventing drug accumulation in 
NCI/ADR-RES cells, we took advantage of the intrinsic fluorescence of 
doxorubicin. NCI/ADR-RES cells were incubated in the presence or absence of the 
mitochondrial respiration inhibitors oligomycin, which blocks mitochondrial ATP 
synthase (Complex V), or rotenone, which blocks Complex I. After 2 h doxorubicin 
was added to the cells, and they were incubated for an additional 3 h. Doxorubicin 
cellular accumulation was then examined by confocal microscopy. Neither 
oligomycin nor rotenone had an effect on cell survival for this short period of time 
(data not shown). As expected, in the absence of oligomycin or rotenone, 
NCI/ADR-RES cells treated with doxorubicin contained little to no intracellular 
doxorubicin. Strikingly, the addition of either rotenone or oligomycin resulted in 
a pronounced accumulation of doxorubicin in the cells (Figure 3-2A and B). We 
also examined the effect of inhibiting mitochondrial respiration on doxorubicin 
accumulation by flow cytometric analysis. NCI/ADR-RES cells were treated with 
increasing doses of oligomycin or rotenone for 2 h followed by incubation with 
doxorubicin for an additional 3 h. Cells were then fixed and analyzed by flow 
cytometry for doxorubicin fluorescence. Similar to the analysis by microscopy, 
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both oligomycin (Figure 3-2C) and rotenone (Figure 3-2D) robustly increased 
doxorubicin accumulation in the cells in a dose-dependent manner. Thus, 
mitochondrial-derived ATP is necessary to prevent doxorubicin accumulation in 
NCI/ADR-RES cells. 
Cancer cells are typically highly dependent on glycolytic pathways for ATP 
generation and for cell proliferation. We therefore examined whether glycolysis as 
source of ATP was also necessary to prevent drug accumulation in chemoresistant 
cells. NCI/ADR-RES cells were treated with 2-deoxyglucose (2-DG), an inhibitor 
of glycolysis, for 2 h. As a control, we also treated cells with oligomycin as 
described above. Doxorubicin was added and 3 h later cells were fixed and 
analyzed by confocal microscopy. In contrast to oligomycin, treatment with 2-DG 
did not increase doxorubicin accumulation (Figure 3-2E and F). As another 
approach to inhibit glycolysis, we incubated NCI/ADR-RES cells in medium 
lacking glucose for 24 h prior to addition of doxorubicin, however a lack of glucose 
also did not restore doxorubicin accumulation (Figure 3-2E and F). We performed 
similar experiments examining doxorubicin fluorescence by flow cytometry in 
NCI/ADR-RES cells treated with increasing doses of 2-DG. The results further 
showed that inhibition of glycolysis with a high dose of 2-DG does not restore 
drug accumulation in NCI/ADR-RES cells cancer cells (Figure 3-2G). To verify the 
activity of the 2-DG used for these studies we measured total ATP levels in the 
cells. NCI/ADR-RES cells were treated with the highest concentration of 
oligomycin or 2-DG used in the above assays for 5 h (same period of time used in 
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the efflux experiments) and then total ATP levels were determined. Relative to 
untreated cells, ATP levels were strongly reduced in NCI/ADR-RES cells treated 
with either oligomycin or 2-DG (Figure 3-2H), indicating that 2-DG was active. 
Thus, inhibition of mitochondrial respiration, but not glycolysis, promotes 
doxorubicin accumulation. Neither oligomycin, rotenone, nor 2-DG had an effect 
in the accumulation of doxorubicin in the parental chemosensitive OVCAR-8 cells 
(Supplementary Figure 3-3A), further demonstrating that regulation of drug 
accumulation is restricted to chemoresistant cancer cells. 
To investigate whether the differential contribution of mitochondrial 
respiration versus glycolysis to the failure of drug accumulation occurs in other 
chemoresistant cells, MES/Dox cells were treated with oligomycin, rotenone, and 
2-DG, followed by incubation with doxorubicin for an additional 3 h and flow 
cytometry analysis. Similar to NCI/ADR/RES cells, treatment of MES/Dox cells 
with either oligomycin or rotenone caused a marked doxorubicin accumulation 
(Figure 3-2I). In contrast, treatment with 2-DG did not restore doxorubicin 
accumulation (Figure 3-2I). No effect of oligomycin, rotenone, or 2-DG was 
detected on doxorubicin accumulation in the parental MES cells (Supplementary 
Figure 3-3B). Together, these results demonstrate the selective contribution of 
mitochondrial respiration, but not glycolysis, in preventing chemotherapeutic 






Figure 3-2. Mitochondrial respiration, but not glycolysis, is 
responsible for reduced drug accumulation in chemoresistant cells 
 
(A and B) NCI/ADR-RES cells were incubated with or without (Veh) oligomycin 
(Oligo, 5 µM) or rotenone (Rote, 50 µM) for 2 h followed by incubation with 
doxorubicin (Dox, 3 µM) for 3 h. Cells were then fixed, stained with DAPI (nuclear 
dye, blue), and analyzed by confocal microscopy for doxorubicin fluorescence 
(red). (A) Representative images. Scale bars represent 20 µm. (B) Quantification of 
doxorubicin intensity relative to nuclear area (n ≥ 12 cells). (C and D) 
NCI/ADR-RES cells were incubated with increasing concentrations of (C) 
oligomycin or (D) rotenone as indicated for 2 h followed by incubation with 
doxorubicin as in (A). Cells were then fixed and analyzed for doxorubicin 
fluorescence by flow cytometry. Median fluorescence intensity (MFI) is shown 
(n = 3). (E and F) NCI/ADR-RES cells were incubated with oligomycin (5 µM) or 
2-deoxyglucose (2-DG, 50 mM) for 2 h or without glucose (No Gluc) for 24 h 
followed by incubation with doxorubicin as in (A). Cells were then fixed, stained, 
and analyzed as in (A and B). (E) Representative images. Scale bars represent 
20 µm. (F) Quantification of doxorubicin intensity relative to nuclear area (n ≥ 46 
cells). (G) NCI/ADR-RES cells were incubated with increasing concentrations of 










































































































































2-deoxyglucose as indicated for 2 h followed by incubation with doxorubicin as in 
(A). Cells were then fixed and analyzed as in (C and D) (n = 3). (H) NCI/ADR-RES 
cells were incubated with oligomycin (5 µM) or 2-deoxyglucose (50 mM) for 5 h 
and then total ATP levels were determined by Luciferase assay (n = 4). (I) 
MES/Dox cells were incubated with oligomycin (5 µM), rotenone (50 µM), or 2-DG 
(50 mM) for 2 h followed by incubation with doxorubicin as in (A). Cells were then 
fixed and analyzed as in (C and D) (n = 3). Mean ± SD provided. *denotes p < 0.05 
by one-way ANOVA and Tukey’s multiple comparisons test. Results are 
representative of 2 - 3 experiments. 
 
3.3. ABC transporter activity in chemoresistant cancer cells is selectively 
dependent on mitochondrial ATP  
A major mechanism that chemoresistant cancer cells use to avoid 
accumulation of chemotherapeutic drugs is the acquisition of ABC transporters 
that actively promote drug efflux. ABC transporters utilize the energy of ATP 
hydrolysis to actively transport substrates against concentration gradients. While 
the expression of specific ABC transporters has been largely studied in 
chemoresistant cancer cells, including NCI/ADR-RES cells (Fairchild et al., 1987; 
Robey et al., 2018), little is known about the regulation of their activity and capacity 
to promote drug efflux. Since the results above show that drug accumulation in 
chemoresistant cancer cells is highly dependent on mitochondrial-derived ATP 
but not glycolytic ATP, we examined the contribution of these two pathways of 
generating energy on the activity of ABC transporters. 
ABCB1 is overexpressed in NCI/ADR-RES cells (Fairchild et al., 1987). We 
therefore measured ABCB1 activity using a calcein retention assay. 
NCI/ADR-RES cells were treated with oligomycin or 2-DG for 2 h followed by 
incubation with calcein for 15 min. Cells were then dissolved in DMSO, and calcein 
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fluorescence was determined. Inhibition of mitochondrial respiration by 
oligomycin caused a marked reduction of ABCB1 activity as indicated by 
increased retention of calcein (Figure 3-3A). In contrast, 2-DG treatment had no 
effect on ABCB1 activity (Figure 3-3A). To further demonstrate the contribution of 
mitochondrial respiration to ABCB1 activity, we used HEK 293T cells which do 
not express ABCB1 (HEK 293T), and HEK 293T-ABCB1 cells generated by stable 
transfection of ABCB1. As expected, relative to control HEK 293T cells, HEK 293T-
ABCB1 cells failed to accumulate calcein due to the presence of ABCB1 (Figure 
3-3B). However, treatment of HEK 293T-ABCB1 cells with oligomycin markedly 
increased calcein levels (Figure 3-3B), while 2-DG treatment had no effect (Figure 
3-3B). Since doxorubicin is also a substrate of ABCB1, we examined doxorubicin 
accumulation by flow cytometry in HEK 293T-ABCB1 cells in the presence or 
absence of different metabolic inhibitors. As expected, almost no doxorubicin 
could be detected in HEK 293T-ABCB1 cells relative to control HEK 293T cells 
(Figure 3-3C). However, treatment with oligomycin or rotenone prevented 
doxorubicin efflux by ABCB1 transporter, while 2-DG had no effect (Figure 3-3C). 
Thus, ABCB1 activity requires mitochondrial-derived ATP. 
To investigate the need of mitochondrial respiration for the activity of other 
ABC transporters, we examined the accumulation of Hoechst 33258, a known dye 
substrate for ABCG2, which is also abundantly expressed by NCI/ADR-RES cells. 
Hoechst accumulation was examined in NCI/ADR-RES cells after pre-treatment 
oligomycin, rotenone, or 2-DG. As expected, no Hoechst could be detected in 
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NCI/ADR-RES cells, but treatment with either oligomycin or rotenone blocked 
ABCG2-mediated efflux and restored Hoechst accumulation (Figure 3-3D). In 
contrast, treatment with 2-DG had no effect (Figure 3-3D). To further verify the 
effect of mitochondrial respiration on ABCG2 activity, we analyzed HEK 293T 
cells that stably overexpress ABCG2 (HEK 293T-ABCG2). Relative to control HEK-
293T cells that do not express ABCG2, the presence of ABCG2 in HEK 293T-
ABCG2 cells prevented these cells from accumulating Hoechst (Figure 3-3E). 
However, treatment with either oligomycin or rotenone restored the ability of 
HEK 293T-ABCG2 cells to accumulate Hoechst, while 2-DG had no effect (Figure 
3-3E), further demonstrating that, as for ABCB1, efflux activity of ABCG2 is also 
dependent on mitochondrial respiration. Thus, while ABC transporters can 
mediate drug efflux and confer resistance to chemotherapy, their activity requires 
ATP specifically generated by mitochondrial respiration. 
To determine the actual ATP cost of ABC transporters relative to the total 
cellular ATP pool, we examined the impact of the high use of ABC transporters on 
total ATP levels. NCI/ADR-RES cells were incubated for 5 h with increasing 
amounts of rhodamine B, a non-chemotherapeutic substrate of ABCB1, with the 
goal of inducing excess ABCB1 activity mediating rhodamine efflux. Total ATP 
levels were then determined by Luciferase assay. Interestingly, relative to cells 
without substrate, rhodamine caused a substantial reduction of total ATP levels in 
a dose-dependent manner (Figure 3-3F). Although rhodamine does not seem to 
have harmful effects, to rule out potential toxic effects of high concentrations of 
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rhodamine that may cause a reduction in the total ATP levels, we performed 
similar experiments using HEK 293T-ABCB1 cells and control HEK 293T cells. 
HEK 293T-ABCB1 cells treated with a high concentration of rhodamine also 
experienced a significant reduction in total ATP levels (Figure 3-3G). In contrast, 
ATP levels in the control HEK 293T cells were not affected by the high 
concentration of rhodamine (Figure 3-3G). Taken together, these results indicate 
that a high concentration of ATP is needed to sustain ABC transporter activity. 
Similar to high Ca2+ microdomains in the cytoplasm, intracellular ATP-rich 
microdomains have been identified using an intracellular probe for ATP 
(Champagne et al., 2016). We have previously shown that these ATP-rich 
microdomains are dependent on high mitochondrial respiration in CD8+ T cells 
triggered by the lack of the negative regulator of mitochondrial respiration MCJ. 
Since it is thought that ABC transporters have a low affinity for ATP in the absence 
of substrate (Linton and Higgins, 2007) and that their activity is highly dependent 
on mitochondrial ATP based on results presented above, we examined the 
presence ATP-rich microdomains in NCI/ADR-RES cells using a fluorescent 
probe for ATP and live cell confocal microscopy analysis. The presence of ATP-
rich microdomains was clear in NCI/ADR-RES cells as determined by distinct 
puncta throughout the cytosol (Figure 3-3H). These areas of high ATP 
concentration were the result of mitochondrial ATP production as they were 
significantly reduced by pre-treatment of NCI/ADR-RES cells with oligomycin or 
rotenone for 2 h prior to analysis (Figure 3-3H). However, treatment with 2-DG 
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had no effect on the presence of these ATP-rich microdomains (Figure 3-3H). Thus, 
increased mitochondrial respiration in chemoresistant cells results in the presence 
of ATP-rich microdomains that serve to increase local ATP levels and can fuel 




Figure 3-3. Mitochondrial respiration provides the energy required 
for ABC transporter activity. 
 
(A) NCI/ADR-RES cells were treated with or without (Veh) oligomycin (Oligo, 
5 µM) or 2-deoxyglucose (2-DG, 50 mM) for 2 h followed by incubation with 
calcein (0.25 µM) for 15 min. Cells were then washed, dissolved in DMSO, and 
calcein fluorescence relative to untreated cells was determined (n = 3). (B) Calcein 
fluorescence in HEK 293T cells (293T) and ABCB1-expressing HEK 293T cells 































































































































































(293T-ABCB1) was determined as in (A) (n ≥ 3). (C) 293T and 293T-ABCB1 cells 
were treated with oligomycin (5 µM), rotenone (50 µM), or 2-DG (50mM) for 2 h 
followed by incubation with doxorubicin (Dox, 3 µM) for 3 h. Cells were then fixed 
and analyzed for doxorubicin fluorescence by flow cytometry. Median 
fluorescence intensity (MFI) is shown (n = 3). (D) NCI/ADR-RES cells were treated 
with oligomycin (5 µM), rotenone (50 µM), or 2-DG (50 mM) for 2 h followed by 
incubation with Hoechst (100 ng/mL) for 3 h. Cells were then fixed and analyzed 
for Hoechst fluorescence by flow cytometry. Median fluorescence intensity (MFI) 
is shown (n = 3). (E) 293T and 293T-ABCB1 cells were treated and analyzed as in 
(D) (n = 3). (F) NCI/ADR-RES cells were incubated with increasing concentrations 
of rhodamine (Rho) B as indicated for 5 h and then total ATP levels were 
determined by Luciferase assay. The percent reduction in ATP relative to 
untreated cells is shown (n = 3). (G) 293T and 293T-ABCB1 cells were incubated 
with or without rhodamine B (100 µM) for 5 h and then analyzed as in (F) (n ≥ 3). 
(H) NCI/ADR-RES cells were incubated with oligomycin (5 µM), rotenone (50 
µM), or 2-DG (50 µM) for 2 h, stained with a fluorescent ATP probe (100 µM) for 5 
min, and then analyzed by live cell confocal microscopy. ATP probe fluorescence 
(green) and bright light differential interference contrast (DIC) are shown. Scale 
bars represent 10 µm. Mean ± SD provided. *denotes p < 0.05 by one-way ANOVA 
and Tukey’s multiple comparisons test. Results are representative of 2 - 3 
experiments. 
 
3.4. Increased mitochondrial respiration due to the loss of MCJ fuels drug efflux 
The above results indicate that increased mitochondrial respiration 
contributes to chemoresistance in cancer cells by promoting drug efflux, 
suggesting that drug-mediated selection for genetic or epigenetic changes within 
cancer cells that affect mitochondrial respiration could lead to chemoresistance. 
The mitochondrial protein MCJ (encoded by the DNAJC15 gene) is an endogenous 
negative regulator of Complex I that restricts the activity of the ETC (Hatle et al., 
2013). In CD8+ T cells and hepatocytes, MCJ deficiency results in increased 
Complex I activity, increased mitochondrial respiration, and the presence of ATP-
rich microdomains (Barbier-Torres et al., 2017; Champagne et al., 2016; Hatle et al., 
2013). Interestingly, we and others have shown that MCJ deficiency in cancer cells 
is linked to increased chemoresistance in breast and ovarian cancer patients and 
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in mouse models of breast cancer (Fernandez-Cabezudo et al., 2016; Strathdee et 
al., 2005). However, previous studies have not addressed the effect of MCJ on 
mitochondrial respiration in cancer cells nor its association with ABC transporter 
activity. 
We first examined whether MCJ acts as a negative regulator of 
mitochondrial respiration in drug sensitive cancer cells. MCF7 cells express high 
levels of MCJ (Hatle et al., 2007). We transfected MCF7 cells with an siRNA specific 
for MCJ (siMCJ) or a control siRNA (C-siRNA). After 2 d, decreased levels of MCJ 
were verified by Western blot analysis (Figure 3-4A). We then examined 
mitochondrial respiration by measuring OCR using the Seahorse MitoStress assay. 
MCF7 cells transfected with siMCJ had higher basal OCR than those transfected 
with control siRNA (Figure 3-4B and C). ATP-linked OCR and maximal 
respiratory capacity were also higher in siMCJ transfected cells (Figure 3-4C). 
Furthermore, the relative production of mitochondrial ATP within the total ATP 
pool was also elevated after MCJ knock down (Figure 3-4D). To determine 
whether increased mitochondrial respiration caused by the loss of MCJ could also 
lead to the presence of ATP-rich microdomains identified in chemoresistant cells, 
siMCJ-transfected MCF7 cells were stained with the ATP probe and analyzed by 
live cell confocal microscopy. Almost no ATP puncta could be found in C-siRNA 
transfected cells (Figure 3-4E). In contrast, MCF7 cells transfected with siMCJ had 
a large number of well-defined ATP-rich domains (Figure 3-4E). Pre-treatment of 
siMCJ transfected MCF7 cells with either oligomycin or rotenone for 2 h prior to 
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analysis reduced the presence of ATP-rich domains, while treatment with 2-DG 
did not (Figure 3-4E). Thus, increased mitochondrial respiration due to the loss of 
MCJ in human drug-sensitive breast cancer cells promotes the formation of 
mitochondrial-derived ATP-rich domains. 
To demonstrate the effect of MCJ on the mitochondrial respiration of 
primary cancers in addition to cancer cell lines, we used mammary tumor cells 
from MMTV-PyMT mice (WT MMTV) and MMTV-PyMT mice crossed with MCJ-
deficient mice (MCJ KO MMTV) previously generated (Fernandez-Cabezudo et al., 
2016). We previously showed that mammary tumor development and tumor 
growth in MCJ KO MMTV mice was comparable to their development in MMTV 
mice, although tumors from MCJ KO MMTV mice are more resistant to 
doxorubicin treatment (Fernandez-Cabezudo et al., 2016). We first examined OCR 
in cells isolated from MMTV and MCJ KO MMTV tumors. MCJ KO tumor cells 
had higher basal OCR compared with wildtype MMTV tumor cells (Figure 3-4F 
and G). Moreover, ATP-linked OCR and maximal respiratory capacities were also 
higher in MCJ KO cancer cells compare to wildtype cancer cells (Figure 3-4G). 
Thus, loss of MCJ in primary cancer cells results in increased mitochondrial 
respiration. 
Since MCJ deficiency leads to resistance to doxorubicin and other 
chemotherapeutic drugs, we investigated whether the lack of MCJ in MCJ KO 
MMTV tumor cells prevented accumulation of doxorubicin due to increased 
mitochondrial-derived ATP. Primary tumor cells isolated from WT MMTV and 
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MCJ KO MMTV mice were expanded in vitro and then pretreated with oligomycin 
for 2 h followed by the addition of doxorubicin for 3 h. Intracellular doxorubicin 
accumulation was then examined by confocal microscopy. While doxorubicin was 
clearly present in WT MMTV tumor cells, it was almost undetectable in MCJ KO 
MMTV cells (Figure 3-4H). However, inhibiting mitochondrial ATP production 
with oligomycin restored doxorubicin accumulation in MCJ KO MMTV cells 
(Figure 3-4H). Oligomycin had little to no effect on doxorubicin accumulation in 
WT MMTV cells (Figure 3-4H). Together these results reveal the mechanism 
whereby loss of MCJ as a mitochondrial regulator can cause chemoresistance in 
cancer cells. Loss of MCJ results in enhanced mitochondrial respiration that is 







Figure 3-4. Loss of MCJ in cancer cells enhances mitochondrial 
respiration 
 
(A) MCJ expression in MCF7 cells transfected with a control siRNA (C-siRNA) or 
an siRNA specific for MCJ (siMCJ) as determined by Western blot analysis. 
GAPDH is shown as a loading control. (B and C) MCF7 cells transfected with 
C-siRNA or siMCJ were analyzed by Seahorse MitoStress Assay for (B) oxygen 
consumption rates (OCR) at baseline and in response to sequential injections of 
oligomycin (O), FCCP (F), and rotenone with antimycin (RA) and for (C) basal, 
ATP linked (ATP), and maximal respiration rates (Max) relative to C-siRNA 
transfected cells (n ≥ 5). (D) Rates of mitochondrial production of ATP relative to 
the total ATP production rate in MCF7 cells transfected with a c-siRNA or siMCJ 
as determined by Seahorse ATP Production Rate Assay (n = 10). (E) MCF7 cells 
transfected with C-siRNA or siMCJ were incubated with or without (Veh) 
oligomycin (Oligo, 5 µM), rotenone (Rote, 50 µM), or 2-deoxyglucose (2-DG, 50µM) 
for 2 h, stained with a fluorescent ATP probe (100 µM) for 5 min, and then analyzed 
by live cell confocal microscopy. ATP probe fluorescence (green) and bright light 
differential interference contrast (DIC) are shown. Scale bars represent 10 µm. (F 
and G) Cancer cells were isolated from mammary tumors of WT MMTV-PyMT 
mice (WT MMTV) and MCJ deficient MMTV-PyMT mice (MCJ KO MMTV), 
Figure 4 – Champagne et al.
F

























































































































































expanded in vitro, and then analyzed for OCR as in (B and C). (B, n = 3; C, n ≥ 8). 
(H) WT MMTV and MCJ KO MMTV cells were incubated with oligomycin (5 µM) 
for 2 h followed by incubation with doxorubicin (Dox, 3 µM) for 3 h. Cells were 
then fixed, stained with DAPI (nuclear dye, blue), and analyzed by confocal 
microscopy for doxorubicin fluorescence (red). Scale bars represent 20 µm. Mean 
± SD provided. *denotes p < 0.05 by unpaired t test. Results are representative of 
2 - 3 experiments. 
 
3.5. MCJ mimetics attenuate mitochondrial respiration in chemoresistant cells 
The results above indicate that inhibiting mitochondrial respiration could 
be a novel approach to overcome cancer chemoresistance. However, rotenone and 
other inhibitors of the ETC are highly toxic as they potently and indiscriminately 
block mitochondrial respiration. Ideally, an approach that safely attenuates ETC 
without a full blockage could be more appropriate as a potential therapeutic. MCJ 
is the first identified endogenous negative regulator of Complex I and 
mitochondrial respiration, and it is abundantly expressed in some of the highly 
metabolically active tissues (e.g., liver, heart) (Hatle et al., 2013). Since the absence 
of MCJ causes chemoresistance, we investigated whether MCJ mimetics could 
restore MCJ function as a brake on the ETC in chemoresistant cancer cells. The N-
terminal region (35 aa) of MCJ has no significant homology to any other currently 
known eukaryotic protein, and it has been predicated to interact with the NDUFv1 
subunit of Complex I (Hatle et al., 2013). We therefore designed peptide mimetics 
of MCJ containing the first 20 aa of the N-terminus of human MCJ (N-MCJ). Two 
different MCJ mimetics were designed with different sequences added to mediate 
delivery into mitochondria (Supplementary Figure 3-4). The MITOx20 mimetic 
contains the N-MCJ sequence in addition to the HIV TAT tag that is routinely used 
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to confer cell permeability to peptides (Nagahara et al., 1998; Schwarze et al., 1999) 
and a mitochondrial targeting sequence (mts) (Addya et al., 1997) (Supplementary 
Figure 3-4). For the MITOx30 mimetic, the same N-MCJ sequence was added to a 
previously described mitochondria-penetrating peptide (MPP) (Horton et al., 
2008). The MPP contains hydrophobic, noncanonical amino acids and provides for 
efficient delivery both into cells and into mitochondria (Supplementary Figure 
3-4). 
We tested whether these N-MCJ mimetics could restore MCJ function in 
inhibiting mitochondrial respiration in cancer cells lacking MCJ using the Seahorse 
Cell MitoStress assay. NCI/ADR-RES cells were incubated with MITOx20 for 12 h 
prior to analysis. As a control we used a peptide similar to MITOx20 that contains 
the HIV TAT tag but lacks the mitochondrial targeting sequence (Control-20). 
Therefore, it can penetrate the cell membrane, but cannot accumulate in 
mitochondria (Supplementary Figure 3-4). MITOx20-treated cells exhibited lower 
basal OCR relative to Control-20-treated cells (Figure 3-5A and B). MITOx20 
treatment also reduced ATP-linked OCR and the maximal respiratory capacity of 
NCI/ADR-RES cells (Figure 3-5B). To confirm that the effects of MITOx20 were 
due to the MCJ N-terminal component, similar experiments were performed using 
MITOx30. As control for MITOx30, we used a peptide comparable to MITOx30 
except that the MCJ sequence was reversed (Control-30). NCI/ADR-RES cells 
treated with MITOx30 showed lower basal OCR relative to cells treated with 
Control-30 (Figure 3-5C and D). In addition, ATP-linked OCR and the maximal 
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respiratory capacity of NCI/ADR-RES cells treated with MITOx30 were also lower 
compared with cells treated with Control-30 (Figure 3-5D). We also examined 
whether the treatment with N-MCJ mimetics had an impact on the overall ATP 
levels in NCI/ADR-RES cells. Both treatment with MITOx20 and MITOx30 
significantly lowered total ATP levels after 12 h of treatment compared to 
untreated cells (Figure 3-5E). In addition, to show that the effect of the N-MCJ 
mimetics was directly on ETC activity, similar to oligomycin or rotenone, we used 
a modified Seahorse MitoStress assay where MITOx30 was injected instead of 
oligomycin (Figure 3-5F). While slower and less pronounced than the effect 
induced by oligomycin, MITOx30 injection caused a major and prolonged 
reduction in baseline OCR as well as in the maximal respiratory capacity of 
NCI/ADR-RES cells (Figure 3-5F). Thus, together these results show that these N-
MCJ mimetics can restore MCJ function by attenuating (but not abrogating) 
mitochondrial respiration in chemoresistant cells. 
Our results above (Figure 3-1) show an enhanced mitochondrial 
metabolism in NCI/ADR-RES cells. To determine whether the treatment with N-
MCJ mimetics could also affect overall mitochondrial metabolism, NCI/ADR-RES 
cells were treated with MITOx30 for 12 h and then analyzed by mass spectrometry-
based metabolomics. Results showed that this short period of treatment with 
MITOx30 was sufficient to alter cell metabolism, primarily by decreasing 
mitochondrial metabolism, as demonstrated by (i) decreases in TCA cycle 
intermediates (citrate, fumarate, malate), (ii) decreases in NAD+, the product of 
 
186 
Complex I, and (iii) increases in the levels of low energy phosphate compounds 
(nucleoside di- and monophosphates) and decreases in nucleoside triphosphates 
(ATP), creatine, and phosphocreatine – markers of energy reservoirs in 
mitochondria (Figure 3-5G, Supplementary Figure 3-5, and  Supplementary Table 
3-2). Overall these results indicate that N-MCJ mimetics are sufficient to attenuate 





Figure 3-5. MCJ mimetics attenuate mitochondrial respiration in 
chemoresistant cancer cells 
 






























































































































































































(A and B) NCI/ADR-RES cells were treated with MITOx20 (25 µM) or Control-20 
(25 µM) for 12 h and the analyzed by Seahorse MitoStress Assay for (A) oxygen 
consumption rates (OCR) at baseline and in response to sequential injections of 
oligomycin (O), FCCP (F), and rotenone with antimycin (RA) and for (B) basal, 
ATP linked (ATP), and maximal respiration rates (Max) relative to Control-20 
treated cells (n ³ 4). (C and D) NCI/ADR-RES cells were treated with MITOx30 
(25 µM) or Control-30 (25 µM) for 12 h and then analyzed as in (A and B) (n = 4). 
(E) NCI/ADR-RES cells were incubated with or without (Vehicle) MITOx20 
(25 µM) or MITOx30 (25 µM) for 5 h and then total ATP levels were determined 
by Luciferase assay (n = 4). (F) NCI/ADR-RES cells were analyzed for OCR at 
baseline and in response to sequential injections of MITOx30 (25 µM), FCCP, and 
rotenone with antimycin (n ³ 4). (G) NCI/ADR-RES cells were treated with 
MITOx30 (25 µM) for 12 h and then the relative abundances of metabolic 
intermediates compared to vehicle treated cells were determined by mass 
spectrometry based metabolomics (n = 4). Mean ± SD shown. *denotes p < 0.05 by 
unpaired t test or one-way ANOVA and Tukey’s multiple comparisons test. 
Results are representative of 2 - 3 experiments. 
 
3.6. MCJ mimetics decrease chemoresistance in vitro by attenuating 
mitochondrial respiration 
Since ABC transporter-mediated chemoresistance is dependent upon 
mitochondrial respiration, and N-MCJ mimetics can attenuate mitochondrial 
respiration and ATP production in chemoresistant cells, we investigated whether 
N-MCJ mimetics could restore doxorubicin accumulation in NCI/ADR-RES cells. 
We choose a low concentration of MITOx20 that had no effect on the viability of 
NCI/ADR-RES cells by itself even after 2 d of treatment (Figure 3-6A). To examine 
the effect of MITOx20 on drug efflux, NCI/ADR-RES cells were treated with 
MITOx20 for 2 h followed by incubation with doxorubicin for 3 h. Doxorubicin 
fluorescence was then examined by confocal microscopy. MITOx20-treated cells 
accumulated higher levels of doxorubicin compared with cells treated with vehicle 
(Figure 3-6B). We also tested the effect of MITOx30. Similar to MITOx20, treatment 
with MITOx30 also restored doxorubicin accumulation in NCI/ADR-RES cells 
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(Figure 3-6C). To confirm that N-MCJ mimetics could reduce ABC transporter 
activity, we examined doxorubicin accumulation by confocal microscopy in HEK 
293T-ABCB1 cells. Cells were treated with MITOx30 for 2 h followed by incubation 
with doxorubicin for 3 h and confocal microscopy analysis. MITOx30 treatment 
enhanced doxorubicin retention in HEK 293T-ABCB1 cells (Figure 3-6D). Thus, by 
attenuating mitochondrial respiration, N-MCJ mimetics lower ABC transporter 
activity and drug efflux in chemoresistant cancer cells. 
To determine whether the treatment with N-MCJ mimetics could overcome 
the resistance to doxorubicin in multidrug resistant cancer cells, NCI/ADR-RES 
cells were incubated with doxorubicin alone or in combination with MITOx30 or 
Control-30 for 3 d and then the number of viable cells was determined by Trypan 
blue exclusion. Neither doxorubicin, MITOx30 or Control-30 alone affected cell 
survival relative to untreated cells (Figure 3-6E). Similarly, the combination of 
doxorubicin and Control-30 had no effect on cell survival (Figure 3-6E). In contrast, 
the combination of doxorubicin with MITOx30 markedly reduced NCI/ADR-RES 
cell viability (Figure 3-6E). Treatment with MITOx20 also enhanced the response 
of NCI/ADR-RES cells to doxorubicin after 2 d (Figure 3-6F). We also examined 
the effect of N-MCJ mimetics on doxorubicin responses in the chemoresistant 
MES/Dox cancer cells. Consistent with results for NCI/ADR-RES cells, while 
doxorubicin alone had no effect, the combination of doxorubicin and MITOx30 
decreased cell survival after 3 d (Figure 3-6G). 
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To further demonstrate the effect of N-MCJ mimetics in overcoming 
chemoresistance in cancer cells in vitro, we performed clonogenic assays. 
NCI/ADR-RES cells were treated with doxorubicin alone or in combination with 
MITOx20 or MITOx30 for 2 d. Cells were then replated at a low density and grown 
in normal culture medium. After 1 wk, cell colonies were counted. Both MITOx20 
and MITOx30 in combination with doxorubicin reduced the number of colonies 
relative to doxorubicin alone (Figure 3-6H). No effect was observed with either 
MITOx20 or MITOx30 alone in the absence of doxorubicin (Figure 3-6I). We also 
examined the effect of MITOx30 in combination with doxorubicin on the 
clonogenicity of MES/Dox cells. Similar to NCI/ADR-RES cells, MITOx30 
together with doxorubicin reduced the number of MES/Dox cell colonies relative 
to doxorubicin alone (Figure 3-6J). Thus, together these results show the efficacy 
of combination therapies of N-MCJ mimetics and chemotherapy in overcoming 







Figure 3-6. MCJ mimetics sensitize chemoresistant cells to 
chemotherapy treatment 
 
(A) NCI/ADR-RES cells were treated with or without (Vehicle) MITOx20 (5 µM) 
for 3 d and then surviving cell counts were determined by Trypan blue exclusion. 
Viability relative to untreated cells is shown (n ³ 4). (B) NCI/ADR-RES cells were 
incubated with MITOx20 (5 µM) for 2 h followed by incubation with doxorubicin 
(Dox, 3 µM) for 3 h. Cells were then fixed, stained with DAPI (nuclear dye, blue), 
and analyzed by confocal microscopy for doxorubicin fluorescence (red). 
Representative images and quantification of doxorubicin intensity relative to 
nuclear area (n ≥ 32 cells) are shown. Scale bars represent 20 µm. (C) 
NCI/ADR-RES and (D) ABCB1-expressing HEK 293T cells were incubated with 
MITOx30 (5 µM) for 2 h followed by incubation with doxorubicin and analysis as 
in (B). Representative images and quantification of doxorubicin intensity relative 
to nuclear area (C, n ≥ 74 cells; D, n ≥ 106 cells) are shown. Scale bars represent 
20 µm. (E) NCI/ADR-RES cells were treated with doxorubicin (3 µM), Control-30 
(5 µM), and/or MITOx30 (5 µM) for 3 d and then cell viability was determined as 
in (A) (n = 4). (F) NCI/ADR-RES cells were treated with doxorubicin (3 µM) 
and/or MITOx20 (5 µM) for 2 d and then cell viability was determined as in (A) 
(n = 3). (G) MES/Dox cells were treated with doxorubicin (3 µM) alone or in 
combination with MITOx30 (5 µM) for 3 d and then cell viability was determined 
as in (A) (n = 3). (H) NCI/ADR-RES cells were treated with doxorubicin (3 µM) in 
combination with MITOx20 (5 µM) or MITOx30 (5 µM) for 2 d, replated at a low 
density (500 cells), grown in normal culture medium for 1 wk, and then the 



















































































































































































































number of colonies formed was determined (n = 4). (I) NCI/ADR-RES cells were 
treated with MITOx20 (5 µM) or MITOx30 (5 µM) for 2 d and then analyzed for 
clonogenicity as in (H) (n = 3). (J) MES/Dox cells were treated with doxorubicin (3 
µM) alone or in combination with MITOx30 (5 µM) for 2 d, replated at a low 
density (400 cells), and then analyzed for clonogenicity as in (H) (n = 4). Mean ± 
SD provided. *denotes p < 0.05 by unpaired t test or one-way ANOVA and Tukey’s 
multiple comparisons test. Results are representative of 2 - 3 experiments. 
 
3.7. MCJ mimetics reverse cancer chemoresistance in vivo 
To determine whether MCJ mimetics show efficacy in reversing cancer 
chemoresistance in vivo, we used MCJ KO MMTV mice since the mammary tumors 
are resistant to doxorubicin and continue to grow with the treatment (Fernandez-
Cabezudo et al., 2016). Once tumors reached a measurable size, mice were treated 
with doxorubicin alone or in combination with MITOx20, MITOx30 or Control-30. 
We first tested the stability of MITOx20 and MITOx30 to serum proteases by 
incubating them in the presence of serum in vitro for 3 and 6 h. Spot blot analysis 
using a specific anti-MCJ antibody that recognizes the N-terminus showed 
minimal reduction even after 6 h of incubation (Figure 3-7A), indicating that these 
peptides are relatively stable. Following the doxorubicin treatment schedule used 
in our previous studies (Fernandez-Cabezudo et al., 2016), treatments with 
doxorubicin (i.p.) and/or N-MCJ or control mimetics (s.c.) were given every other 
day for a total of 12 d after which mice treated with doxorubicin alone had to be 
euthanized as tumors reached the maximum approved size. As determined by the 
increase in tumor volume at 12 d relative to the initial size, the tumors of mice 
treated with doxorubicin alone or doxorubicin with Control-20 were markedly 
increased (Figure 3-7B). In contrast, tumors of mice treated with doxorubicin in 
 
192 
combination with either MITOx20 or MITOx30 showed a prominent reduction in 
size (Figure 3-7B). We found no obvious harmful effects of MITOx20 or MITOx30 
in combination with doxorubicin in these mice even after the 12 d of treatment, 
and mice remained highly active with no signs of stress. Following H&E staining, 
histological analysis of the liver and heart showed no evidence of toxicity 
(Supplementary Figure 3-6). In addition to the final tumor size, we also followed 
tumor volume over time. Tumors of mice that received either doxorubicin alone 
or in combination with Control-30 did not respond to treatment and continued 
growing (Figure 3-7C). In contrast, there was a rapid delay (evident after 4 d) in 
the growth of tumors followed by a progressive reduction in tumor size in mice 
treated with doxorubicin in combination with either MITOx20 or MITOx30 (Figure 
3-7C). Thus, N-MCJ mimetics show efficacy in vivo in overcoming chemoresistance 
of mouse tumors that lack MCJ. 
To further demonstrate the potential of N-MCJ mimetics to overcome 
chemoresistance in human cancer, we used a xenograft model with the 
chemoresistant NCI/ADR-RES cells grafted into immunocompromised NSG mice 
commonly used for human tumor studies. Once tumors reach sufficient size, mice 
were treated with doxorubicin alone or in combination with MITOx20 or 
MITOx30. As determined by the change in tumor volume relative to the initial size, 
the combination of doxorubicin with either MITOx20 or MITOx30 successfully 
reduced the final tumor volume (Figure 3-7D). Similar to the mouse tumor model, 
the response to doxorubicin in combination with N-MCJ mimetics was evident 
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shortly after initiation of therapy (Figure 3-7E). Thus, restoring MCJ function with 
N-MCJ mimetics increased responses to standard chemotherapy even in highly 





Figure 3-7. Reversal of chemotherapy resistance in mouse models 
of chemoresistant cancer 
 
(A) Spot blot analysis of MITOx20, MITOx30, and Control-30 prior to (0 h) or after 
incubation with serum (3 or 6 h) using an antibody specific for the N-terminus of 
MCJ. (B and C) MCJ deficient MMTV-PyMT mice were treated with doxorubicin 
alone (Dox, n = 5) or in combination with Control-30 (n = 4), MITOx20 (n = 6), or 
MITOx30 (n = 5) every other day for 12 d. (B) Tumor volumes at the end of 
treatment relative to the initial size. (C) Change in tumor volume over time during 
treatment relative to the initial tumor size. (D and E) NSG mice with 
NCI/ADR-RES cell xenografts were treated with doxorubicin alone or in 
combination with MITOx20 or MITOx30 every other day for 8 d (n = 6). (D) Tumor 
volumes at the end of treatment relative to the initial size. (E) Change in tumor 
volumes over time during treatment relative to the initial tumor size. Dotted lines 
represent initial tumor volumes prior to treatment (100 %). Mean ± SD provided. 
* denotes p < 0.05 by one-way ANOVA and Tukey’s multiple comparisons test. 
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Chemotherapy (e.g., anthracyclines, taxanes, cyclophosphamides) remains 
part of the standard of care for most types of cancers worldwide. In addition to 
being used as frontline therapy, chemotherapy is also used as neoadjuvant therapy 
to reduce tumor size prior to surgery or in combination with several of the newer 
biological therapies (e.g., antibodies against CTLA4, PD1, Her2) (Apetoh et al., 
2015; Wargo et al., 2015). Thus, while the development of new immunotherapy 
strategies (e.g., immune checkpoints and adoptive T cell therapies) is currently the 
main focus in cancer treatment, chemotherapy remains the frontline therapy for 
many cancers and also represents an affordable option worldwide. However, the 
development of chemoresistance and the resulting need for high doses of 
chemotherapeutic drugs with associated toxicity still represent the major 
limitation of this cancer treatment (Lyman, 2009; Pai and Nahata, 2000). 
Unraveling the mechanisms of chemoresistance and developing novel strategies 
to overcome them while minimizing drug toxicity is therefore still a priority 
(Gottesman et al., 2002; Robey et al., 2018). In this study, we uncover a novel 
approach to overcome chemoresistance informed by a new understanding of a 
common mechanism that protects cancer from chemotherapy. We show that 
mitochondrial metabolism and mitochondrial-derived ATP are essential for the 
activity of the ABC transporters to promote drug efflux and chemoresistance in 
cancer cells. In addition, we demonstrate a novel target that acts as negative 
regulator of mitochondrial metabolism and new compounds that restore activity 
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of that target and can be further developed as therapeutic agents for combination 
with standard chemotherapy. 
ABC transporters have the ability to transport multiple substrates across 
the cytoplasmic membrane against the gradient by using ATP as the source of 
energy (Pan et al., 2016; Ween et al., 2015). Some of these transporters can mediate 
the efflux of a number of chemotherapeutic drugs. While the correlation between 
the presence of these transporters and chemoresistance in cancer cell lines is clear, 
the correlation between the presence of specific drug efflux transporters and poor 
chemotherapy response in primary tumors in cancer patients is not well 
established despite a number of clinical studies (Chen et al., 2016; Robey et al., 2018; 
Ween et al., 2015). As a result, the presence of ABC transporters has not yet been 
used as biomarker for poor response to chemotherapy, and interest in these 
transporters in cancer has waned. Other than gene expression, little is known 
about the regulation of ABC transporter activity. ABC transporters are thought to 
have a low affinity for ATP in the absence of substrate, and up to two ATP 
molecules are needed for the transport of one molecule of substrate (Linton and 
Higgins, 2007; Patzlaff et al., 2003; Poolman et al., 2005). Here we reveal for the first 
time the unique need of ATP derived from mitochondria for the activity of ABC 
transporters. Interestingly, we also show that ATP derived from glycolysis is 
unnecessary for the activity of ABC transporters in cancer cells. Our findings could 
explain the paradox of why the sole presence of the ABC transporters in tumors 
may not correlate with poor response to chemotherapy. In line with the Warburg 
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effect, it is well known that cancer cell metabolism is biased towards glycolysis 
instead of mitochondria respiration (Koppenol et al., 2011; Warburg, 1956). Thus, 
expression of ABC transporters in highly glycolytic cancer cells with minimal 
mitochondrial respiration would not be sufficient to confer chemoresistance. Here 
we also show that, relative to parental drug-sensitive cancer cells, derived 
chemoresistant cancer cells have elevated mitochondrial respiratory capacity. 
Thus, acquisition of ABC transporters as well as highly effective mitochondrial 
respiration are needed to establish chemoresistance in cancer cells. 
In this regard, it is well known that stem cancer cells respond poorly to 
chemotherapy and are most likely the cause of acquired chemoresistance after the 
initial successful response of the primary tumor (Abdullah and Chow, 2013). In 
contrast to glycolytic cancer cells, stem cancer cells display elevated mitochondrial 
respiration (Peiris-Pages et al., 2016; Viale and Draetta, 2015). Interestingly, ABCB1 
and ABCG2 have been used as markers for identification of stem cancer cells (Ding 
et al., 2010; Haraguchi et al., 2006; Moitra, 2015), although their potential roles in 
mediating chemoresistance in these cells has not been established. Thus, this is 
another case where chemoresistance is associated with increased levels of 
mitochondrial-derived ATP in addition to the overexpression of ABC transporters. 
An association between mitochondrial respiration and chemoresistance has also 
been reported in slow-cycling melanoma cancer cell lines, but the potential 
involvement of ABC transporters was not investigated (Cierlitza et al., 2015; 
Roesch et al., 2013). 
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A question that remains following our findings: why is only mitochondrial 
ATP but not glycolytic ATP required for ABC transporter activity? Because of the 
potential low affinity of ABC transporters for ATP (Linton and Higgins, 2007), a 
high concentration of ATP would be needed for their activity. This requirement 
could be difficult to achieve only with cytoplasmic levels of ATP generated by 
glycolysis. However, since mitochondria are dynamic organelles that can move 
throughout the cytosol, they can traffic to the cytoplasmic membrane where most 
ABC transporters localize and contribute to the generation of ATP-rich 
microdomains. We have previously shown the presence of ATP-rich 
microdomains that are dependent on mitochondrial ATP synthesis in CD8+ T cells 
with high mitochondrial activity (Champagne et al., 2016). Here we also show the 
presence of these ATP-rich domains in chemoresistant cancer cell lines with high 
mitochondrial activity. These microdomains with high concentrations of ATP 
could be required to sustain the activity of ABC transporters. 
MCJ has been shown to be an endogenous negative regulator of 
mitochondrial respiration in a number of primary tissues including the heart, liver, 
CD8+ T cells, and macrophages (Barbier-Torres et al., 2017; Champagne et al., 2016; 
Hatle et al., 2013; Navasa, Martin, et al., 2015). MCJ restricts OXPHOS and 
mitochondrial ATP production by limiting Complex I activity (Barbier-Torres et 
al., 2017; Hatle et al., 2013). Here we show that MCJ also acts as a negative regulator 
of mitochondrial respiration in cancer cells and that loss of MCJ leads to increased 
mitochondrial ATP production. Importantly, we show for the first time that high 
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levels of mitochondrial derived ATP achieved in the absence of MCJ are sufficient 
to fuel the activity of ABC transporters and promote drug efflux. Loss of MCJ 
expression correlates with poor responses to chemotherapy and poor prognoses 
in ovarian cancer patients (Shridhar et al., 2001; Strathdee et al., 2005). We have 
shown that loss of MCJ expression causes chemoresistance in vitro in cancer cell 
lines and in vivo in mouse models of mammary cancer (Fernandez-Cabezudo et al., 
2016; Hatle et al., 2007). In addition, retrospective and prospective studies in breast 
cancer patients revealed that loss of MCJ in primary tumors correlates with poor 
responses to chemotherapy, but not with responses to hormone therapy (which is 
not affected by ABC transporters) (Fernandez-Cabezudo et al., 2016). Thus, it is 
possible that a combination of the expression of MCJ together with ABCB1 or other 
ABC transporters will serve as a biomarker that effectively predicts 
chemoresistance with high confidence. Thus, cancer cells that express drug-efflux 
ABC transporters, but have lost MCJ expression, will have the highest probability 
of chemoresistance. 
A number of ABC inhibitors have been developed and clinically tested, 
most of which interfere with substrate binding to the transporter (Kathawala et al., 
2015; Li et al., 2016; Saraswathy and Gong, 2013). Despite promising preclinical 
studies, these inhibitors failed to show efficacy in clinical trials. Toxicity due to off 
target effects was the main problem for first generation inhibitors of ABCB1. A 
lack of sufficient efficacy in combination with chemotherapy relative to 
chemotherapy alone was the challenge for second generation inhibitors despite 
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significant inhibition of the three most commonly expressed ABC transporters 
(ABCB1, ABCG2, ABCC1) (Coley, 2010; Kohler and Stein, 2003). The third 
generation of ABCB1 inhibitors showed some efficacy in clinical trials, but their 
high toxicity has compromised their use for cancer treatment. Thus, no ABC 
transporters inhibitors have been highly successful (Robey et al., 2018; Ween et al., 
2015). Here we show the efficacy of deliverable N-MCJ mimetics in attenuating 
mitochondrial respiration, reducing ABC transporter drug efflux, and increasing 
responses to standard chemotherapy in cancer cells in vitro. Moreover, N-MCJ 
mimetics showed efficacy in reducing tumor size in vivo when administered in 
combination with doxorubicin without increasing drug toxicity. Together, these 
results suggest that attenuating mitochondrial respiration by restoring MCJ 
expression in combination with standard chemotherapy can be a novel therapeutic 
approach in cancer patients by increasing sensitivity to lower chemotherapy doses 
in those cancer cells that have lost MCJ. We therefore propose that N-MCJ 
mimetics could be developed as a novel “adjuvant” chemotherapy to be 
administered with lower doses of standard chemotherapy. 
 
5. Experimental Procedures 
5.1. Cell lines and culture conditions 
NCI/ADR-RES (formerly MCF7/Adr), MES, MES/Dox, and MCF7/Tx400 
cells were previously described (Batist et al., 1986; Harker et al., 1983; Hatle et al., 
2007; Huff et al., 2006; Robey et al., 2003; Robey et al., 2008). MCF7 cells were 
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purchased from American Type Culture Collection (ATCC). OVCAR-8 cells were 
kindly provided by Dr. Ernst Lengyel at the University of Chicago. All cancer cell 
lines were maintained in RPMI 1640 supplemented with 10 % FBS, 2 mM 
glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin. HEK 293T cell 
lines were previously described (Robey et al., 2003; Robey et al., 2008) and 
maintained in RPMI as above additionally supplemented with 2 mg/mL 
Geneticin. Chemotherapeutic agents added to maintain chemoresistant 
phenotypes were removed at least 1 wk prior to experiments. MCF7 cell 
transfections were performed using siPORT NeoFX Transfection Agent 
(ThermoFisher Scientific) following the recommended protocol for an 
oligonucleotide siRNA based on the previously described MCJ targeting sequence 
(Hatle et al., 2007). FBS was obtained from Serum Source International, while all 
other cell culture reagents were from ThermoFisher Scientific. Doxorubicin was 
obtained from the University of Vermont Medical Center Pharmacy. Oligomycin, 
rotenone, 2-deoxyglucose, paclitaxel, and Hoechst 33258 were purchased from 
Sigma Aldrich.  
5.2. Mouse models 
All mice were maintained in the animal facility at the University of Vermont 
under Institutional Animal Care and Use Committee (IACUC) approved 
conditions. WT and MCJ deficient MMTV-PyMT were previously described 
(Fernandez-Cabezudo et al., 2016). NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ, 
 
201 
Jackson Laboratories) were injected with 5 – 7 x 106 NCI/ADR-RES cells (i.p.) in 
150 µL PBS. For both models, mice were treated with vehicle, doxorubicin (i.p., 2 
mg/kg for MMTV mice, 1 mg/kg for NSG mice), and/or and MCJ mimetics (s.c., 
10 mg/kg) every other day after tumors reached 0.15 - 0.25 cm3. Tumor 
measurements were performed using a caliper to determine the tumor volumes 
using the formula Vol = length x width x height (above skin level). Animal studies 
were performed under the oversight of the University of Vermont IACUC. 
5.3. Extracellular flux analysis 
Oxygen consumption rates (OCR) and extracellular acidification rates 
(ECAR) were analyzed under basal conditions and in response to sequential 
injections of oligomycin (2 µM), FCCP (2 µM), and rotenone with antimycin A (1 
µM each) using the Seahorse MitoStress Test Kit. OCR analysis was also performed 
after incubation with N-MCJ mimetics for 12 h. ATP production rates were 
determined using the XF Real-Time ATP Rate Assay Kit following the 
recommended protocol. All extracellular flux analyses were performed using an 
XF24 or XF96 Extracellular Flux Analyzer as recommended by the manufacturer 
(all Agilent Technologies). 
5.4. Mass spectrometry based metabolomics 
Metabolic profile comparisons of OVCAR-8 and NCI/ADR-RES cells were 
performed on equal numbers of cells. Cells were cultured under normal 
conditions, detached using trypsin-EDTA (0.05 %), counted, normalized to 0.5 x 
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106 in each sample, and then cell pellets were snap frozen in liquid nitrogen prior 
to analysis. To determine the effect of N-MCJ mimetic treatment, equal numbers 
of NCI/ADR-RES cells were plated and allowed to adhere for 2 d followed by the 
addition of vehicle or MITOx30 (25 µM) for 12 h. Cells were then collected and 
processed as above. Metabolomics and flux analyses were performed as 
previously reported (D'Alessandro et al., 2015). Briefly, 2 x 106 cells and 20 µl of 
cell media were extracted in 1 mL and 980 µL of cold lysis and extraction buffer 
(methanol : acetonitrile : water, 5:3:2), respectively. After discarding protein 
pellets, 10 µL of water and methanol soluble fractions were run through a Kinetex 
C18 1.7 µm, 100 x 2.1 mm (Phenomenex) reversed phase column (Positive ion 
mode - phase A: water, 0.1 % formic acid; B: acetonitrile, 0.1 % formic acid; 
Negative ion mode - phase A: 1 mM NH4Ac 95:5 water : acetonitrile; phase B: 1 
mM NH4Ac 95:5 acetonitrile : water) via an ultra-high performance 
chromatographic system (UHPLC - Vanquish, Thermo Fisher). UHPLC was 
coupled in line with a high-resolution quadrupole Orbitrap instrument run in both 
polarity modes (QExactive, Thermo Fisher) at 70,000 resolution (at 200 m/z). 
Gradients and other technical parameters and the variants employed herein have 
been extensively described (D'Alessandro et al., 2017; Nemkov et al., 2017). 
Metabolite assignment and peak integration for relative quantitation were 
performed through the software Maven (Princeton), against the KEGG pathway 
database and an in-house validated standard library (> 1,000 compounds, Sigma 
Aldrich, IROATech). Integrated peak areas were exported to Excel (Microsoft) and 
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elaborated for statistical analysis (unpaired t test) and hierarchical clustering 
analysis (HCA) through Prism (GraphPad Software) and GENE-E (Broad 
Institute), respectively. 
5.5. Flow cytometry analysis 
For detection of ABC transporter substrate accumulation, cells were 
pretreated with metabolic inhibitors as indicated for 2 h followed by the addition 
of doxorubicin (3 µM) or Hoechst 33258 (100 ng/mL) for 3 h. Cells were then 
washed, fixed in PBS supplemented with 1 % paraformaldehyde, and then 
immediately analyzed using a BD Biosciences LSRII Flow Cytometer at the 
University of Vermont Flow Cytometry and Cell Sorting Facility. Median 
fluorescence intensities relative to intreated cells were determined using FlowJo 
Software. 
5.6. Confocal microscopy analysis 
All confocal microscopy analyses were performed using a Zeiss LSM 510 
Meta Confocal Laser Scanning microscope (Carl Zeiss Microscopy) at the 
University of Vermont Microscopy Imaging Center as previously described 
(Champagne et al., 2016). Analysis of doxorubicin pixel fluorescence intensity per 
nuclear area was performed using ImageJ software (version 1.51h, NIH). For 
analysis of subcellular ATP distribution, cells were plated in glass bottom plates 
(MatTek) and allowed to adhere for 3 d. Cells were then pretreated with metabolic 
inhibitors as indicated for 2 h followed by the addition of a fluorescent ATP/ADP 
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probe (Rao et al., 2012) (100 µM) for 5 min. Cells were then washed with and 
immediately imaged in PBS. For analysis of doxorubicin accumulation, cells were 
plated on glass coverslips and allowed to adhere for 3 d. Cells were then pretreated 
with metabolic inhibitors as indicated for 2 h followed by the addition of 
doxorubicin (3 µM) for 3 h. Cells were then washed, fixed in PBS supplemented 
with 1 % paraformaldehyde, and stained with DAPI. Coverslips were mounted to 
glass microscope slides using Vectashield Antifade Mounting Medium (Vector 
Laboratories) and sealed with nail polish prior to imaging.  
5.7. Calcein retention 
Effects of metabolic inhibitors on calcein retention were determined using 
the Vybrant Multidrug Resistance Assay Kit (ThermoFisher Scientific). Cells were 
pretreated with metabolic inhibitors as indicated for 2 h followed by the addition 
of calcein (0.25  µM) for 15 min. Cells were then washed, dissolved in DMSO, and 
then calcein absorbance was determined using an ELx800 Absorbance Microplate 
Reader (BioTek). 
5.8. Intracellular ATP concentration 
Intracellular ATP concentration in cells (104) was determined using the 
ATPlite Luminescence Assay System (PerkinElmer) and a TD-20/20 Luminometer 
(Turner BioSystems) as recommended by the manufacturers.  
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5.9. MCJ expression 
Western blot analyses were performed on whole cell lysates derived using 
RIPA buffer supplemented with 1 mM PMSF, 1 mM Na3VO4, and 0.5 % Protease 
Inhibitor Cocktail (Sigma Aldrich). Lysates were separated by electrophoresis, 
transferred to PVDF membranes, and then analyzed using anti-MCJ and anti-
GAPDH antibodies as previously described (Fernandez-Cabezudo et al., 2016; 
Hatle et al., 2013). 
5.10. Cell viability in response to drug treatments 
For analysis of cell survival, cells were plated in normal culture medium 
and allowed to adhere for 2 d. Culture medium was then replaced with medium 
containing doxorubicin and/or N-MCJ mimetics, and cells were incubated for an 
additional 2 - 3 d as indicated. Cells were then washed with PBS, detached with 
0.05 % trypsin-EDTA, and live cell counts were determined by Trypan blue 
exclusion. Viability was then calculated relative to untreated cells. For 
clonogenicity assays, cells were plated and allowed to adhere for 2 d followed by 
the addition of doxorubicin (1 µM for MES/Dox cells, 3 µM for NCI/ADR-RES 
cells) and/or N-MCJ mimetics (5 µM) in fresh culture medium for 2 d. Cells were 
then replated in normal culture medium, incubated for 1 wk, washed with PBS, 
fixed with PBS supplemented with 1 % paraformaldehyde, stained with crystal 
violet (0.01 % in water), and then colony counts were determined. MTT cell 
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viability assays were performed as previously described (Hatle et al., 2007). MTT 
(thiazolyl blue tetrazolium bromide) was purchased from Acros Organics. 
5.11. Peptide stability 
N-MCJ mimetic stability was determined by diluting stocks (1 mM in 
water) 1:1 in human serum and incubating at ambient temperature for the 
indicated times. For detection, 1 µL of diluent was spotted onto nitrocellulose and 
allowed to air dry. Blots were then subjected to UV crosslinking for 30 s (UVP 
Ultraviolent Crosslinker CL-1000) and analyzed by Western blot as described 
above. 
5.12. Statistical analyses 
Statistical significance was determined by unpaired t test for two groups or 
by one-way ANOVA with Tukey’s multiple comparisons test for three or more 
groups using Graphpad Prism software. P < 0.05 was considered statistically 
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Supplementary Figure 3-1. Derived chemoresistant cancer cells do 
not have increased rates of glycolysis compared to their 
chemosensitive parental cell lines 
 
(A) Viability of OVCAR-8 and NCI/ADR-RES cells in the presence of increasing 
concentrations of doxorubicin (Dox) as determined by MTT assay. (B) Baseline 
extracellular acidification rates (ECAR) of OVCAR-8 and NCI/ADR-RES cells as 
determined by extracellular flux analysis. (C) Viability of MES and MES/Dox cells 
in the presence of increasing concentrations of doxorubicin as determined by MTT 
assay. (D) Baseline ECAR of MES and MES/Dox cells as determined by 
extracellular flux analysis. (E) Viability of MCF7 and MCF7/Tx400 cells in the 
presence of increasing concentrations of doxorubicin as determined by MTT assay. 
(F) Baseline ECAR of MCF7 and MCF7/Tx400 cells as determined by extracellular 





























































































































Supplementary Figure 1. Derived chemoresistant cancer cells do not have increased rates
of glycolysis compared to their chemosensitive parental cell lines. (A) Viability of OVCAR-8
and NCI/ADR-RES cells i the presence of increasing concentrations of doxorubicin (Dox) as
determined by MTT assay. (B) Baseline extracellular acidification rates (ECAR) of OVCAR-8 and
NCI/ADR-RES cells as determined by extracellular flux analysis. (C) Viability of MES and
MES/Dox cells in the presence of increasing concentrations of doxorubicin as determined by MTT
assay. (D) Baseline ECAR of MES and MES/Dox c lls as determined by extr c llular flux
analysis. (E) Viability of MCF7 and MCF7/Tx400 cells in the presence of increasing
concentrations of doxorubicin as determined by MTT assay. (F) Baseline ECAR of MCF7 and





Supplementary Figure 3-2. NCI/ADR-RES cells have increased 
rates of amino acid and nucleotide metabolism compared to 
OVCAR-8 cells 
 
Altered metabolic pathways in NCI/ADR-RES cells relative to OVCAR-8 cells as 
determined by mass spectrometry based metabolomics and metabolite sets 
enrichment analysis (MSEA). Pathway impact, number of metabolites detected 
that support the assignment of a pathway; -log(p), negative log of the p value 





Supplementary Figure 3-3. Metabolic inhibitors do not 
significantly increase the accumulation of doxorubicin in 
chemosensitive cancer cells 
 
(A) OVCAR-8 and (B) MES cells were treated with or without (Veh) oligomycin 
(Oligo, 5 µM), rotenone (Rote, 50 µM), or 2-deoxyglucose (2-DG, 50 mM) for 2 h 
followed by incubation with doxorubicin (Dox, 3 µM) for 3 h. Cells were then fixed 
and doxorubicin fluorescence was determined by flow cytometry analysis. 







Supplementary Figure 3-4. Peptide mimetics of MCJ 
 
(Upper) N-MCJ mimetics compared to the domains of the full length MCJ (not to 
scale). (Lower) Amino acid sequences of N-MCJ mimetics. Abbreviations used: 
N-term, N-terminus; TM, transmembrane domain; C-term, C-terminus; TAT, HIV 
TAT sequences; N-MCJ, first 20 aa of the MCJ N-terminus; mts, mitochondrial 






































Supplementary Figure 3. Metabolic inhibitors do not significantly increase the
accumulation of doxorubicin in chemosensitive cancer cells. (A) OVCAR-8 and (B) MES
cells were treated with or without (Veh) oligomycin (Oligo, 5 μM), rotenone (Rote, 50 μM), or 2-
deoxyglucose (2-DG, 50 mM) for 2 h followed by incubation with doxorubicin (Dox, 3 μM) for 3 h.
Cells were then fixed and doxorubicin fluorescence was determined by flow cytometry analysis.
Median fluorescence intensity (MFI) is shown. Mean ± SD (n = 3) provided.
Supplementary Figure 4. Peptide mimetics of MCJ. (Upper) N-MCJ mimetics compared to the
domains of the full length MCJ (not to scale). (Lower) Amino acid sequences of N-MCJ mimetics.
Abbreviations used: N-term, N-terminus; TM, transmembrane do ain; C-term, C-terminus; TAT,
HIV TAT sequences; N- J, first 20 a of the MCJ N-terminus; mts, mitochondrial targeting
sequence; mpp, mitochondrial penetrating peptide; rev, reversed aa sequence.
MITOx20 N-MCJ (20 aa)TAT mts
Control-20 N-MCJ (20 aa)TAT
MITOx30 N-MCJ (20 aa)mpp
Control-30 N-MCJ (20 aa) (rev)mpp
N-term (35 aa) TM C-termMCJ











Supplementary Figure 3-5. MCJ mimetics alter amino acid and 
nucleotide metabolism in MCJ-deficient cancer cells  
 
Altered metabolic pathways in NCI/ADR-RES cells treated with MITOx30 for 12 
h relative to vehicle treated cells as determined by mass spectrometry based 
metabolomics and metabolite sets enrichment analysis (MSEA). Pathway impact, 
number of metabolites detected that support the assignment of a pathway; -log(p), 






Supplementary Figure 3-6. MCJ mimetics do not increase 
doxorubicin toxicity 
 
Representative images from H&E staining of (A) liver and (B) heart sections of 
control (untreated) mice or mice treated with doxorubicin (Dox) alone or in 
combination with MITOx20 or MITOx30. Treatments were performed every other 
day. Mice were sacrificed after 11 d.  
Control
Dox + MITOx20 Dox + MITOx30
Dox
A
Supplementary Figure 6. (A and B) Representative images from H&E staining of (A) liver and
(B) heart sections from control (untreated) mice or mice treated with doxorubicin (Dox) alone or in
combination with MITOx20 or MITOx30. Treatments were performed every other day. Mice were
sacrificed after 11 d.




6.2. Supplementary Tables 
 




*Peak Area †Fold 
Increase 
‡p-value OVCAR NCI/ADR-RES 
Amino acids Alanine 2.15E+07 2.45E+07 1.14 0.010 
Arginine 2.02E+07 2.45E+07 1.21 0.002 
Asparagine 4.36E+06 5.44E+06 1.25 0.013 
Aspartate 3.12E+07 3.73E+07 1.20 0.017 
Cysteine 5.21E+06 5.37E+06 1.03 0.615 
Glutamate 3.08E+08 2.88E+08 0.94 0.196 
Glutamine 5.34E+07 5.12E+07 0.96 0.510 
Glycine 3.64E+06 3.44E+06 0.94 0.509 
Histidine 2.98E+06 4.54E+06 1.53 0.000 
Leucine/Isoleucine 9.27E+07 1.22E+08 1.31 0.004 
Lysine 5.04E+06 8.68E+06 1.72 0.000 
Methionine 4.37E+06 5.86E+06 1.34 0.027 
Phenylalanine 3.83E+06 5.51E+06 1.44 0.004 
Proline 1.55E+08 1.50E+08 0.97 0.137 
Serine 1.55E+06 2.25E+06 1.45 0.006 
Threonine 5.86E+06 7.69E+06 1.31 0.012 
Tryptophan 8.57E+06 1.10E+07 1.29 0.033 
Tyrosine 4.33E+06 6.43E+06 1.49 0.005 
Valine 4.06E+07 5.24E+07 1.29 0.000 
Nucleotides ATP 5.44E+05 2.50E+06 4.59 0.000 
ADP 1.30E+06 5.85E+06 4.50 0.000 
AMP 8.25E+05 1.86E+07 22.52 0.000 
dAMP 3.19E+05 3.13E+05 0.98 0.986 
Adenosine 4.99E+04 5.45E+04 1.09 0.489 
Adenine 1.84E+06 4.75E+06 2.58 0.000 
GDP 3.78E+05 1.36E+06 3.59 0.000 
GMP 1.08E+05 2.32E+06 21.52 0.000 
Guanosine 5.81E+05 1.03E+05 0.18 0.002 
Guanine 2.12E+06 4.16E+05 0.20 0.000 
CTP 6.89E+05 4.56E+05 0.66 0.037 
CDP 7.08E+05 1.08E+06 1.53 0.002 
CMP 1.48E+05 7.58E+05 5.12 0.000 
Cytidine 1.23E+06 2.06E+06 1.67 0.001 
Thymidine 2.43E+05 3.04E+05 1.25 0.014 
Thymine 1.22E+05 1.27E+05 1.04 0.927 
UTP 4.66E+05 1.77E+06 3.79 0.000 
UDP 6.82E+05 4.68E+06 6.87 0.000 
UMP 1.35E+05 3.33E+06 24.68 0.000 
Uracil 9.31E+06 6.94E+06 0.75 0.006 
IMP 2.48E+04 4.98E+05 20.10 0.000 
Inosine 1.77E+07 1.22E+07 0.69 0.026 
 
*Median value. †Fold increase of peak area calculated as ADR-RES/OVCAR-8. ‡Determined by 
unpaired t test (n = 4).  
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Supplementary Table 3-1 (continued) 
 
Nucleotides Hypoxanthine 5.30E+07 4.10E+07 0.77 0.012 
Xanthine 1.33E+07 7.54E+06 0.57 0.002 
Allantoin 1.28E+05 1.46E+05 1.14 0.074 
5-Hydroxyisourate 1.16E+07 6.64E+06 0.57 0.000 
Urate 2.41E+04 3.49E+04 1.45 0.005 
N-Formyl-GAR 2.32E+05 3.88E+05 1.67 0.002 
5,6-Dihydrothymine 1.96E+06 1.77E+06 0.90 0.054 
Nicotinamide 1.60E+07 3.28E+07 2.05 0.000 
Adenylosuccinic acid 1.87E+04 4.50E+05 24.05 0.000 
UDP-glucose 1.85E+06 2.85E+06 1.54 0.000 
NADPH 2.93E+04 4.61E+04 1.57 0.044 
NAD+ 2.42E+06 4.09E+06 1.69 0.001 
NADH 2.15E+05 1.64E+05 0.76 0.001 
Phosphates Diphosphate 1.84E+07 1.42E+07 0.77 0.001 
Glycolysis Glucose 1.16E+07 1.50E+07 1.29 0.022 
Glucose-6-phosphate 7.60E+05 9.38E+05 1.23 0.024 
Fructose-1,6-bisphosphate 5.43E+05 6.36E+05 1.17 0.009 
Glyceraldehyde-3-phosphate 9.18E+04 8.85E+04 0.96 0.736 
2/3-Phosphoglycerate 3.72E+05 3.31E+05 0.89 0.014 
Pyruvate 3.74E+05 2.99E+05 0.80 0.017 
Lactate 2.87E+07 2.17E+07 0.75 0.018 
Other sugars Maltose 7.44E+04 9.78E+04 1.31 0.029 
Mannitol 2.21E+05 2.90E+05 1.31 0.003 
Arabitol 1.26E+05 3.47E+05 2.75 0.000 
TCA cycle Citrate 4.79E+06 6.35E+06 1.33 0.003 
α-Ketoglutarate 1.37E+05 7.73E+04 0.56 0.000 
2-Oxoglutaramate 8.97E+04 8.09E+04 0.90 0.557 
Succinate 3.09E+06 4.66E+06 1.51 0.000 
Fumarate 2.72E+06 2.11E+06 0.78 0.000 
Malate 2.15E+07 1.47E+07 0.68 0.000 
2-Hydroxyglutarate 1.56E+05 1.06E+05 0.68 0.003 
Pentose Phosphate 
Pathway 
Erythrose-4-phosphate 7.01E+04 6.25E+04 0.89 0.163 
Sedoheptulose-1-phosphate 3.36E+05 3.94E+05 1.17 0.009 
α-Ribose-1-phosphate 1.74E+06 1.51E+06 0.87 0.075 
GSH homeostasis Glutathione 3.06E+08 3.24E+08 1.06 0.484 
Glutathione disulfide 4.85E+05 6.21E+05 1.28 0.022 
5-Oxoproline 2.59E+07 1.88E+07 0.73 0.000 
S-Glutathionylcysteine 1.43E+05 1.64E+05 1.15 0.604 
Cys-Gly 4.65E+06 5.61E+06 1.21 0.063 
Ascorbate 5.03E+04 1.29E+05 2.57 0.000 
Dehydroascorbate 1.56E+05 1.30E+05 0.83 0.043 
Gamma-glutamyls γ-Glutamylcysteine 2.00E+06 2.89E+06 1.44 0.002 
γ-Glutamylglutamine 1.37E+06 3.71E+05 0.27 0.000 
Ser & 1C metabolism Homocysteine 2.65E+04 6.23E+04 2.35 0.000 
Cystathionine 1.08E+06 3.14E+06 2.91 0.000 
Dimethylglycine 1.12E+06 9.88E+05 0.88 0.002 
Phosphoserine 3.05E+06 1.49E+06 0.49 0.001 
S-Adenosylhomocysteine 1.98E+05 1.94E+05 0.98 0.725 
S-Adenosylmethionine 5.53E+05 8.05E+05 1.46 0.019 
Urea cycle Ornithine 3.92E+04 7.40E+05 18.85 0.002 
Citrulline 1.82E+06 4.87E+06 2.67 0.000 
Argininosuccinate 1.21E+06 1.03E+06 0.85 0.190 
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Polyamines Putrescine 2.45E+06 2.51E+06 1.02 0.767 
Spermidine 4.37E+06 2.61E+06 0.60 0.002 
Spermine 1.17E+06 6.06E+05 0.52 0.062 
Aminosugars N-Acetylneuraminate 2.59E+05 3.54E+05 1.37 0.067 
UDP-N-Acetylglucosamine 4.02E+06 5.93E+06 1.47 0.000 
CMP-N-Acetylneuraminate 2.20E+05 2.32E+05 1.06 0.592 
Arg & Pro 
metabolism 
Carnosine 3.12E+04 3.57E+04 1.15 0.644 
Phosphocreatine 1.63E+05 5.42E+04 0.33 0.000 
Creatine 1.18E+09 1.42E+09 1.20 0.000 
Creatinine 7.22E+06 9.53E+06 1.32 0.000 
N-Succinylcitrulline 2.52E+05 6.33E+04 0.25 0.000 
trans-4-Hydroxyproline 3.15E+06 4.05E+06 1.29 0.000 
Panthothenate Pantothenol 1.75E+06 8.90E+05 0.51 0.000 
5,6-Dihydrouracil 6.44E+05 7.73E+05 1.20 0.000 
4'--Phosphopantothenate 2.09E+05 3.00E+05 1.43 0.003 
Sulfur metabolism Taurine 3.86E+07 1.75E+07 0.45 0.000 
Hypotaurine 3.38E+05 2.07E+05 0.61 0.000 
Thiocysteine 1.46E+06 1.33E+06 0.91 0.102 
Indole & Tryptophan 5-Hydroxyindoleacetate 8.34E+05 1.77E+06 2.13 0.000 
Indole 1.57E+04 1.87E+04 1.19 0.182 
Indole-3-acetate 1.05E+05 1.35E+05 1.28 0.001 
Quinolinic acid 9.82E+04 4.56E+04 0.46 0.001 
Glycerophospholipid 
biosynthesis 
Glycerol-3-phosphate 9.08E+05 8.83E+05 0.97 0.889 
Ethanolamine phosphate 2.32E+05 9.83E+04 0.42 0.000 
Sphingosine 1.66E+06 7.64E+05 0.46 0.012 
Acetylcholine 2.55E+06 1.85E+06 0.73 0.001 
CDP-choline 7.74E+05 1.44E+06 1.87 0.003 
Choline 3.74E+08 3.69E+08 0.99 0.730 
Sphingolipids Sphinganine-1-phosphate 3.09E+04 3.22E+04 1.04 0.409 
Carnitine & fatty acid 
metabolism 
Carnitine 1.11E+07 1.09E+07 0.98 0.220 
Acetylcarnitine 4.51E+06 2.54E+06 0.56 0.001 
Propionylcarnitine 1.81E+06 5.03E+05 0.28 0.000 
Butanoylcarnitine 2.00E+06 4.95E+05 0.25 0.000 
Hexanoylcarnitine 1.72E+05 1.71E+05 0.99 0.516 
Tetradecanoylcarnitine 1.07E+06 5.08E+05 0.48 0.003 
Hexadecenoylcarnitine 3.56E+05 9.85E+04 0.28 0.006 
Octadecenoylcarnitine 6.93E+05 1.95E+05 0.28 0.012 
Linoleoyl-CoA 1.23E+06 1.40E+05 0.11 0.003 
Saturated Fatty acids Pentanoate 5.24E+04 4.11E+04 0.78 0.063 
Hexanoic acid 3.07E+05 3.09E+05 1.01 0.438 
Heptanoic acid 1.52E+05 1.20E+05 0.79 0.005 
Octanoic acid 5.07E+05 4.45E+05 0.88 0.015 
Nonanoic acid 1.54E+06 2.33E+06 1.51 0.017 
Decanoic acid 4.93E+05 8.00E+05 1.62 0.006 
Dodecanoic acid 3.15E+05 5.47E+05 1.74 0.007 
Tetradecanoic acid 2.86E+06 5.03E+06 1.76 0.029 
Hexadecanoic acid 3.09E+07 4.07E+07 1.32 0.161 
Octadecanoic acid 3.24E+07 3.55E+07 1.10 0.017 
Monounsaturated 
Fatty Acids 
Tetradecenoic acid 1.66E+05 3.05E+05 1.83 0.006 
Hexadecenoic acid 1.94E+06 3.98E+06 2.05 0.061 








Octadecadienoic acid 1.03E+07 1.81E+07 1.76 0.089 
Octadecatrienoic acid 4.28E+05 6.65E+05 1.55 0.254 
Arachidonic acid 4.62E+06 5.85E+06 1.27 0.226 
Stearidonic acid 2.13E+04 1.55E+04 0.73 0.225 
Docosahexaenoic acid 2.00E+06 2.22E+06 1.11 0.808 
Adrenic acid 3.38E+06 1.42E+06 0.42 0.008 
Eicosapentaenoic acid 1.86E+05 1.78E+05 0.96 0.854 
Essential fatty acids Dihomo-γ-linolenic acid 9.16E+05 1.27E+06 1.39 0.219 
Docosapentaenoic acid 1.23E+06 5.14E+05 0.42 0.016 
Lipids Undecanoic acid 1.02E+05 1.50E+05 1.47 0.004 
Bile acids Glycochenodeoxycholate 6.42E+04 5.15E+04 0.80 0.267 
Taurodeoxycholate 3.79E+04 3.51E+04 0.93 0.489 
Arachidonate 
metabolism 
13-Hydroxyoctadecadienoic acid 1.04E+05 1.20E+05 1.15 0.385 
Prostaglandin A2 1.01E+04 1.12E+04 1.12 0.284 
Prostaglandin D2 3.01E+05 4.29E+05 1.42 0.011 
Leukotriene A4 1.30E+04 2.32E+04 1.79 0.001 
Sterols Cholesterol sulfate 1.90E+05 1.24E+05 0.65 0.001 
Other 2-Methyleneglutarate 3.25E+04 9.57E+04 2.94 0.045 
Leucocyanidin 2.34E+05 3.51E+05 1.50 0.052 
Methylenediurea 1.14E+07 1.35E+07 1.19 0.002 
3-Oxalomalate 6.14E+06 4.67E+06 0.76 0.007 
2-Deoxy-α-glucoside 1.36E+06 3.06E+06 2.25 0.000 
N-Acylmannosaminolactone 1.65E+05 3.70E+05 2.24 0.001 
N6-Methyllysine 3.92E+05 3.59E+05 0.92 0.238 
Shikimate-3-phosphate 1.20E+05 1.21E+05 1.01 0.730 
Glucono-1,5-lactone 3.11E+04 3.70E+04 1.19 0.282 
Catechin 1.43E+06 5.52E+05 0.39 0.000 
Riboflavin 6.52E+04 4.37E+04 0.67 0.025 
Glucosinolate 1.44E+05 2.36E+05 1.64 0.001 
Ribose-5-diphosphate 1.49E+05 1.45E+05 0.97 0.539 
S-Acylglutathione 3.96E+05 4.82E+05 1.22 0.107 
9-Oxononanoic acid 1.14E+05 1.28E+05 1.12 0.156 
Noradrenaline 6.04E+05 7.30E+05 1.21 0.033 
N-Acetylmethionine 8.34E+05 1.77E+06 2.13 0.000 




Supplementary Table 3-2. Metabolome Analysis of NCI/ADR-RES Cells 
Treated with MITOx30 
 
Pathway Compound *Peak Area 
†Fold 
Increase 
‡p-value Vehicle MITOx30 
Amino acids Alanine 2.55E+06 2.90E+06 1.14 0.021 
Arginine 1.33E+06 1.78E+06 1.33 0.001 
Asparagine 2.47E+05 2.65E+05 1.07 0.530 
Aspartate 9.31E+06 8.62E+06 0.93 0.577 
Cysteine 3.78E+05 6.75E+05 1.79 0.000 
Glutamate 4.84E+07 5.48E+07 1.13 0.318 
Glutamine 1.68E+05 2.46E+05 1.47 0.003 
Glycine 1.14E+06 1.52E+06 1.34 0.005 
Histidine 4.27E+05 4.44E+05 1.04 0.317 
Leucine 7.59E+06 1.06E+07 1.39 0.003 
Lysine 7.09E+05 1.00E+06 1.41 0.021 
Methionine 1.06E+06 1.28E+06 1.21 0.053 
Phenylalanine 1.52E+06 1.89E+06 1.24 0.001 
Proline 1.65E+07 1.63E+07 0.99 0.803 
Serine 4.17E+05 4.49E+05 1.08 0.187 
Threonine 4.42E+05 5.75E+05 1.30 0.019 
Tryptophan 3.95E+05 4.70E+05 1.19 0.068 
Tyrosine 1.88E+06 2.23E+06 1.19 0.052 
Valine 7.00E+06 8.18E+06 1.17 0.041 
Cystine 1.56E+05 1.94E+05 1.24 0.062 
Nucleotides ATP 2.93E+06 2.64E+06 0.90 0.804 
ADP 8.98E+05 3.09E+06 3.44 0.008 
AMP 3.92E+06 9.75E+06 2.49 0.001 
dAMP 4.25E+05 4.63E+05 1.09 0.486 
Adenosine 3.27E+04 1.32E+04 0.40 0.073 
Adenine 6.68E+05 5.16E+05 0.77 0.079 
GTP 4.99E+05 3.83E+05 0.77 0.223 
GDP 3.96E+05 6.59E+05 1.67 0.083 
GMP 1.29E+05 4.06E+05 3.15 0.017 
Guanosine 1.26E+05 7.07E+04 0.56 0.011 
Guanine 5.94E+04 1.33E+05 2.24 0.000 
CTP 3.78E+05 1.83E+05 0.48 0.067 
CDP 3.13E+05 2.84E+05 0.91 0.171 
CMP 1.07E+05 3.12E+05 2.91 0.001 
Cytidine 1.10E+05 2.11E+05 1.92 0.025 
Cytosine 8.62E+04 9.02E+04 1.05 0.884 
dTMP 3.36E+04 2.70E+04 0.80 0.118 
UTP 1.08E+06 6.94E+05 0.64 0.103 
UDP 1.11E+06 1.17E+06 1.06 0.883 
UMP 2.97E+05 2.43E+06 8.21 0.000 
Uracil 5.10E+05 4.44E+05 0.87 0.343 
IMP 1.97E+05 2.95E+05 1.50 0.000 
Inosine 2.78E+06 1.76E+06 0.63 0.018 
Hypoxanthine 6.31E+06 4.16E+06 0.66 0.004 
Xanthine 2.98E+05 3.18E+05 1.07 0.605 
 
*Median value. †Fold increase of peak area calculated as MITOx30/Vehicle. ‡Determined by 
unpaired t test (n = 4).  
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Nucleotides Allantoate 6.62E+04 8.69E+04 1.31 0.049 
5,6-Dihydrothymine 2.10E+06 1.48E+06 0.70 0.002 
Nicotinamide 5.89E+06 7.59E+06 1.29 0.001 
Adenylosuccinic acid 5.85E+04 1.13E+05 1.93 0.006 
UDP-glucose 8.28E+05 7.54E+05 0.91 0.082 
NAD+ 3.17E+06 2.53E+06 0.80 0.025 
Phosphates Phosphate 1.56E+06 3.03E+06 1.95 0.001 
Diphosphate 2.34E+06 4.85E+06 2.07 0.010 
Glycolysis Glucose 6.60E+05 5.25E+05 0.80 0.001 
Fructose-1,6-bisphosphate 1.92E+05 1.92E+05 1.00 0.574 
2/3-Phosphoglycerate 2.85E+05 2.04E+05 0.72 0.008 
Phosphoenolpyruvate 3.24E+04 1.88E+04 0.58 0.002 
Lactate 5.03E+06 4.96E+06 0.99 0.487 
Other sugars Mannitol 4.46E+06 1.55E+05 0.03 0.212 
TCA cycle Citrate 3.78E+06 2.68E+06 0.71 0.002 
α-Ketoglutarate 7.49E+04 5.82E+04 0.78 0.728 
Succinate 1.22E+06 1.80E+06 1.48 0.009 
Fumarate 8.86E+05 6.91E+05 0.78 0.041 
Malate 1.02E+07 7.78E+06 0.77 0.020 
Oxaloacetate 3.28E+05 2.86E+05 0.87 0.128 
2-Hydroxyglutarate 1.52E+05 1.32E+05 0.87 0.717 
Pentose Phosphate 
Pathway 
Erythrose-4-phosphate 3.05E+04 2.18E+04 0.72 0.823 
Sedoheptulose-1-phosphate 9.87E+04 1.24E+05 1.26 0.011 
α-Ribose-1-phosphate 1.54E+06 1.47E+06 0.95 0.814 
Phosphoribosylpyrophosphate 1.80E+04 2.05E+04 1.14 0.872 
GSH homeostasis Glutathione 7.48E+07 8.09E+07 1.08 0.249 
Glutathione disulfide 5.15E+04 4.14E+04 0.80 0.023 
5-Oxoproline 2.24E+06 2.53E+06 1.13 0.128 
Cys-Gly 1.92E+05 2.13E+05 1.11 0.038 
Ascorbate 5.69E+04 5.58E+04 0.98 0.840 
Dehydroascorbate 9.16E+04 1.15E+05 1.26 0.252 
Gamma-glutamyls γ-Glutamylcysteine 4.74E+04 1.70E+05 3.60 0.000 
γ-Glutamylalanine 2.84E+05 3.05E+05 1.08 0.571 
γ-Glutamyl-GABA 5.05E+04 3.65E+04 0.72 0.530 
γ-Glutamylglutamine 1.82E+04 1.68E+04 0.92 0.290 
Ser & 1C metabolism Cystathionine 2.43E+05 3.02E+05 1.24 0.205 
Dimethylglycine 1.00E+06 7.39E+05 0.74 0.002 
Phosphoserine 4.37E+05 3.52E+05 0.81 0.154 
S-Adenosylmethionine 4.03E+05 3.79E+05 0.94 0.953 
Urea cycle Citrulline 7.78E+05 9.85E+05 1.27 0.034 
Polyamines Putrescine 2.37E+06 2.75E+06 1.16 0.606 
Spermidine 2.69E+06 1.67E+06 0.62 0.082 
Spermine 2.60E+06 1.07E+06 0.41 0.020 
Aminosugars N-Acetylneuraminate 2.49E+05 6.31E+05 2.53 0.004 
α-Glucosamine-1-phosphate 5.94E+04 5.70E+04 0.96 0.947 
UDP-N-acetylglucosamine 2.33E+06 2.20E+06 0.95 0.278 
CMP-N-acetylneuraminate 1.09E+05 1.13E+05 1.04 0.677 
Arg & Pro metabolism Phosphocreatine 2.70E+05 5.96E+04 0.22 0.003 
Creatine 3.43E+08 3.04E+08 0.89 0.035 
Creatinine 9.06E+05 9.50E+05 1.05 0.891 
Hydroxyproline 8.56E+05 7.22E+05 0.84 0.222 
N-Succinylglutamate 2.30E+04 1.88E+04 0.82 0.513 
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Panthothenate Pantothenol 1.30E+05 1.50E+05 1.15 0.182 
Sulfur metabolism Taurine 2.13E+06 9.74E+05 0.46 0.000 
Hypotaurine 1.90E+05 9.94E+04 0.52 0.014 
Methionine-S-oxide 3.33E+05 3.94E+05 1.18 0.011 
Indole & Tryptophan 3-Methyleneoxindole 7.38E+04 8.78E+04 1.19 0.004 
4-Oxalocrotonate 7.60E+06 7.79E+06 1.03 0.521 
Signaling Adrenaline 1.42E+05 2.06E+05 1.45 0.388 
Inositol Inositol-1,2,3,5,6-pentakisphos. 1.88E+05 1.25E+05 0.67 0.110 
Glycerophospholipid 
biosynthesis 
Glycerol-3-phosphate 1.63E+05 1.92E+05 1.18 0.059 
Ethanolamine phosphate 3.69E+04 6.41E+04 1.74 0.213 
N-Methylethanolamine phos. 4.42E+05 4.04E+05 0.91 0.087 
Acetylcholine 3.16E+06 2.40E+06 0.76 0.001 
CDP-choline 1.49E+05 1.74E+05 1.17 0.156 
Choline 2.77E+07 2.87E+07 1.03 0.898 
Carnitine Carnitine 8.87E+06 8.77E+06 0.99 0.545 
Saturated fatty acids Octanoic acid 1.15E+04 3.48E+04 3.03 0.006 
Nonanoic acid 2.15E+04 4.69E+04 2.18 0.007 
Xenobiotics Pentobarbital 7.15E+04 6.30E+04 0.88 0.795 
Other Triacanthine 2.24E+06 1.89E+06 0.84 0.025 
4-Aminobenzoate 1.23E+05 1.45E+05 1.18 0.041 
Leucocyanidin 4.73E+04 4.44E+04 0.94 0.875 
Methylenediurea 3.73E+06 3.18E+06 0.85 0.044 
β-Butoxyethylnicotinate 1.13E+06 1.48E+06 1.32 0.113 
cis-4-Coumarate 2.47E+05 3.12E+05 1.26 0.051 
Shikimate-3-phosphate 5.98E+04 8.17E+04 1.37 0.020 
Poly-γ-glutamate 8.44E+06 9.79E+06 1.16 0.207 
Catechin 6.62E+05 3.92E+05 0.59 0.009 
Ribose-5-diphosphate 2.38E+04 1.94E+04 0.82 0.413 
Thioredoxin disulfide 1.49E+05 7.03E+04 0.47 0.006 
S-Acylglutathione 2.53E+05 2.73E+05 1.08 0.306 
N-Acylglutamate 2.19E+04 1.91E+04 0.87 0.265 
Glycerone sulfate 6.38E+04 5.44E+04 0.85 0.438 
N-Acylaspartate 7.41E+04 8.07E+04 1.09 0.969 
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CHAPTER 4. Concluding Remarks 
MCJ is a negative regulator of mitochondrial metabolism that functions 
through direct interactions with Complex I. MCJ is predicted to bind the NDUFv1 
subunit of Complex I (Hatle et al., 2013), however the binding interactions that 
facilitate the function of MCJ are currently unknown. Considering that the 
NDUFv1 contains the NADH binding site of Complex I (Deng et al., 1990), MCJ 
may disrupt the binding of NADH and NDUFv1 in order to regulate Complex I 
activity. It is also possible that NADH (or NAD+) may act directly on MCJ, thereby 
transiently affecting the regulatory activity of MCJ. 
While the crystal structure of MCJ has not been solved, the N-terminus is likely 
the domain governing its regulatory function as it has a unique amino acid 
sequence compared to all currently known eukaryotic proteins (Hatle et al., 2007; 
Shridhar et al., 2001). Additionally, as shown in this dissertation (CHAPTER 3) a 
peptide mimetic of the N-terminus is sufficient to regulate mitochondrial 
metabolism in MCJ deficient cancer cells. Due to the unique character of the 
N-terminus, MCJ may be a druggable target, and there may not be significant off-
target effects on other proteins. Therefore, the development of small molecule 
inhibitors or agonists of MCJ function may provide therapeutic benefits. 
Inhibitors of MCJ may improve the efficacy of vaccines to viral infections, such 
as those for influenza. Currently approved vaccines for influenza elicit a strong 
antibody response to surface viral proteins (notably hemagglutinin), however 
 
227 
genetic drift/shift and strong immune selection of circulating viruses often 
renders responses ineffective (Krammer, 2015). In addition, antibody titers wane 
over time, which results in a loss of protection. As such, yearly immunizations are 
needed to maintain protection. The ultimate goal of influenza vaccine research is 
to produce a “universal” vaccine that could eliminate the need for annual 
vaccinations (Pica and Palese, 2013). 
CD8+ T cell responses are often targeted to internal viral proteins, which 
typically undergo less change over time. Therefore, vaccines that elicit stronger 
CD8+ T cell memory may provide lasting protection. The polio vaccine is a notable 
example that stimulates strong T cell memory and effectively provides protection 
for life. As shown previously (CHAPTER 2), loss of MCJ in mouse models is highly 
protective to secondary influenza virus infection through the promotion of CD8+ 
T cell effector functions and memory development. Inhibiting MCJ during 
immunization could therefore lead to improved CD8+ T cell memory development 
and to enhanced vaccine responses. 
In addition, there is ongoing research into the production of vaccines for cancer 
(Banchereau and Palucka, 2018; Finn, 2018). As for viral infections, the cytotoxic 
effector function of CD8+ T cells is important for the elimination of transformed 
cells. While the role of MCJ in cancer immunity has not yet been addressed, it is 
likely that an MCJ inhibitor could also promote the efficacy of cancer vaccines. 
MCJ deficiency in the liver also has several positive outcomes, therefore 
inhibitors may provide therapeutic benefits in liver diseases. Loss of MCJ in the 
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liver is highly protective to the development of steatosis (fatty liver) in mouse 
models of fasting (Hatle et al., 2013). Steatosis is the first clinical manifestation of 
non-alcoholic fatty liver disease (NAFLD) in humans, and it is thought that excess 
buildup of fatty acids eventually leads to inflammation, hepatocyte death, and 
fibrosis in the liver (although the exact mechanisms are currently unclear). NAFLD 
progression can lead to cirrhosis and liver cancer, however there are currently no 
specific treatments in the clinic for this disease. Since loss of MCJ function can 
effectively prevents steatosis, it is possible that inhibitors of MCJ may improve the 
outcomes of NAFLD patients.  
MCJ may also represent a target for the treatment of metabolic syndrome. The 
most common comorbidity of a number of metabolic diseases is obesity, notably 
abdominal fat deposition. A large-scale genome wide association study (GWAS) 
identified MCJ as the closest gene to a single nucleotide polymorphism that 
strongly correlated with increased waist circumference in humans (Heard-Costa 
et al., 2009). While this finding is only a correlation that has not been fully 
examined, it implicates MCJ in the maintenance of fat metabolism and storage. 
Thus, inhibition of MCJ may provide a therapeutic benefit to metabolic syndrome 
patients. 
In addition, loss of MCJ has been shown to substantially decrease liver toxicity 
after acetaminophen overdose. The only treatment currently available is 
administration of N-acetylcysteine (NAC), however the efficacy is substantially 
diminished in a relative short amount of time post overdose (< 10 hours). It has 
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been shown that downregulation of MCJ expression up to 24 hours after the 
overdose substantially protects the liver in mouse models (Barbier-Torres et al., 
2017). In addition, high MCJ expression in the liver of patients experiencing drug 
induced liver injury is predictive of poor outcomes (Barbier-Torres et al., 2017), 
therefore inhibition of MCJ function may provide a strong benefit to these patients. 
Substantial benefits in these systems that occur in the absence of MCJ lead to 
an unanswered question: what advantageous trait does MCJ provide when its loss 
is apparently positive? For CD8+ T cells, it is possible that while a deficiency in 
MCJ is favorable for viral immunity, susceptibility to autoimmune disease is 
enhanced. CD8+ T cells are implicated in the pathology of several autoimmune 
diseases due – at least in part – to aberrant cytotoxic activity (Blanco et al., 2005; 
Gravano and Hoyer, 2013). Since MCJ deficiency enhances the cytotoxic capacity 
of CD8+ T cells (CHAPTER 2), the risk of developing autoimmunity may be 
increased in the absence of MCJ. While CD4+ T cells are also implicated in 
autoimmunity, only a limited number of these cells have been shown to exhibit 
cytotoxic function (Takeuchi and Saito, 2017). Therefore within the immune 
system, the beneficial function of MCJ may be to limit cytotoxicity by CD8+ T cells 
to prevent excessive normal tissue damage and autoimmunity. 
While loss of MCJ in the liver is not detrimental under controlled laboratory 
conditions (Hatle et al., 2013), survival during prolonged periods of metabolic 
stress may require MCJ function. A notable role of the liver is in the regulation of 
lipid metabolism (Berg et al., 2002; Voet and Voet, 2011). While mouse models of 
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fasting (< 2 days) indicate that loss of MCJ is beneficial as hepatocytes have an 
increased capacity to metabolize lipids, the effects of starvation conditions are 
unknown (Hatle et al., 2013). There may be a decreased length of time that MCJ 
deficient mice can survive without food, thereby leading to an earlier death due to 
starvation. Therefore from an evolutionary standpoint, the presence of MCJ in the 
liver is an advantageous trait when resources are limited. In line with this, NAFLD 
may be a modern negative consequence of this ancestral need in times of food 
scarcity as MCJ tips the balance toward lipid storage rather than breakdown. 
Similar to starvation conditions, MCJ loss may be detrimental during cold 
stress. Metabolic reactions produce significant amounts of heat, which maintains 
body temperature in endotherms (Berg et al., 2002; Voet and Voet, 2011). It was 
recently shown that mitochondria generate a large amount of heat relative to other 
cellular components (Chretien et al., 2018), therefore regulation of mitochondrial 
respiration by MCJ may play a role in thermal regulation. Thus, a deficiency in 
MCJ may lead to dysregulated body temperatures in times of stress. 
MCJ is highly expressed in the heart, however its role in heart function and 
cardiovascular health has not been addressed. It is known that production of ROS 
by mitochondria promotes tissue damage during ischemia-reperfusion (IR) injury, 
which occurs during a myocardial infarction (MI; also known as a heart attack). 
The current standard of care for MI patients is to immediately remove the clot, 
which rapidly restores blood flow and increases oxygen concentrations in the 
ischemic tissue. This results in a burst of mitochondrial ROS production and 
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causes IR injury. Complex I produces a significant amount of ROS (Chouchani et 
al., 2014; Scialo et al., 2017), but whether MCJ exacerbates or assuages IR injury is 
unknown. However, considering that MCJ deficiency has been correlated with 
decreased ROS production in CD8+ T cells (Champagne et al., 2016), it is possible 
that loss of MCJ in cardiac cells may be protective of IR injury. 
While many studies have shown benefits due to the loss of MCJ, deficiency can 
be detrimental in the context of cancer. As shown previously (CHAPTER 3), loss 
of MCJ in cancer cells supports chemoresistance through the promotion of drug 
efflux by ABC transporters. Restoration of MCJ function using peptide mimetics 
substantially reverses this mechanism of resistance, therefore activating the 
function of MCJ can provide benefits for the treatment of chemoresistant cancer.  
The role of MCJ in metastasis is currently unknown. Mitochondria can promote 
tumor progression and are likely involved in metastasis (Wallace, 2012; Zong et 
al., 2016). In line with this, mitochondria can traffic to the leading edge of the cell 
and provide the ATP required to facilitate migration (Cunniff et al., 2016). While a 
potential role for MCJ in this process is unknown, it is feasible that loss of MCJ (or 
other negative regulators of mitochondrial metabolism) improves migratory 
capacity. Thus, promoting MCJ function during cancer treatment may also have 
the added benefit of limiting the metastatic potential of tumor cells. 
While there is likely a strong benefit in cancer treatment due to limiting ABC 
transporter activity, there may also be negative consequences. Active transport of 
substrates generally requires ATP, therefore restricting mitochondria respiration 
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may have detrimental off-target effects. This is especially true for patients with 
disorders associated with ABC transporters and similar proteins as disease 
symptoms may be worsened (e.g., cystic fibrosis, adrenoleukodystrophy, Stargardt 
disease). Additionally, restriction of TAP (transporter associated with antigen 
processing), the ABC transporter required to deliver peptide antigen to MHC 
class I molecules in the ER, may have negative consequences for antigen 
presentation to T cells and associated immune responses. Therefore, a balance will 
need to be maintained between inhibiting ABC transporters that mediate 
chemoresistance and those required for critical cell functions. 
Overall this dissertation describes how the regulation of mitochondrial 
metabolism by MCJ has profound effects on cellular metabolism and how this can 
be exploited for therapeutic purposes. Future studies will likely elucidate new 
avenues of manipulating MCJ function for the treatment of human disease. 
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